<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:PPCB="http://propanc.com/20260930"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2026"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ppcb-20260930.xsd" xlink:type="simple"/>
    <context id="From2026-07-01to2026-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-11-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
        </entity>
        <period>
            <instant>2026-11-12</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PPCB:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PPCB:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PPCB:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PPCB:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PPCB:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PPCB:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2026-03-012026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
        </entity>
        <period>
            <startDate>2026-03-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-10-012026-10-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-10-01</startDate>
            <endDate>2026-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_srt_WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_srt_WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_SeriesCPreferredStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PPCB:SeriesCPreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_SeriesCPreferredStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PPCB:SeriesCPreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_ConvertibleSeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PPCB:ConvertibleSeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_ConvertibleSeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PPCB:ConvertibleSeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-08-012026-08-31_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PPCB:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-01</startDate>
            <endDate>2026-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="AsOf2024-05-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="AsOf2024-08-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2026-02-122026-02-12_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-12</startDate>
            <endDate>2026-02-12</endDate>
        </period>
    </context>
    <context id="From2026-04-282026-04-28_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-28</startDate>
            <endDate>2026-04-28</endDate>
        </period>
    </context>
    <context id="From2026-09-032026-09-03_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-09-03</startDate>
            <endDate>2026-09-03</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-01_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-01</instant>
        </period>
    </context>
    <context id="From2024-08-012024-08-01_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-08-192025-08-19_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-19</startDate>
            <endDate>2025-08-19</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2026-02-122026-02-12_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-12</startDate>
            <endDate>2026-02-12</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-03_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-03</instant>
        </period>
    </context>
    <context id="AsOf2025-02-28_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="From2024-12-032024-12-03_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-03</startDate>
            <endDate>2024-12-03</endDate>
        </period>
    </context>
    <context id="AsOf2025-04-02_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-02</instant>
        </period>
    </context>
    <context id="AsOf2025-01-31_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="From2025-08-192025-08-19_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-19</startDate>
            <endDate>2025-08-19</endDate>
        </period>
    </context>
    <context id="AsOf2025-04-12_custom_LoanAgreementMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-12</instant>
        </period>
    </context>
    <context id="From2025-04-122025-04-12_custom_LoanAgreementMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-12</startDate>
            <endDate>2025-04-12</endDate>
        </period>
    </context>
    <context id="From2025-08-192025-08-19_custom_LoanAgreementMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-19</startDate>
            <endDate>2025-08-19</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-13_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-13</instant>
        </period>
    </context>
    <context id="From2025-06-132025-06-13_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-13</startDate>
            <endDate>2025-06-13</endDate>
        </period>
    </context>
    <context id="From2025-08-192025-08-19_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-19</startDate>
            <endDate>2025-08-19</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-03_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-03</instant>
        </period>
    </context>
    <context id="AsOf2025-08-14_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-14</instant>
        </period>
    </context>
    <context id="AsOf2023-07-05_custom_LetterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-05</instant>
        </period>
    </context>
    <context id="From2023-07-052023-07-05_custom_LetterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-05</startDate>
            <endDate>2023-07-05</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-05_custom_LetterAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-05</instant>
        </period>
    </context>
    <context id="From2023-07-052023-07-05_custom_LetterAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-05</startDate>
            <endDate>2023-07-05</endDate>
        </period>
    </context>
    <context id="From2023-07-052023-07-05_custom_LetterAgreementMember_us-gaap_WarrantMember_us-gaap_MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-05</startDate>
            <endDate>2023-07-05</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-05_custom_LetterAgreementMember_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-05</instant>
        </period>
    </context>
    <context id="AsOf2023-07-05_us-gaap_MeasurementInputExpectedTermMember_us-gaap_WarrantMember_custom_LetterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-05</instant>
        </period>
    </context>
    <context id="AsOf2023-07-05_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_WarrantMember_custom_LetterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-05</instant>
        </period>
    </context>
    <context id="AsOf2023-07-05_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_WarrantMember_custom_LetterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-05</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_LetterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_LetterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_LetterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_LetterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_LetterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_SecuritiesPurchaseAgreementMember_custom_CrownBridgePartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PPCB:CrownBridgePartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_SecuritiesPurchaseAgreementMember_custom_CrownBridgePartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PPCB:CrownBridgePartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-10-03_custom_SecuritiesPurchaseAgreementMember_custom_CrownBridgePartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PPCB:CrownBridgePartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-03</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_CrownBridgePartnersLLCMember_custom_ExchangeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:ExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PPCB:CrownBridgePartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_CrownBridgePartnersLLCMember_custom_ExchangeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:ExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PPCB:CrownBridgePartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2026-01-072026-01-07_custom_CrownBridgePartnersLLCMember_custom_ExchangeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:ExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PPCB:CrownBridgePartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-07</startDate>
            <endDate>2026-01-07</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-07_custom_ExchangeAgreementMember_custom_CrownBridgePartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:ExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PPCB:CrownBridgePartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-07</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_CrownBridgePartnersLLCMember_custom_ExchangeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:ExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PPCB:CrownBridgePartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_RelatedPartyMember_custom_LoansInDefaultMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">PPCB:LoansInDefaultMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_SeriesBPreferredStockMember_custom_MrNathanielszMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrNathanielszMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-11-042025-11-04_us-gaap_SeriesCPreferredStockMember_custom_HexstoneCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:HexstoneCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-04</startDate>
            <endDate>2025-11-04</endDate>
        </period>
    </context>
    <context id="AsOf2025-11-04_us-gaap_SeriesCPreferredStockMember_custom_HexstoneCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:HexstoneCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-04</instant>
        </period>
    </context>
    <context id="From2025-11-042025-11-04_custom_HexstoneCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:HexstoneCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-04</startDate>
            <endDate>2025-11-04</endDate>
        </period>
    </context>
    <context id="AsOf2025-11-04_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:HexstoneCapitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-04</instant>
        </period>
    </context>
    <context id="From2025-11-042025-11-04_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:HexstoneCapitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-04</startDate>
            <endDate>2025-11-04</endDate>
        </period>
    </context>
    <context id="AsOf2026-02-28_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:HexstoneCapitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-28</instant>
        </period>
    </context>
    <context id="AsOf2026-05-31_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:HexstoneCapitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-31</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:HexstoneCapitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2026-05-052026-05-05_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:HexstoneCapitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-05</startDate>
            <endDate>2026-05-05</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-06-30_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:HexstoneCapitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:HexstoneCapitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-11-04_us-gaap_SeriesCPreferredStockMember_custom_MonteCarloMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:MonteCarloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-04</instant>
        </period>
    </context>
    <context id="From2026-05-052026-05-05_us-gaap_SeriesCPreferredStockMember_custom_MonteCarloMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:MonteCarloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-05</startDate>
            <endDate>2026-05-05</endDate>
        </period>
    </context>
    <context id="From2026-08-012026-08-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-01</startDate>
            <endDate>2026-08-31</endDate>
        </period>
    </context>
    <context id="From2026-08-012026-08-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-01</startDate>
            <endDate>2026-08-31</endDate>
        </period>
    </context>
    <context id="From2026-09-012026-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-09-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-09-012026-09-30_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-09-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-10-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-10-31</instant>
        </period>
    </context>
    <context id="AsOf2026-08-31_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PPCB:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-08-31</instant>
        </period>
    </context>
    <context id="From2026-08-012026-08-31_custom_SeriesCWarrantsMember103576656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PPCB:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-01</startDate>
            <endDate>2026-08-31</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-08-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-08-31</endDate>
        </period>
    </context>
    <context id="From2026-07-242026-07-24_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-24</startDate>
            <endDate>2026-07-24</endDate>
        </period>
    </context>
    <context id="AsOf2026-07-24_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-24</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PPCB:ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_CommonStockMember_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PPCB:ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_CommonStockMember_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PPCB:ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PPCB:ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember_srt_MinimumMember_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PPCB:ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember_srt_MaximumMember_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PPCB:ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-07-012026-06-30_us-gaap_CommonStockMember_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PPCB:ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_CommonStockMember_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PPCB:ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PPCB:ConsultingInvestorRelationsAndBusinessAdvisoryServicesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PPCB:ConsultingInvestorRelationsAndBusinessAdvisoryServicesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PPCB:ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PPCB:ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2026-07-012026-08-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-08-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-08-31</instant>
        </period>
    </context>
    <context id="From2019-05-012019-05-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-12-092025-12-09_us-gaap_IndemnificationGuaranteeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-09</startDate>
            <endDate>2025-12-09</endDate>
        </period>
    </context>
    <context id="From2026-06-012026-06-30_custom_HelenaPartnersIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PPCB:HelenaPartnersIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-06-30_custom_HelenaPartnersIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PPCB:HelenaPartnersIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_From2012ThroughThe2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:From2012ThroughThe2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2012-06-012012-06-30_us-gaap_RoyaltyAgreementTermsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-06-01</startDate>
            <endDate>2012-06-30</endDate>
        </period>
    </context>
    <context id="From2012-06-012012-06-30_us-gaap_LicenseAgreementTermsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-06-01</startDate>
            <endDate>2012-06-30</endDate>
        </period>
    </context>
    <context id="From2018-09-132018-09-13_custom_OneYearCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:OneYearCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-13</startDate>
            <endDate>2018-09-13</endDate>
        </period>
    </context>
    <context id="From2018-09-132018-09-13_custom_TwoYearCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:TwoYearCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-13</startDate>
            <endDate>2018-09-13</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-10-01_custom_TwoYearCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:TwoYearCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="From2020-11-012020-11-30_custom_TwoYearCollaborationAgreementMember_custom_InstallmentOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:InstallmentOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:TwoYearCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="From2021-03-012021-03-31_custom_TwoYearCollaborationAgreementMember_custom_InstallmentTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:InstallmentTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:TwoYearCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-12-012021-12-31_custom_TwoYearCollaborationAgreementMember_custom_InstallmentThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:InstallmentThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:TwoYearCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-09-012022-09-30_custom_TwoYearCollaborationAgreementMember_custom_InstallmentFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:InstallmentFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:TwoYearCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-10-01_custom_UniversityOfJaenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PPCB:UniversityOfJaenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-10-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="From2022-07-272022-07-27_custom_UniversityOfJaenMember_custom_ResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:ResearchAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PPCB:UniversityOfJaenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-27</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="From2022-08-012022-08-31_custom_InstallmentOneMember_custom_ResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:InstallmentOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:ResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="From2022-09-012022-09-30_custom_InstallmentTwoMember_custom_ResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:InstallmentTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:ResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-12-012022-12-31_custom_InstallmentThreeMember_custom_ResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:InstallmentThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:ResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-03-012023-03-31_custom_InstallmentFourMember_custom_ResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:InstallmentFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:ResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-07-31_custom_InstallmentFiveMember_custom_ResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:InstallmentFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:ResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="From2026-03-012026-03-31_custom_TwoYearCollaborationAgreementMember_custom_YearOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:YearOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:TwoYearCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_TwoYearCollaborationAgreementMember_custom_YearOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:YearOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:TwoYearCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_TwoYearCollaborationAgreementMember_custom_YearTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:YearTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:TwoYearCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-03-012026-03-31_custom_TwoYearCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:TwoYearCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-02-012026-02-28_custom_TwoYearCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:TwoYearCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-28</endDate>
        </period>
    </context>
    <context id="From2026-12-312026-12-31_custom_TwoYearCollaborationAgreementMember_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:TwoYearCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-12-31</startDate>
            <endDate>2026-12-31</endDate>
        </period>
    </context>
    <context id="From2027-06-012027-06-30_custom_TwoYearCollaborationAgreementMember_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:TwoYearCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-06-01</startDate>
            <endDate>2027-06-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_TwoYearCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:TwoYearCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_UniversityOfJaenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PPCB:UniversityOfJaenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-06-012026-06-30_custom_InstallmentOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:InstallmentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-07-31_custom_InstallmentTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:InstallmentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-07-31</endDate>
        </period>
    </context>
    <context id="From2026-09-012026-09-30_custom_InstallmentThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:InstallmentThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-09-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2027-01-012027-01-31_custom_InstallmentFourMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:InstallmentFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-01-01</startDate>
            <endDate>2027-01-31</endDate>
        </period>
    </context>
    <context id="From2027-01-012027-01-31_custom_InstallmentFourMember_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:InstallmentFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-01-01</startDate>
            <endDate>2027-01-31</endDate>
        </period>
    </context>
    <context id="From2027-05-012027-05-30_custom_InstallmentFiveMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:InstallmentFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-05-01</startDate>
            <endDate>2027-05-30</endDate>
        </period>
    </context>
    <context id="From2027-05-012027-05-30_custom_InstallmentFiveMember_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:InstallmentFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-05-01</startDate>
            <endDate>2027-05-30</endDate>
        </period>
    </context>
    <context id="From2027-09-012027-09-30_custom_InstallmentSixMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:InstallmentSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-09-01</startDate>
            <endDate>2027-09-30</endDate>
        </period>
    </context>
    <context id="From2027-09-012027-09-30_custom_InstallmentSixMember_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PPCB:InstallmentSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-09-01</startDate>
            <endDate>2027-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-232026-01-23_custom_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-23</startDate>
            <endDate>2026-01-23</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-23_custom_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-23</instant>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-04_custom_NewOneYearOperatingLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:NewOneYearOperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-04</instant>
        </period>
    </context>
    <context id="From2025-05-042025-05-04_custom_NewOneYearOperatingLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:NewOneYearOperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-04</startDate>
            <endDate>2025-05-04</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
        </entity>
        <period>
            <instant>2025-05-04</instant>
        </period>
    </context>
    <context id="From2025-05-042025-05-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
        </entity>
        <period>
            <startDate>2025-05-04</startDate>
            <endDate>2025-05-04</endDate>
        </period>
    </context>
    <context id="AsOf2016-05-05_custom_NorthHorizonPtyLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PPCB:NorthHorizonPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-05</instant>
        </period>
    </context>
    <context id="From2016-05-052016-05-05_custom_NorthHorizonPtyLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PPCB:NorthHorizonPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-05</startDate>
            <endDate>2016-05-05</endDate>
        </period>
    </context>
    <context id="AsOf2016-05-05_custom_NorthHorizonPtyLtdMember_custom_NathanielszMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:NathanielszMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PPCB:NorthHorizonPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-05</instant>
        </period>
    </context>
    <context id="From2016-05-052016-05-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
        </entity>
        <period>
            <startDate>2016-05-05</startDate>
            <endDate>2016-05-05</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-04_custom_NewThreeYearOperatingLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:NewThreeYearOperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-04</instant>
        </period>
    </context>
    <context id="From2022-05-042022-05-04_custom_ThreeYearOperatingLeaseAgreementMember_custom_NorthHorizonPtyLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:ThreeYearOperatingLeaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PPCB:NorthHorizonPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-04</startDate>
            <endDate>2022-05-04</endDate>
        </period>
    </context>
    <context id="From2025-05-042025-05-04_custom_OneYearOperatingLeaseAgreementMember_custom_NorthHorizonPtyLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:OneYearOperatingLeaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PPCB:NorthHorizonPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-04</startDate>
            <endDate>2025-05-04</endDate>
        </period>
    </context>
    <context id="From2015-02-252015-02-25_custom_NathanielszEmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:NathanielszEmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-25</startDate>
            <endDate>2015-02-25</endDate>
        </period>
    </context>
    <context id="From2015-02-252015-02-25_custom_NathanielszEmploymentAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:NathanielszEmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-25</startDate>
            <endDate>2015-02-25</endDate>
        </period>
    </context>
    <context id="From2018-03-162018-03-16_custom_NathanielszEmploymentAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:NathanielszEmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-16</startDate>
            <endDate>2018-03-16</endDate>
        </period>
    </context>
    <context id="From2018-03-162018-03-16_custom_NathanielszEmploymentAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:NathanielszEmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-16</startDate>
            <endDate>2018-03-16</endDate>
        </period>
    </context>
    <context id="From2022-08-012022-08-01_custom_NathanielszEmploymentAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:NathanielszEmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="From2022-08-012022-08-01_custom_NathanielszEmploymentAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:NathanielszEmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="From2025-10-172025-10-17_custom_MrsNathanielszMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrsNathanielszMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-17</startDate>
            <endDate>2025-10-17</endDate>
        </period>
    </context>
    <context id="From2025-10-172025-10-17_custom_MrsNathanielszMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrsNathanielszMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-17</startDate>
            <endDate>2025-10-17</endDate>
        </period>
    </context>
    <context id="From2021-08-122021-08-12_custom_MrNathanielszMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrNathanielszMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="From2020-07-012021-06-30_custom_MrNathanielszMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrNathanielszMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_MrNathanielszMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrNathanielszMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2022-08-012022-08-01_custom_MrNathanielszMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrNathanielszMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_MrNathanielszMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrNathanielszMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-01-31_custom_MrNathanielszMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrNathanielszMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2025-06-012025-06-30_custom_MrNathanielszMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrNathanielszMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_MrNathanielszMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrNathanielszMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_MrNathanielszMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrNathanielszMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-07-012026-06-30_custom_MrNathanielszMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrNathanielszMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_MrNathanielszMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrNathanielszMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_MrNathanielszMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrNathanielszMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_MrNathanielszMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrNathanielszMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2019-05-142019-05-14_custom_ServicesAgreementMember_custom_DrKenyonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:DrKenyonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:ServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-14</startDate>
            <endDate>2019-05-14</endDate>
        </period>
    </context>
    <context id="From2019-05-142019-05-14_custom_EmploymentAgreementMember_custom_MrNathanielszMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrNathanielszMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-14</startDate>
            <endDate>2019-05-14</endDate>
        </period>
    </context>
    <context id="From2022-10-262022-10-26_custom_NathanielszEmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:NathanielszEmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-26</startDate>
            <endDate>2022-10-26</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_NathanielszEmploymentAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:NathanielszEmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_NathanielszEmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:NathanielszEmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-10-01_custom_ServicesAgreementMember_custom_DrKenyonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:DrKenyonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PPCB:ServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-01</instant>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_srt_DirectorMember_custom_MrJosephHimyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrJosephHimyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_srt_DirectorMember_custom_MrJosephHimyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrJosephHimyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_srt_DirectorMember_custom_DrRalfBrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:DrRalfBrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_srt_DirectorMember_custom_DrRalfBrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:DrRalfBrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_srt_DirectorMember_custom_DrRalfBrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:DrRalfBrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_srt_DirectorMember_custom_MrCarloCampicianoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrCarloCampicianoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_srt_DirectorMember_custom_MrCarloCampicianoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:MrCarloCampicianoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_LenderOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:LenderOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_LenderTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:LenderTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_LenderThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PPCB:LenderThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_ConvertibleDebtBenchmarkMember_us-gaap_LenderConcentrationRiskMember_custom_LenderOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">PPCB:LenderOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">PPCB:ConvertibleDebtBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:LenderConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_ConvertibleDebtBenchmarkMember_us-gaap_LenderConcentrationRiskMember_custom_LenderTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">PPCB:LenderTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">PPCB:ConvertibleDebtBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:LenderConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_ConvertibleDebtBenchmarkMember_us-gaap_LenderConcentrationRiskMember_custom_LenderThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">PPCB:LenderThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">PPCB:ConvertibleDebtBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:LenderConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_AccountsReceivableMember_us-gaap_CreditConcentrationRiskMember_custom_ReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">PPCB:ReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-06-30_us-gaap_AccountsReceivableMember_us-gaap_CreditConcentrationRiskMember_custom_ReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">PPCB:ReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="From2026-10-012026-10-31_us-gaap_SubsequentEventMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PPCB:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-10-01</startDate>
            <endDate>2026-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-10-31_custom_SeriesCWarrantsMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PPCB:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-10-31</instant>
        </period>
    </context>
    <context id="AsOf2026-10-31_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517681</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-10-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>PPCB:Segment</measure>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="AUD">
        <measure>iso4217:AUD</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2026-07-01to2026-09-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2026-07-01to2026-09-30" id="Fact000004">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2026-07-01to2026-09-30" id="Fact000005">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2026-07-01to2026-09-30" id="Fact000006">0001517681</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2026-09-30"
      id="xdx2ixbrl0119"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2026-06-30"
      id="xdx2ixbrl0120"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2026-09-30_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0136"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2026-06-30_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0137"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2026-09-30_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0155"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2026-06-30_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0156"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0251"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:SettlementExpense
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0356"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0360"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-07-012025-09-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-07-012025-09-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-07-012025-09-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2025-07-012025-09-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2025-07-012025-09-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0430"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0449"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0453"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0470"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0491"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0501"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0502"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-07-012026-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-07-012026-09-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0516"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0522"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2026-07-012026-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2026-07-012026-09-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0524"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0525"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0533"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0534"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0535"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2026-07-012026-09-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0539"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2026-07-012026-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0540"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2026-07-012026-09-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0541"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringPeriodValueWarrantExercised
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0546"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringPeriodValueWarrantExercised
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0547"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringPeriodValueWarrantExercised
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0549"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringPeriodValueWarrantExercised
      contextRef="From2026-07-012026-09-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0550"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringPeriodValueWarrantExercised
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0552"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringPeriodValueWarrantExercised
      contextRef="From2026-07-012026-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringPeriodValueWarrantExercised
      contextRef="From2026-07-012026-09-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0554"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringThePeriodValuePurchaseOfTreasuryShares
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0559"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringThePeriodValuePurchaseOfTreasuryShares
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0560"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringThePeriodValuePurchaseOfTreasuryShares
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0561"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringThePeriodValuePurchaseOfTreasuryShares
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0562"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringThePeriodValuePurchaseOfTreasuryShares
      contextRef="From2026-07-012026-09-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0563"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringThePeriodValuePurchaseOfTreasuryShares
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0564"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringThePeriodValuePurchaseOfTreasuryShares
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringThePeriodValuePurchaseOfTreasuryShares
      contextRef="From2026-07-012026-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0570"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0572"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0573"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2026-07-012026-09-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0574"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0575"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0576"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2026-07-012026-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0577"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2026-07-012026-09-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0578"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0579"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0583"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0584"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0585"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0586"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2026-07-012026-09-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0587"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0588"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0589"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2026-07-012026-09-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0591"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0594"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0595"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0596"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0597"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0598"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0599"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0601"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0602"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0605"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0606"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0616"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0626"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0627"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0637"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0674"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0677"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNoncashExpense
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0680"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0683"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0719"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0722"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0728"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0732"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0734"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0737"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:PurchaseOfTreasuryShares
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0744"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0746"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0749"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0752"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0755"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0782"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0783"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:ReductionOfPutPremiumRelatedToConversionsOfConvertibleNotes
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0788"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:ConversionOfConvertibleNotesAndAccruedInterestToCommonStock
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0791"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:DefferredOfferingCostChargedToAdditionalPaidInCapitalUponClosingOfOffering
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0794"
      unitRef="USD"
      xsi:nil="true"/>
    <PPCB:IssuanceOfCommonStockForPrepaidServicesNetOfAmortizedPortion
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl0797"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-07-012025-09-30_custom_SeriesCPreferredStockWarrantsMember"
      id="xdx2ixbrl0912"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-07-012025-09-30_custom_ConvertibleSeriesCPreferredStockMember"
      id="xdx2ixbrl0916"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-07-012026-09-30_us-gaap_ConvertibleDebtSecuritiesMember"
      id="xdx2ixbrl0918"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl1362"
      unitRef="Shares"
      xsi:nil="true"/>
    <PPCB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceForfeited
      contextRef="From2026-07-01to2026-09-30"
      id="xdx2ixbrl1364"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <PPCB:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2026-09-30"
      id="xdx2ixbrl1380"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2026-07-01to2026-09-30" id="Fact000016">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2026-07-01to2026-09-30" id="Fact000017">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2026-07-01to2026-09-30" id="Fact000018">2026-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2026-07-01to2026-09-30" id="Fact000019">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2026-07-01to2026-09-30" id="Fact000020">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2026-07-01to2026-09-30" id="Fact000021">001-42806</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2026-07-01to2026-09-30" id="Fact000022">PROPANC BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2026-07-01to2026-09-30" id="Fact000023">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2026-07-01to2026-09-30" id="Fact000024">33-0662986</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2026-07-01to2026-09-30" id="Fact000025">302</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2026-07-01to2026-09-30" id="Fact000026">6 Butler Street</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2026-07-01to2026-09-30" id="Fact000027">Camberwell, VIC</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="From2026-07-01to2026-09-30" id="Fact000028">3124</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="From2026-07-01to2026-09-30" id="Fact000029">AU</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="From2026-07-01to2026-09-30" id="Fact000030">+61-03</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2026-07-01to2026-09-30" id="Fact000031">9882-0780</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus contextRef="From2026-07-01to2026-09-30" id="Fact000032">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2026-07-01to2026-09-30" id="Fact000033">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2026-07-01to2026-09-30" id="Fact000034">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2026-07-01to2026-09-30" id="Fact000035">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2026-07-01to2026-09-30" id="Fact000036">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2026-07-01to2026-09-30" id="Fact000037">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-11-12"
      decimals="INF"
      id="Fact000038"
      unitRef="Shares">1048247</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityListingParValuePerShare
      contextRef="From2026-07-01to2026-09-30"
      decimals="INF"
      id="Fact000039"
      unitRef="USDPShares">0.001</dei:EntityListingParValuePerShare>
    <us-gaap:Cash
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000047"
      unitRef="USD">258366</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000048"
      unitRef="USD">832006</us-gaap:Cash>
    <PPCB:GoodsAndServicesTaxReceivableCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000050"
      unitRef="USD">12359</PPCB:GoodsAndServicesTaxReceivableCurrent>
    <PPCB:GoodsAndServicesTaxReceivableCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000051"
      unitRef="USD">13694</PPCB:GoodsAndServicesTaxReceivableCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000053"
      unitRef="USD">7674443</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000054"
      unitRef="USD">7661967</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000056"
      unitRef="USD">52926</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000057"
      unitRef="USD">34923</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000059"
      unitRef="USD">7998094</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000060"
      unitRef="USD">8542590</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000062"
      unitRef="USD">2287540</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000063"
      unitRef="USD">4190543</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000065"
      unitRef="USD">2085</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000066"
      unitRef="USD">2074</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000068"
      unitRef="USD">34986</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000069"
      unitRef="USD">40790</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000071"
      unitRef="USD">4030</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000072"
      unitRef="USD">3915</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000074"
      unitRef="USD">10326735</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000075"
      unitRef="USD">12779912</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000083"
      unitRef="USD">1162623</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000084"
      unitRef="USD">1131429</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000086"
      unitRef="USD">797031</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000087"
      unitRef="USD">855350</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000089"
      unitRef="USD">118927</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000090"
      unitRef="USD">128318</us-gaap:InterestPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000092"
      unitRef="USD">364801</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2026-06-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000093"
      unitRef="USD">460809</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000095"
      unitRef="USD">364801</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2026-06-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000096"
      unitRef="USD">460809</us-gaap:LoansPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000098"
      unitRef="USD">25731</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2026-06-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000099"
      unitRef="USD">24489</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000101"
      unitRef="USD">770910</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000102"
      unitRef="USD">754038</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000104"
      unitRef="USD">3240023</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000105"
      unitRef="USD">3354433</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000110"
      unitRef="USD">17010</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2026-06-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000111"
      unitRef="USD">23818</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000113"
      unitRef="USD">17010</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000114"
      unitRef="USD">23818</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000116"
      unitRef="USD">3257033</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000117"
      unitRef="USD">3378251</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000128"
      unitRef="Shares">1500005</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-06-30"
      decimals="INF"
      id="Fact000130"
      unitRef="Shares">1500005</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000132"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-06-30"
      decimals="INF"
      id="Fact000134"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-09-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000139"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-06-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000141"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-09-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000143"
      unitRef="Shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-06-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000145"
      unitRef="Shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-09-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000147"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-06-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000149"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-09-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000151"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-06-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000153"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-09-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000158"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-06-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000160"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-09-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000162"
      unitRef="Shares">5</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-06-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000164"
      unitRef="Shares">5</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-09-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000166"
      unitRef="Shares">1</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-06-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000168"
      unitRef="Shares">1</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-09-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000170"
      unitRef="Shares">1</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-06-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000172"
      unitRef="Shares">1</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000177"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-06-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000179"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <PPCB:PreferredStockStatedValue
      contextRef="AsOf2026-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000181"
      unitRef="USD">10000</PPCB:PreferredStockStatedValue>
    <PPCB:PreferredStockStatedValue
      contextRef="AsOf2026-06-30_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000183"
      unitRef="USD">10000</PPCB:PreferredStockStatedValue>
    <PPCB:PreferredStockSharesDesignatedAndAuthorized
      contextRef="AsOf2026-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000185"
      unitRef="Shares">9900</PPCB:PreferredStockSharesDesignatedAndAuthorized>
    <PPCB:PreferredStockSharesDesignatedAndAuthorized
      contextRef="AsOf2026-06-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000187"
      unitRef="Shares">9900</PPCB:PreferredStockSharesDesignatedAndAuthorized>
    <PPCB:PreferredStockLiquidationPreferenceShares
      contextRef="AsOf2026-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000189"
      unitRef="Shares">150</PPCB:PreferredStockLiquidationPreferenceShares>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2026-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000191"
      unitRef="USD">1500000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <PPCB:PreferredStockLiquidationPreferenceShares
      contextRef="AsOf2026-06-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000193"
      unitRef="Shares">200</PPCB:PreferredStockLiquidationPreferenceShares>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2026-06-30_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000195"
      unitRef="USD">2000000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2026-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000174"
      unitRef="USD">2</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2026-06-30_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000175"
      unitRef="USD">2</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2026-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000197"
      unitRef="USD">2</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2026-06-30_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000198"
      unitRef="USD">2</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000203"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-06-30"
      decimals="INF"
      id="Fact000205"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000207"
      unitRef="Shares">10000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-06-30"
      decimals="INF"
      id="Fact000209"
      unitRef="Shares">10000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000211"
      unitRef="Shares">983260</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000213"
      unitRef="Shares">983260</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-06-30"
      decimals="INF"
      id="Fact000215"
      unitRef="Shares">331083</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-06-30"
      decimals="INF"
      id="Fact000217"
      unitRef="Shares">331083</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000200"
      unitRef="USD">983</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000201"
      unitRef="USD">331</us-gaap:CommonStockValue>
    <PPCB:CommonStockIssuableShares
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000222"
      unitRef="Shares">65003</PPCB:CommonStockIssuableShares>
    <PPCB:CommonStockIssuableShares
      contextRef="AsOf2026-06-30"
      decimals="INF"
      id="Fact000224"
      unitRef="Shares">48793</PPCB:CommonStockIssuableShares>
    <PPCB:CommonStockIssuable
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000219"
      unitRef="USD">65</PPCB:CommonStockIssuable>
    <PPCB:CommonStockIssuable
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000220"
      unitRef="USD">49</PPCB:CommonStockIssuable>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000226"
      unitRef="USD">159550063</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000227"
      unitRef="USD">152755731</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000229"
      unitRef="USD">1136679</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000230"
      unitRef="USD">1176255</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000232"
      unitRef="USD">-153072389</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000233"
      unitRef="USD">-144484230</us-gaap:RetainedEarningsAccumulatedDeficit>
    <PPCB:TreasuryStockPricePerShare
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000238"
      unitRef="USDPShares">0.001</PPCB:TreasuryStockPricePerShare>
    <PPCB:TreasuryStockPricePerShare
      contextRef="AsOf2026-06-30"
      decimals="INF"
      id="Fact000240"
      unitRef="USDPShares">0.001</PPCB:TreasuryStockPricePerShare>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000235"
      unitRef="USD">545701</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000236"
      unitRef="USD">46477</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000242"
      unitRef="USD">7069702</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000243"
      unitRef="USD">9401661</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000245"
      unitRef="USD">10326735</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000246"
      unitRef="USD">12779912</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000257"
      unitRef="USD">182728</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000258"
      unitRef="USD">137341</us-gaap:GeneralAndAdministrativeExpense>
    <PPCB:CompensationAndRelatedTaxes
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000260"
      unitRef="USD">2244382</PPCB:CompensationAndRelatedTaxes>
    <PPCB:CompensationAndRelatedTaxes
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000261"
      unitRef="USD">110002</PPCB:CompensationAndRelatedTaxes>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000263"
      unitRef="USD">5678233</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000264"
      unitRef="USD">4351231</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:OccupancyNet
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000266"
      unitRef="USD">9523</us-gaap:OccupancyNet>
    <us-gaap:OccupancyNet
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000267"
      unitRef="USD">14789</us-gaap:OccupancyNet>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000269"
      unitRef="USD">457677</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000270"
      unitRef="USD">60201</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000272"
      unitRef="USD">8572543</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000273"
      unitRef="USD">4673564</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000275"
      unitRef="USD">-8572543</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000276"
      unitRef="USD">-4673564</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000281"
      unitRef="USD">18244</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000282"
      unitRef="USD">305649</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestIncomeOther
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000284"
      unitRef="USD">31</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000285"
      unitRef="USD">19</us-gaap:InterestIncomeOther>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000288"
      unitRef="USD">-19706</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000290"
      unitRef="USD">4024</us-gaap:OtherNonoperatingIncomeExpense>
    <PPCB:SettlementExpense
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000293"
      unitRef="USD">20000</PPCB:SettlementExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000297"
      unitRef="USD">195861</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000299"
      unitRef="USD">18573</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000300"
      unitRef="USD">-34699</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000302"
      unitRef="USD">-15616</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000303"
      unitRef="USD">-164174</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000305"
      unitRef="USD">-8588159</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000306"
      unitRef="USD">-4837738</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000311"
      unitRef="USD">-8588159</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000312"
      unitRef="USD">-4837738</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-07-01to2026-09-30"
      decimals="INF"
      id="Fact000314"
      unitRef="USDPShares">-12.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-07-01to2026-09-30"
      decimals="INF"
      id="Fact000316"
      unitRef="USDPShares">-12.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000318"
      unitRef="USDPShares">-98.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000320"
      unitRef="USDPShares">-98.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-07-01to2026-09-30"
      decimals="INF"
      id="Fact000322"
      unitRef="Shares">702966</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-07-01to2026-09-30"
      decimals="INF"
      id="Fact000324"
      unitRef="Shares">702966</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000326"
      unitRef="Shares">49326</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000328"
      unitRef="Shares">49326</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000330"
      unitRef="USD">-8588159</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000331"
      unitRef="USD">-4837738</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000336"
      unitRef="USD">-39576</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000337"
      unitRef="USD">17044</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000339"
      unitRef="USD">-39576</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000340"
      unitRef="USD">17044</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000342"
      unitRef="USD">-8627735</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000343"
      unitRef="USD">-4820694</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000358"
      unitRef="Shares">1</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000362"
      unitRef="Shares">46447</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000348"
      unitRef="USD">46</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_custom_CommonStockIssuableMember"
      decimals="INF"
      id="Fact000364"
      unitRef="Shares">31</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000350"
      unitRef="USD">138255226</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000351"
      unitRef="USD">-125621520</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000352"
      unitRef="USD">1318917</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000353"
      unitRef="USD">-46477</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000354"
      unitRef="USD">13906192</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000377"
      unitRef="Shares">780</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000369"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000371"
      unitRef="USD">438063</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000375"
      unitRef="USD">438064</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000390"
      unitRef="Shares">4000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000382"
      unitRef="USD">4</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000384"
      unitRef="USD">3314454</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000388"
      unitRef="USD">3314458</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-07-012025-09-30_custom_CommonStockIssuableMember"
      decimals="INF"
      id="Fact000403"
      unitRef="Shares">2044</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-07-012025-09-30_custom_CommonStockIssuableMember"
      decimals="0"
      id="Fact000396"
      unitRef="USD">2</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000397"
      unitRef="USD">1408746</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000401"
      unitRef="USD">1408748</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000410"
      unitRef="USD">114399</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000414"
      unitRef="USD">114399</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000423"
      unitRef="USD">17044</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000425"
      unitRef="USD">17044</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000433"
      unitRef="USD">-4837738</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000436"
      unitRef="USD">-4837738</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000451"
      unitRef="Shares">1</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000455"
      unitRef="Shares">51227</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000441"
      unitRef="USD">51</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_custom_CommonStockIssuableMember"
      decimals="INF"
      id="Fact000457"
      unitRef="Shares">2075</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_custom_CommonStockIssuableMember"
      decimals="0"
      id="Fact000442"
      unitRef="USD">2</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000443"
      unitRef="USD">143530888</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000444"
      unitRef="USD">-130459258</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000445"
      unitRef="USD">1335961</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000446"
      unitRef="USD">-46477</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000447"
      unitRef="USD">14361167</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000472"
      unitRef="Shares">1</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000474"
      unitRef="Shares">200</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000461"
      unitRef="USD">2</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000476"
      unitRef="Shares">331083</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000462"
      unitRef="USD">331</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-06-30_custom_CommonStockIssuableMember"
      decimals="INF"
      id="Fact000478"
      unitRef="Shares">48794</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_custom_CommonStockIssuableMember"
      decimals="0"
      id="Fact000463"
      unitRef="USD">49</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000464"
      unitRef="USD">152755731</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000465"
      unitRef="USD">-144484230</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000466"
      unitRef="USD">1176255</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000467"
      unitRef="USD">-46477</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000468"
      unitRef="USD">9401661</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000493"
      unitRef="Shares">1</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000495"
      unitRef="Shares">200</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000482"
      unitRef="USD">2</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000497"
      unitRef="Shares">331083</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000483"
      unitRef="USD">331</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-06-30_custom_CommonStockIssuableMember"
      decimals="INF"
      id="Fact000499"
      unitRef="Shares">48794</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_custom_CommonStockIssuableMember"
      decimals="0"
      id="Fact000484"
      unitRef="USD">49</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000485"
      unitRef="USD">152755731</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000486"
      unitRef="USD">-144484230</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000487"
      unitRef="USD">1176255</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000488"
      unitRef="USD">-46477</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000489"
      unitRef="USD">9401661</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000512"
      unitRef="Shares">48763</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000504"
      unitRef="USD">49</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-07-012026-09-30_custom_CommonStockIssuableMember"
      decimals="INF"
      id="Fact000514"
      unitRef="Shares">-48763</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-07-012026-09-30_custom_CommonStockIssuableMember"
      decimals="0"
      id="Fact000505"
      unitRef="USD">-49</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000527"
      unitRef="Shares">-250</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000518"
      unitRef="USD">-2</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000529"
      unitRef="Shares">253266</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000519"
      unitRef="USD">253</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2026-07-012026-09-30_custom_CommonStockIssuableMember"
      decimals="INF"
      id="Fact000531"
      unitRef="Shares">64972</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2026-07-012026-09-30_custom_CommonStockIssuableMember"
      decimals="0"
      id="Fact000520"
      unitRef="USD">65</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000521"
      unitRef="USD">-316</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000544"
      unitRef="Shares">350000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000536"
      unitRef="USD">350</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000538"
      unitRef="USD">4794650</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000542"
      unitRef="USD">4795000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <PPCB:StockIssuedDuringPeriodSharesWarrantExercised
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000557"
      unitRef="Shares">200</PPCB:StockIssuedDuringPeriodSharesWarrantExercised>
    <PPCB:StockIssuedDuringPeriodValueWarrantExercised
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000548"
      unitRef="USD">2</PPCB:StockIssuedDuringPeriodValueWarrantExercised>
    <PPCB:StockIssuedDuringPeriodValueWarrantExercised
      contextRef="From2026-07-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000551"
      unitRef="USD">1999998</PPCB:StockIssuedDuringPeriodValueWarrantExercised>
    <PPCB:StockIssuedDuringPeriodValueWarrantExercised
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000555"
      unitRef="USD">2000000</PPCB:StockIssuedDuringPeriodValueWarrantExercised>
    <PPCB:StockIssuedDuringThePeriodValuePurchaseOfTreasuryShares
      contextRef="From2026-07-012026-09-30_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000567"
      unitRef="USD">-499224</PPCB:StockIssuedDuringThePeriodValuePurchaseOfTreasuryShares>
    <PPCB:StockIssuedDuringThePeriodValuePurchaseOfTreasuryShares
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000568"
      unitRef="USD">-499224</PPCB:StockIssuedDuringThePeriodValuePurchaseOfTreasuryShares>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2026-07-012026-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000581"
      unitRef="Shares">148</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2026-07-012026-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000590"
      unitRef="USD">-39576</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000592"
      unitRef="USD">-39576</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000600"
      unitRef="USD">-8588159</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000603"
      unitRef="USD">-8588159</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000618"
      unitRef="Shares">1</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000620"
      unitRef="Shares">150</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000607"
      unitRef="USD">2</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000622"
      unitRef="Shares">983260</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000608"
      unitRef="USD">983</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-09-30_custom_CommonStockIssuableMember"
      decimals="INF"
      id="Fact000624"
      unitRef="Shares">65003</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_custom_CommonStockIssuableMember"
      decimals="0"
      id="Fact000609"
      unitRef="USD">65</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000610"
      unitRef="USD">159550063</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000611"
      unitRef="USD">-153072389</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000612"
      unitRef="USD">1136679</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000613"
      unitRef="USD">-545701</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000614"
      unitRef="USD">7069702</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000639"
      unitRef="Shares">1</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000641"
      unitRef="Shares">150</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000628"
      unitRef="USD">2</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000643"
      unitRef="Shares">983260</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000629"
      unitRef="USD">983</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-09-30_custom_CommonStockIssuableMember"
      decimals="INF"
      id="Fact000645"
      unitRef="Shares">65003</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_custom_CommonStockIssuableMember"
      decimals="0"
      id="Fact000630"
      unitRef="USD">65</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000631"
      unitRef="USD">159550063</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000632"
      unitRef="USD">-153072389</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000633"
      unitRef="USD">1136679</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000634"
      unitRef="USD">-545701</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000635"
      unitRef="USD">7069702</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000650"
      unitRef="USD">-8588159</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000651"
      unitRef="USD">-4837738</us-gaap:NetIncomeLoss>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000656"
      unitRef="USD">4795000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000657"
      unitRef="USD">726248</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000659"
      unitRef="USD">1931989</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000660"
      unitRef="USD">3024605</us-gaap:ShareBasedCompensation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000662"
      unitRef="USD">18573</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000663"
      unitRef="USD">-34699</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:Depreciation
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000665"
      unitRef="USD">354</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000666"
      unitRef="USD">125</us-gaap:Depreciation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000668"
      unitRef="USD">644</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000669"
      unitRef="USD">150902</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000671"
      unitRef="USD">6023</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000672"
      unitRef="USD">3577</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000675"
      unitRef="USD">-19706</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000678"
      unitRef="USD">195861</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNoncashExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000681"
      unitRef="USD">4906</us-gaap:OtherNoncashExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000684"
      unitRef="USD">-37450</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000689"
      unitRef="USD">-1409</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000690"
      unitRef="USD">3043</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000692"
      unitRef="USD">41462</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000693"
      unitRef="USD">362329</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000695"
      unitRef="USD">17817</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000696"
      unitRef="USD">7438</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000698"
      unitRef="USD">24850</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000699"
      unitRef="USD">-186804</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000701"
      unitRef="USD">12835</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000702"
      unitRef="USD">13982</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000704"
      unitRef="USD">-62127</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000705"
      unitRef="USD">-361479</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000707"
      unitRef="USD">-9391</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000708"
      unitRef="USD">-3298</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000710"
      unitRef="USD">-5825</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000711"
      unitRef="USD">2723</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000713"
      unitRef="USD">-1970250</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000714"
      unitRef="USD">-1939067</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000720"
      unitRef="USD">2491</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000723"
      unitRef="USD">-2491</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000729"
      unitRef="USD">100000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000731"
      unitRef="USD">2000000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000735"
      unitRef="USD">203350</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000738"
      unitRef="USD">671777</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000740"
      unitRef="USD">96652</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000741"
      unitRef="USD">150808</us-gaap:RepaymentsOfRelatedPartyDebt>
    <PPCB:PurchaseOfTreasuryShares
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000743"
      unitRef="USD">499224</PPCB:PurchaseOfTreasuryShares>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000747"
      unitRef="USD">3314458</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000750"
      unitRef="USD">75000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000753"
      unitRef="USD">78249</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000756"
      unitRef="USD">15000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000758"
      unitRef="USD">1404124</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000759"
      unitRef="USD">2526772</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000761"
      unitRef="USD">-7514</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000762"
      unitRef="USD">5435</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000764"
      unitRef="USD">-573640</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000765"
      unitRef="USD">590649</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000767"
      unitRef="USD">832006</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000768"
      unitRef="USD">12088</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000770"
      unitRef="USD">258366</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000771"
      unitRef="USD">602737</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000779"
      unitRef="USD">26991</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000780"
      unitRef="USD">115691</us-gaap:InterestPaidNet>
    <PPCB:ReductionOfPutPremiumRelatedToConversionsOfConvertibleNotes
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000789"
      unitRef="USD">114399</PPCB:ReductionOfPutPremiumRelatedToConversionsOfConvertibleNotes>
    <PPCB:ConversionOfConvertibleNotesAndAccruedInterestToCommonStock
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000792"
      unitRef="USD">335850</PPCB:ConversionOfConvertibleNotesAndAccruedInterestToCommonStock>
    <PPCB:DefferredOfferingCostChargedToAdditionalPaidInCapitalUponClosingOfOffering
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000795"
      unitRef="USD">281773</PPCB:DefferredOfferingCostChargedToAdditionalPaidInCapitalUponClosingOfOffering>
    <PPCB:IssuanceOfCommonStockForPrepaidServicesNetOfAmortizedPortion
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000798"
      unitRef="USD">682500</PPCB:IssuanceOfCommonStockForPrepaidServicesNetOfAmortizedPortion>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000800">&lt;p id="xdx_809_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zX0r4Mlsk2Vd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1 &#x2013; &lt;span id="xdx_82A_zWs4kqZDf0pf"&gt;NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--NatureOfOperationsPolicyTextBlock_zaLKh2BXEyo8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zqFodBkLSZr1"&gt;Nature
of Operations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.2pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Propanc
Biopharma, Inc. (the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) is based in Camberwell, Victoria
Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer
treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to
prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product
candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes
acting synergistically. It is currently in the preclinical phase of development.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company was originally formed in Melbourne, Victoria, Australia on October 15, 2007 as Propanc PTY LTD. On November 23, 2010, Propanc
Health Group Corporation was incorporated in the State of Delaware, and in January 2011, to reorganize the Company, all of the outstanding
shares of Propanc PTY LTD were acquired on a one-for-one basis by Propanc Health Group Corporation, with Propanc PTY LTD becoming a wholly-owned
subsidiary of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 22, 2016, the Company formed another wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose
of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of September 30,
2026, there has been no activity within this entity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
April 20, 2017, the Company changed its name to &#x201c;Propanc Biopharma, Inc.&#x201d; to reflect the Company&#x2019;s stage of operations
and development better.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 85 granted,
allowed, or accepted patents and 5 provisional patents filed, or under examination in key global jurisdictions relating to the use of
proenzymes against solid tumors, covering the lead product candidate PRP.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company hopes to capture and protect additional patentable subject matter based on the Company&#x2019;s field of technology relating to
pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product
candidate, PRP, through various stages of development.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2026, the Company received written consent in lieu of a meeting by the holders of a majority of the voting power of the Company&#x2019;s
outstanding capital stock as of March 2026 and the Company&#x2019;s Board of Directors approving such actions as are necessary for the
Company to proceed to effectuate and execute a reverse stock split of &lt;span id="xdx_906_eus-gaap--StockholdersEquityReverseStockSplit_c20260301__20260331_zHLWe2DJngz8" title="Stockholders equity reverse stock split details"&gt;the Company&#x2019;s issued and outstanding shares of common stock at a ratio of one post-split share per twenty-five pre-split shares (1:25)&lt;/span&gt;. The reverse stock split became effective as of May 18, 2026.
Proportional adjustments for the reverse stock split were made to the Company&#x2019;s outstanding stock options, warrants and equity
incentive plans. All share and per-share data and amounts have been retroactively adjusted as of the earliest period presented in the
consolidated financial statements to reflect the reverse stock split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2026, the Company received written consent in lieu of a meeting by the holders of a majority of the voting power of the Company&#x2019;s
outstanding capital stock as of October 2026 and the Company&#x2019;s Board of Directors approving such actions as are necessary for the
Company to proceed to effectuate and execute a reverse stock split of &lt;span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20261001__20261031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHkDUzXmLUQ4" title="Reverse stock split description"&gt;the Company&#x2019;s issued and outstanding shares of common stock
at a ratio of one post-split share per ten pre-split shares (1:10) (the &#x201c;Reverse Stock Split&#x201d;)&lt;/span&gt;. The Reverse Stock Split became
effective as of October 26, 2026. Proportional adjustments for the Reverse Stock Split were made to the Company&#x2019;s outstanding stock
options, warrants and equity incentive plans. All share and per-share data and amounts have been retroactively adjusted as of the earliest
period presented in the consolidated financial statements to reflect the Reverse Stock Split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoHJiXKtBa0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_z94GYgTRJ1G7"&gt;Basis
of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s interim unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q (this &#x201c;Quarterly
Report&#x201d;) have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;US
GAAP&#x201d;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;). In the opinion
of the Company&#x2019;s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring
adjustments) necessary to present fairly our consolidated results of operations for the three months ended September 30, 2026 and 2025
and cash flows for the three months ended September 30, 2026 and 2025 and our consolidated financial position at September 30, 2026 have
been made. The Company&#x2019;s results of operations for the three months ended September 30, 2026 are not necessarily indicative of
the operating results to be expected for the full fiscal year ending June 30, 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
information and disclosures normally included in the notes to the Company&#x2019;s annual audited consolidated financial statements have
been condensed or omitted from the Company&#x2019;s interim unaudited condensed consolidated financial statements included in this Quarterly
Report. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s
audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2026. The June 30, 2026 balance sheet
is derived from those statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zaBiJwrH93ml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zCgcCDr2AO23"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned
subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited
was an inactive wholly-owned subsidiary through September 30, 2026 and still remains inactive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPANC
BIOPHARMA, INC. AND SUBSIDIARY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--UseOfEstimates_zWLj2U5OYB35" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zaq4kyGYKhrj"&gt;Use
of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives of long-lived assets,
valuation of the collectability of a refundable advance deposit, present value of the operating lease liability and related right-of-use
asset, valuation of derivatives, valuation of convertible preferred stock, valuation of warrant liability, valuation of equity based
instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain
average exchange rates applied in lieu of spot rates on transaction dates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zBudQeIcibn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_z7f14awlHCbi"&gt;Foreign
Currency Translation and Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s wholly-owned subsidiary&#x2019;s functional currency is the Australian dollar (AUD). For financial reporting purposes,
the Australian dollar has been translated into the Company&#x2019;s reporting currency, which is the United States dollar ($) and/or (USD).
Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated
at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction
date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component
of stockholders&#x2019; equity (deficit) as &#x201c;Accumulated other comprehensive income (loss).&#x201d; Gains and losses resulting from
foreign currency translations are included in the statements of operations and comprehensive income (loss) as a component of other comprehensive
income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after
the balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets
and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the
consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated
in a currency other than the functional currency included in the consolidated results of operations as incurred. Effective fiscal year
2021, the parent company determined that the intercompany loans will not be repaid in the foreseeable future and thus, per Accounting
Standards Codification (&#x201c;ASC&#x201d;) 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within
cumulative translation adjustment, a component of accumulated other comprehensive income (loss). As of September 30, 2026 and 2025, the
Company recognized a cumulative exchange gain (loss) of approximately $&lt;span id="xdx_907_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_c20260701__20260930_zAEZ7USnsy7g" title="Foreign currency transaction gain loss"&gt;91,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_c20250701__20250930_zUBejZ38os4k" title="Foreign currency translation gain (loss)"&gt;191,000&lt;/span&gt;, respectively, on intercompany loans made
by the parent to the subsidiary that have not been repaid as of September 30, 2026, which is included as a component of accumulated other
comprehensive income on the accompanying condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock_zQG9I6Tk4GUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2026 and June 30, 2026, the exchange rates used to translate amounts in Australian dollars into USD for the purposes
of preparing the consolidated financial statements were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_z2PnnvCzX1Y1" style="display: none"&gt;SCHEDULE OF TRANSACTION EXCHANGE RATES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;br/&gt;
2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt;
2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Exchange rate on balance sheet dates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;USD : AUD exchange rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20260930_zseTlpVPsCVb" style="width: 16%; text-align: right" title="Foreign currency exchange rate, translation"&gt;0.6949&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20260630_z3FfUXDF10Z" style="width: 16%; text-align: right" title="Foreign currency exchange rate, translation"&gt;0.6912&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Average exchange rate for the period&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;USD : AUD exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20260930__srt--RangeAxis__srt--WeightedAverageMember_zZ6ljGqLGvPf" style="text-align: right" title="Foreign currency exchange rate, translation"&gt;0.7063&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20260630__srt--RangeAxis__srt--WeightedAverageMember_zeXkjLoU7WX6" style="text-align: right" title="Foreign currency exchange rate, translation"&gt;0.6771&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zkHEaN8Af5Sg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_zGX042nJ11k3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
change in Accumulated Other Comprehensive Income (Loss) by component during the three months ended September 30, 2026 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zOs1cDp0LII1" style="display: none"&gt;SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Foreign&lt;br/&gt; Currency Items:&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%"&gt;Balance, June 30, 2026&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iS_pp0p0_c20260701__20260930_znlrWGx3sOhb" style="width: 14%; text-align: right" title="Beginning balance"&gt;1,176,255&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Unrealized foreign currency translation loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_pp0p0_c20260701__20260930_zJWpBPMps5D" style="border-bottom: Black 1pt solid; text-align: right" title="Unrealized foreign currency translation loss"&gt;(39,576&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance, September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iE_pp0p0_c20260701__20260930_zQ47vdASwj2c" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance"&gt;1,136,679&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_z76MGzZKmNOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z6YNLNUDMSik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zl9q1qXcmpx1"&gt;Fair
Value of Financial Instruments and Fair Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and
cash equivalents, receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short
maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest
rates available for debt with similar terms and maturities are substantially the same.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring
fair value and requires certain disclosures. This standard does not require any new fair value measurements but rather applies to all
other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related
to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income
approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement
cost).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPANC
BIOPHARMA, INC. AND SUBSIDIARY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad
levels. The following is a brief description of those three levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us,
which reflect those that a market participant would use.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zjggX2IOFzV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zoE94Jo9MVn6"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial
institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were &lt;span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20260930_ztIx83ETgGU2" title="Cash and cash equivalents"&gt;&lt;span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20260630_z74j9bY9Wy6a" title="Cash and cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt; cash equivalents
as of September 30, 2026 or June 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--PrepaidExpensesPolicyTextBlock_zqYktAifn95h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zpQzEwJ6hAP1"&gt;Prepaid
expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses &#x2013; current portion and long-term portion of $&lt;span id="xdx_90D_eus-gaap--PrepaidExpenseCurrent_iI_c20260930_zxetdqyrUTdj" title="Prepaid expenses, current"&gt;7,674,443&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--PrepaidExpenseNoncurrent_iI_c20260930_znXLp9gEw8sj" title="Prepaid expenses,  non current"&gt;2,287,540&lt;/span&gt;, respectively, at September 30, 2026, consist primarily
of costs paid for future services which will occur between 1 month to three years. Prepaid expenses &#x2013; current portion and long-term
portion of $&lt;span id="xdx_904_eus-gaap--PrepaidExpenseCurrent_iI_c20260630_zFUbdIac6CWl" title="Prepaid expenses, current"&gt;7,661,967&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--PrepaidExpenseNoncurrent_iI_c20260630_zsjY1VrbZVdf" title="Prepaid expenses, long-term portion"&gt;4,190,543&lt;/span&gt;, respectively, at June 30, 2026, consist primarily of costs paid for future services which will
occur between 6 months to three years. Prepaid expenses principally include prepayments in fully vested, non-forfeitable equity instruments
for general consulting, investor relations, and business advisory services, which are being amortized over the terms of their respective
agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zT593t9Jowi5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zYUeycbfDq6b"&gt;Property
and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred;
additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost
and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of
property and equipment is provided using the straight line method. The depreciable amount is the cost less its residual value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_ecustom--ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock_zBaeMU4e9QT9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated useful lives are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zCzv5ciYjbdf" style="display: none"&gt;SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 30%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery
    and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 70%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_z3rITwvWwfn7" title="Property plant and equipment, useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    &lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zIDkKACL4Nx6" title="Property plant and equipment, useful life"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_zmLYRMlOkNNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zD9Ju1lyQg0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zAGbhPuR53Id"&gt;Patents&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Patents
are stated at cost and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by
a regulatory agency. However, the Company will expense any patent costs as long as we are in the startup stage. Accordingly, as the Company&#x2019;s
products are not currently approved for market, all patent costs incurred from 2013 through September 30, 2026 were expensed immediately.
This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zNrtgrpdIEk8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zZVK2xSFDQW4"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC 360-10, &#x201c;Long-lived assets,&#x201d; which include property and equipment and intangible assets, are reviewed
for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability
of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted
future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future
cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the
assets. Fair value is generally determined using the asset&#x2019;s expected future discounted cash flows or market value, if readily
determinable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--EmployeeStockOwnershipPlanESOPPolicy_zyhs7haEH6bd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zPTSDdkrxY43"&gt;Employee
Benefit/Liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liabilities
arising in respect of wages and salaries, accumulated annual leave, accumulated long service leave and any other employee benefits expected
to be settled within twelve months of the reporting date are measured based on the employee&#x2019;s remuneration rates applicable at
the reporting date. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to
be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve
months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_ecustom--GoodsAndServicesTaxPolicyTextBlock_z649QFpmFCE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zMt6saGLp4Hg"&gt;Australian
Goods and Services Tax (&#x201c;GST&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues,
expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive
of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPANC
BIOPHARMA, INC. AND SUBSIDIARY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities,
which are disclosed as operating cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2026 and June 30, 2026, the Company was owed $&lt;span id="xdx_909_ecustom--GoodsAndServicesTaxReceivableCurrent_iI_c20260930_z9DJoh9sr5U2" title="GST tax receivable"&gt;12,359&lt;/span&gt; and $&lt;span id="xdx_901_ecustom--GoodsAndServicesTaxReceivableCurrent_iI_c20260630_zGVXcXJdlUb2" title="GST tax receivable"&gt;13,694&lt;/span&gt;, respectively, from the Australian Taxation Office.
These amounts were fully collected subsequent to the balance sheet reporting dates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--DerivativesPolicyTextBlock_z9cjqIrvc3Yf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_ziHpic4jqkt3"&gt;Derivative
Instruments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
Topic 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt; (&#x201c;ASC Topic 815&#x201d;), establishes accounting and reporting standards for derivative
instruments and for hedging activities by requiring that all derivatives be recognized in the balance sheet and measured at fair value.
Gains or losses resulting from changes in the fair value of derivatives are recognized in earnings. On the date of conversion or payoff
of debt, the Company records the fair value of the conversion shares, removes the fair value of the related derivative liability, removes
any discounts and records a net gain or loss on debt extinguishment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--ConvertibleNotesPolicyTextBlock_zONSt1paMwoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zkb3kCzPWguc"&gt;Convertible
Notes With Variable Conversion Options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and
accrued interest may be converted, by the holder, into shares of the Company&#x2019;s common stock, par value $&lt;span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260930_zXlrXPsOqtfi" title="Common stock, par value"&gt;0.001&lt;/span&gt; per share (&#x201c;common
stock&#x201d;) at a fixed discount to the price of the common stock at or around the time of conversion. The Company treats these convertible
notes as stock settled debt under ASC 480, &#x201c;&lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;&#x201d; and measures the fair value of
the notes at the time of issuance, which is the result of the share price discount at the time of conversion and records the put premium
as interest expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--WarrantLiabilityPolicyTextBlock_zgPo2emy80qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zhoIJvDpMQ0e"&gt;Warrant
Liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounted for the Series C warrants issued in November 2025, in accordance with the guidance contained in ASC 815 &#x201c;Derivatives
and Hedging&#x201d; whereby under that provision these warrants do not meet the criteria for equity treatment and must be recorded as
a liability. Accordingly, the Company classified these warrant instruments as liabilities at fair value and adjusted the instruments
to fair value at each reporting period. This liability was re-measured at each balance sheet date until the warrants were exercised or
expire, and any change in fair value were recognized in the Company&#x2019;s statement of operations. The fair value of these warrants
was estimated using a Monte Carlo simulation model. Such warrant classification was also subject to re-evaluation at each reporting period
(see Note 5).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_zS5ZlNoqHFX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_z2hZEmFtC8Al"&gt;Series
C Preferred Stock Subject to Possible Redemption&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounted for its Series C Convertible Preferred Stock subject to possible redemption in accordance with the guidance in ASC
Topic 480 &#x201c;Distinguishing Liabilities from Equity.&#x201d; Conditionally redeemable Series C Preferred stock that featured mandatory
redemption rights not solely within the Company&#x2019;s control was classified as temporary equity. The Company&#x2019;s Series C Preferred
stock features certain redemption rights that were considered to be outside of the Company&#x2019;s control and subject to occurrence
of uncertain future events. Accordingly, Series C preferred stock subject to possible redemption was presented at redemption value as
temporary equity, outside of the stockholders&#x2019; equity section of the Company&#x2019;s consolidated balance sheets (see Note 5).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zdHl53FQLlmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_z6yvIvuBYWK4"&gt;Income
Taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.2pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the
United States Internal Revenue Service, respectively. The Company follows ASC 740 &#x201c;&lt;i&gt;Accounting for Income Taxes&lt;/i&gt;,&#x201d; when
accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred
income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets
and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the
periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce
deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or
minus the change during the period in deferred tax assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows ASC 740, Sections 25 through 60, &#x201c;&lt;i&gt;Accounting for Uncertainty in Income Taxes&lt;/i&gt;.&#x201d; These sections provide
detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial
statements. Tax positions must meet a &#x201c;more-likely-than-not&#x201d; recognition threshold at the effective date to be recognized
upon the adoption of ASC 740 and in subsequent periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zjFi5Hk3PMse" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zFgbRGEh63M2"&gt;Research
and Development Costs and Tax Credits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC 730-10, &lt;i&gt;&#x201c;Research and Development-Overall,&#x201d;&lt;/i&gt; research and development costs are expensed when incurred.
Total research and development costs for the three months ended September 30, 2026 and 2025 were $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20260701__20260930_zi0Nyfid35zj" title="Research and development costs"&gt;457,677&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20250701__20250930_ztjVqY9bRCT1" title="Research and development costs"&gt;60,201&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount
is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the
Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The
tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income
tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company&#x2019;s
net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate
is applied to that gross amount. The concession is recognized as a tax benefit, in operations, upon receipt.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPANC
BIOPHARMA, INC. AND SUBSIDIARY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zcc8lfNEKhPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zgKyhTDVcGib"&gt;Stock
Based Compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records stock-based compensation in accordance with ASC 718, &#x201c;&lt;i&gt;Stock Compensation&lt;/i&gt;&#x201d;. ASC 718 requires the fair
value of all stock-based employee compensation awarded to employees to be recorded as an expense over the shorter of the service period
or the vesting period. The Company values employee and non-employee stock-based compensation at fair value using the Black-Scholes Option
Pricing Model.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria
of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of
adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zfIVbeTRZRGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_z6KiqhEgaiNg"&gt;Revenue
Recognition&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies ASC Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). ASC 606 establishes a single comprehensive
model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue
recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers
in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also
requires certain additional disclosures. Subject to these criteria, the Company intends to recognize revenue relating to royalties on
product sales in the period in which the sale occurs and the royalty term has begun.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--LegalCostsPolicyTextBlock_zIoyRbOkqxsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zdsTAYeCWgV1"&gt;Legal
Expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
legal costs for litigation are charged to expense as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--LesseeLeasesPolicyTextBlock_zYUh2XROi4wj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zdlgVlybuVVl"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows ASC Topic 842, Leases (Topic 842) and applies the package of practical expedients, which permit it not to reassess under
the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company
elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less. Operating lease right of use assets (&#x201c;ROU&#x201d;)
represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value
of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company
uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future
payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general
and administrative expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zxRXPqRZ7MVd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zr7MBZ4uKete"&gt;Basic
and Diluted Net Loss Per Common Share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period.
Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for
the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental
common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially
dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share
amounts for all periods presented are identical. The Company&#x2019;s CEO holds Series B Preferred Stock that, when combined, confers
upon him a majority vote, including regarding authorization of additional common shares and/or the authorization of a reverse split the
stock as considered necessary. Such securities are considered dilutive securities which were excluded from the computation since the
effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zUumyWbU1ACa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zYOxXlEVOUqk" style="display: none"&gt;SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Stock Warrants with no designations&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTjCdVO8d2eb" style="width: 14%; text-align: right" title="Warrants with no designations"&gt;120&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zRnM2pErScql" style="width: 14%; text-align: right" title="Warrants with no designations"&gt;121&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Series C Preferred Stock Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCPreferredStockWarrantsMember_zzt7TGKw9uql" style="text-align: right" title="Series C Preferred Stock Warrants"&gt;23,459,532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCPreferredStockWarrantsMember_zXIJvIUG9Cfk" style="text-align: right" title="Series C Preferred Stock Warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0912"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Convertible Series C Preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesCPreferredStockMember_ziSSrYnDtDT2" style="text-align: right" title="Convertible Series C Preferred stock"&gt;374,354&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesCPreferredStockMember_zsZRHPNWiU01" style="text-align: right" title="Convertible Series C Preferred stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Convertible Debt&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z7Un7sdmy6rb" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible Debt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0918"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zQuDbIxU20wl" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible Debt"&gt;514&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260701__20260930_zBYOxxetPR7l" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities"&gt;23,834,006&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250701__20250930_zAWcgptKlCHd" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities"&gt;635&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A6_zpAvYAnKl0Eg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z9rVAdgjyScg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zD3mEK4MiIF8"&gt;Segment
Reporting&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses &#x201c;the management approach&#x201d; in determining reportable operating segments. Operating segments are defined as components
of an entity where discrete financial information is evaluated regularly by the chief operating decision maker (&#x201c;CODM&#x201d;).
The management approach considers the internal organization and reporting used by the Company&#x2019;s CODM for making operating decisions
and assessing performance as the source for determining the Company&#x2019;s reportable segments. All activities are related to the development
of cancer treatment and the Company has not commenced commercial operations or generated revenues to date. All activities are related
to the development of the cancer treatment and the Company has not commenced commercial operations or generated revenues to date. The
CODM is the chief executive officer of the Company, who reviews operating results and utilizes consolidated financial information, including
operating expenses, operating loss, and net loss as reported on the consolidated statements of operations, to make decisions about operating
decisions, allocate resources and assess performance for the entire Company. Consolidated net loss is our segment&#x2019;s primary measure
of loss. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets. The single segment
constitutes all the consolidated entity, and the accompanying consolidated financial statements and the notes to the accompanying consolidated
financial statements are representative of such amounts. For the three months ended September 30, 2026 and 2025, the Company operates
in &lt;span id="xdx_90D_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20260701__20260930_zxnYqhxgnTDc" title="Number of operating segments"&gt;&lt;span id="xdx_903_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20250701__20250930_z8ubGEx7qFV2" title="Number of operating segments"&gt;one&lt;/span&gt;&lt;/span&gt; operating segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPANC
BIOPHARMA, INC. AND SUBSIDIARY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_znw0JfKyWuxk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zxXNVmJM31E6"&gt;Reclassifications&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact
on the Company&#x2019;s previously reported financial position or results of operations or cash flows and relates to the presentation
of $&lt;span id="xdx_901_ecustom--CompensationAndRelatedTaxes_c20250701__20250930_znRydhFq1Mw6" title="Compensation and related taxes"&gt;110,002&lt;/span&gt;
compensation and related taxes and $&lt;span id="xdx_90A_eus-gaap--ProfessionalAndContractServicesExpense_c20250701__20250930_zndtCCq5R8Ul" title="Professional and consulting expenses"&gt;4,351,231&lt;/span&gt;
professional and consulting expenses being reclassified out of administration expenses and shown separately on the consolidated
statements of operations for the three months ended September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z1q1EWfhUDU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_z97sVWqA6zDi"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have reviewed the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;)
accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods.
We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that
any new or modified principles will have a material impact on the Company&#x2019;s reported financial position or operations in the near
term with the exception of those disclosed below. The applicability of any standard is subject to formal review of the Company&#x2019;s
financial management.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 4, 2024 the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (DISE) requiring additional disclosure of the
nature of expenses included in the income statement in response to longstanding requests from investors for more information about an
entity&#x2019;s expenses. This standard requires disclosures about specific types of expenses included in the expense captions presented
on the face of the income statement as well as disclosures about selling expenses. ASU 2024-03 applies to all public business entities
(PBEs) and is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods within annual reporting
periods beginning after December 15, 2027. Management does not believe the adoption of ASU 2024-03 will have a material impact on the
consolidated financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 8, 2025, the FASB issued ASU 2025-11 &#x2013; Interim Reporting (&#x201c;ASU 2025-11&#x201d;) which is intended to improve the
navigability of the guidance in ASC 270, Interim Reporting, and clarify when it applies. Under the amendments, an entity is subject to
ASC 270 if it provides interim financial statements and notes in accordance with GAAP. ASU 2025-11 also addresses the form and content
of such financial statements, interim disclosures requirements, and establishes a principle under which an entity must disclose events
since the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for interim reporting
periods within annual reporting periods beginning after December 15, 2027 and early adoption is permitted. The Company is currently evaluating
the impact the adoption of ASU 2025-11 may have on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 17, 2025, the FASB issued ASU 2025-12, Codification Improvements. The amendments in this update are to make other incremental
improvements to GAAP and facilitate codification updates for a broad range of Topics arising from technical corrections, unintended application
of the codification, clarifications, and other minor improvements. The resulting amendments are collectively referred to as Codification
improvements. ASU 2025-12 is effective for all entities for annual reporting periods beginning after December 15, 2026, and interim reporting
periods within those annual reporting periods. Management does not believe the adoption of ASU 2025-12 will have a material impact on
the consolidated financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_858_zjenbvttqF56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <PPCB:NatureOfOperationsPolicyTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000802">&lt;p id="xdx_841_ecustom--NatureOfOperationsPolicyTextBlock_zaLKh2BXEyo8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zqFodBkLSZr1"&gt;Nature
of Operations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.2pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Propanc
Biopharma, Inc. (the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) is based in Camberwell, Victoria
Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer
treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to
prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product
candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes
acting synergistically. It is currently in the preclinical phase of development.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company was originally formed in Melbourne, Victoria, Australia on October 15, 2007 as Propanc PTY LTD. On November 23, 2010, Propanc
Health Group Corporation was incorporated in the State of Delaware, and in January 2011, to reorganize the Company, all of the outstanding
shares of Propanc PTY LTD were acquired on a one-for-one basis by Propanc Health Group Corporation, with Propanc PTY LTD becoming a wholly-owned
subsidiary of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 22, 2016, the Company formed another wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose
of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of September 30,
2026, there has been no activity within this entity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
April 20, 2017, the Company changed its name to &#x201c;Propanc Biopharma, Inc.&#x201d; to reflect the Company&#x2019;s stage of operations
and development better.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 85 granted,
allowed, or accepted patents and 5 provisional patents filed, or under examination in key global jurisdictions relating to the use of
proenzymes against solid tumors, covering the lead product candidate PRP.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company hopes to capture and protect additional patentable subject matter based on the Company&#x2019;s field of technology relating to
pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product
candidate, PRP, through various stages of development.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2026, the Company received written consent in lieu of a meeting by the holders of a majority of the voting power of the Company&#x2019;s
outstanding capital stock as of March 2026 and the Company&#x2019;s Board of Directors approving such actions as are necessary for the
Company to proceed to effectuate and execute a reverse stock split of &lt;span id="xdx_906_eus-gaap--StockholdersEquityReverseStockSplit_c20260301__20260331_zHLWe2DJngz8" title="Stockholders equity reverse stock split details"&gt;the Company&#x2019;s issued and outstanding shares of common stock at a ratio of one post-split share per twenty-five pre-split shares (1:25)&lt;/span&gt;. The reverse stock split became effective as of May 18, 2026.
Proportional adjustments for the reverse stock split were made to the Company&#x2019;s outstanding stock options, warrants and equity
incentive plans. All share and per-share data and amounts have been retroactively adjusted as of the earliest period presented in the
consolidated financial statements to reflect the reverse stock split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2026, the Company received written consent in lieu of a meeting by the holders of a majority of the voting power of the Company&#x2019;s
outstanding capital stock as of October 2026 and the Company&#x2019;s Board of Directors approving such actions as are necessary for the
Company to proceed to effectuate and execute a reverse stock split of &lt;span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20261001__20261031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHkDUzXmLUQ4" title="Reverse stock split description"&gt;the Company&#x2019;s issued and outstanding shares of common stock
at a ratio of one post-split share per ten pre-split shares (1:10) (the &#x201c;Reverse Stock Split&#x201d;)&lt;/span&gt;. The Reverse Stock Split became
effective as of October 26, 2026. Proportional adjustments for the Reverse Stock Split were made to the Company&#x2019;s outstanding stock
options, warrants and equity incentive plans. All share and per-share data and amounts have been retroactively adjusted as of the earliest
period presented in the consolidated financial statements to reflect the Reverse Stock Split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</PPCB:NatureOfOperationsPolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2026-03-012026-03-31" id="Fact000804">the Company&#x2019;s issued and outstanding shares of common stock at a ratio of one post-split share per twenty-five pre-split shares (1:25)</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2026-10-012026-10-31_us-gaap_SubsequentEventMember"
      id="Fact000806">the Company&#x2019;s issued and outstanding shares of common stock
at a ratio of one post-split share per ten pre-split shares (1:10) (the &#x201c;Reverse Stock Split&#x201d;)</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000808">&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoHJiXKtBa0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_z94GYgTRJ1G7"&gt;Basis
of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s interim unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q (this &#x201c;Quarterly
Report&#x201d;) have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;US
GAAP&#x201d;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;). In the opinion
of the Company&#x2019;s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring
adjustments) necessary to present fairly our consolidated results of operations for the three months ended September 30, 2026 and 2025
and cash flows for the three months ended September 30, 2026 and 2025 and our consolidated financial position at September 30, 2026 have
been made. The Company&#x2019;s results of operations for the three months ended September 30, 2026 are not necessarily indicative of
the operating results to be expected for the full fiscal year ending June 30, 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
information and disclosures normally included in the notes to the Company&#x2019;s annual audited consolidated financial statements have
been condensed or omitted from the Company&#x2019;s interim unaudited condensed consolidated financial statements included in this Quarterly
Report. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s
audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2026. The June 30, 2026 balance sheet
is derived from those statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000810">&lt;p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zaBiJwrH93ml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zCgcCDr2AO23"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned
subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited
was an inactive wholly-owned subsidiary through September 30, 2026 and still remains inactive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPANC
BIOPHARMA, INC. AND SUBSIDIARY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2026-07-01to2026-09-30" id="Fact000812">&lt;p id="xdx_84F_eus-gaap--UseOfEstimates_zWLj2U5OYB35" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zaq4kyGYKhrj"&gt;Use
of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives of long-lived assets,
valuation of the collectability of a refundable advance deposit, present value of the operating lease liability and related right-of-use
asset, valuation of derivatives, valuation of convertible preferred stock, valuation of warrant liability, valuation of equity based
instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain
average exchange rates applied in lieu of spot rates on transaction dates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000814">&lt;p id="xdx_847_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zBudQeIcibn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_z7f14awlHCbi"&gt;Foreign
Currency Translation and Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s wholly-owned subsidiary&#x2019;s functional currency is the Australian dollar (AUD). For financial reporting purposes,
the Australian dollar has been translated into the Company&#x2019;s reporting currency, which is the United States dollar ($) and/or (USD).
Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated
at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction
date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component
of stockholders&#x2019; equity (deficit) as &#x201c;Accumulated other comprehensive income (loss).&#x201d; Gains and losses resulting from
foreign currency translations are included in the statements of operations and comprehensive income (loss) as a component of other comprehensive
income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after
the balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets
and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the
consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated
in a currency other than the functional currency included in the consolidated results of operations as incurred. Effective fiscal year
2021, the parent company determined that the intercompany loans will not be repaid in the foreseeable future and thus, per Accounting
Standards Codification (&#x201c;ASC&#x201d;) 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within
cumulative translation adjustment, a component of accumulated other comprehensive income (loss). As of September 30, 2026 and 2025, the
Company recognized a cumulative exchange gain (loss) of approximately $&lt;span id="xdx_907_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_c20260701__20260930_zAEZ7USnsy7g" title="Foreign currency transaction gain loss"&gt;91,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_c20250701__20250930_zUBejZ38os4k" title="Foreign currency translation gain (loss)"&gt;191,000&lt;/span&gt;, respectively, on intercompany loans made
by the parent to the subsidiary that have not been repaid as of September 30, 2026, which is included as a component of accumulated other
comprehensive income on the accompanying condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock_zQG9I6Tk4GUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2026 and June 30, 2026, the exchange rates used to translate amounts in Australian dollars into USD for the purposes
of preparing the consolidated financial statements were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_z2PnnvCzX1Y1" style="display: none"&gt;SCHEDULE OF TRANSACTION EXCHANGE RATES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;br/&gt;
2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt;
2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Exchange rate on balance sheet dates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;USD : AUD exchange rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20260930_zseTlpVPsCVb" style="width: 16%; text-align: right" title="Foreign currency exchange rate, translation"&gt;0.6949&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20260630_z3FfUXDF10Z" style="width: 16%; text-align: right" title="Foreign currency exchange rate, translation"&gt;0.6912&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Average exchange rate for the period&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;USD : AUD exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20260930__srt--RangeAxis__srt--WeightedAverageMember_zZ6ljGqLGvPf" style="text-align: right" title="Foreign currency exchange rate, translation"&gt;0.7063&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20260630__srt--RangeAxis__srt--WeightedAverageMember_zeXkjLoU7WX6" style="text-align: right" title="Foreign currency exchange rate, translation"&gt;0.6771&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zkHEaN8Af5Sg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_zGX042nJ11k3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
change in Accumulated Other Comprehensive Income (Loss) by component during the three months ended September 30, 2026 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zOs1cDp0LII1" style="display: none"&gt;SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Foreign&lt;br/&gt; Currency Items:&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%"&gt;Balance, June 30, 2026&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iS_pp0p0_c20260701__20260930_znlrWGx3sOhb" style="width: 14%; text-align: right" title="Beginning balance"&gt;1,176,255&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Unrealized foreign currency translation loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_pp0p0_c20260701__20260930_zJWpBPMps5D" style="border-bottom: Black 1pt solid; text-align: right" title="Unrealized foreign currency translation loss"&gt;(39,576&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance, September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iE_pp0p0_c20260701__20260930_zQ47vdASwj2c" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance"&gt;1,136,679&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_z76MGzZKmNOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000816"
      unitRef="USD">91000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000818"
      unitRef="USD">191000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000820">&lt;p id="xdx_894_eus-gaap--ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock_zQG9I6Tk4GUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2026 and June 30, 2026, the exchange rates used to translate amounts in Australian dollars into USD for the purposes
of preparing the consolidated financial statements were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_z2PnnvCzX1Y1" style="display: none"&gt;SCHEDULE OF TRANSACTION EXCHANGE RATES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;br/&gt;
2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt;
2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Exchange rate on balance sheet dates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;USD : AUD exchange rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20260930_zseTlpVPsCVb" style="width: 16%; text-align: right" title="Foreign currency exchange rate, translation"&gt;0.6949&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20260630_z3FfUXDF10Z" style="width: 16%; text-align: right" title="Foreign currency exchange rate, translation"&gt;0.6912&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Average exchange rate for the period&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;USD : AUD exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20260930__srt--RangeAxis__srt--WeightedAverageMember_zZ6ljGqLGvPf" style="text-align: right" title="Foreign currency exchange rate, translation"&gt;0.7063&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20260630__srt--RangeAxis__srt--WeightedAverageMember_zeXkjLoU7WX6" style="text-align: right" title="Foreign currency exchange rate, translation"&gt;0.6771&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000822"
      unitRef="Pure">0.6949</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="AsOf2026-06-30"
      decimals="INF"
      id="Fact000824"
      unitRef="Pure">0.6912</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="AsOf2026-09-30_srt_WeightedAverageMember"
      decimals="INF"
      id="Fact000826"
      unitRef="Pure">0.7063</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="AsOf2026-06-30_srt_WeightedAverageMember"
      decimals="INF"
      id="Fact000828"
      unitRef="Pure">0.6771</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000830">&lt;p id="xdx_891_eus-gaap--ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_zGX042nJ11k3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
change in Accumulated Other Comprehensive Income (Loss) by component during the three months ended September 30, 2026 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zOs1cDp0LII1" style="display: none"&gt;SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Foreign&lt;br/&gt; Currency Items:&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%"&gt;Balance, June 30, 2026&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iS_pp0p0_c20260701__20260930_znlrWGx3sOhb" style="width: 14%; text-align: right" title="Beginning balance"&gt;1,176,255&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Unrealized foreign currency translation loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_pp0p0_c20260701__20260930_zJWpBPMps5D" style="border-bottom: Black 1pt solid; text-align: right" title="Unrealized foreign currency translation loss"&gt;(39,576&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance, September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iE_pp0p0_c20260701__20260930_zQ47vdASwj2c" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance"&gt;1,136,679&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000832"
      unitRef="USD">1176255</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000834"
      unitRef="USD">-39576</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000836"
      unitRef="USD">1136679</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2026-07-01to2026-09-30" id="Fact000838">&lt;p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z6YNLNUDMSik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zl9q1qXcmpx1"&gt;Fair
Value of Financial Instruments and Fair Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and
cash equivalents, receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short
maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest
rates available for debt with similar terms and maturities are substantially the same.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring
fair value and requires certain disclosures. This standard does not require any new fair value measurements but rather applies to all
other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related
to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income
approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement
cost).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPANC
BIOPHARMA, INC. AND SUBSIDIARY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad
levels. The following is a brief description of those three levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us,
which reflect those that a market participant would use.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000840">&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zjggX2IOFzV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zoE94Jo9MVn6"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial
institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were &lt;span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20260930_ztIx83ETgGU2" title="Cash and cash equivalents"&gt;&lt;span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20260630_z74j9bY9Wy6a" title="Cash and cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt; cash equivalents
as of September 30, 2026 or June 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000842"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000844"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <PPCB:PrepaidExpensesPolicyTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000846">&lt;p id="xdx_849_ecustom--PrepaidExpensesPolicyTextBlock_zqYktAifn95h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zpQzEwJ6hAP1"&gt;Prepaid
expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses &#x2013; current portion and long-term portion of $&lt;span id="xdx_90D_eus-gaap--PrepaidExpenseCurrent_iI_c20260930_zxetdqyrUTdj" title="Prepaid expenses, current"&gt;7,674,443&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--PrepaidExpenseNoncurrent_iI_c20260930_znXLp9gEw8sj" title="Prepaid expenses,  non current"&gt;2,287,540&lt;/span&gt;, respectively, at September 30, 2026, consist primarily
of costs paid for future services which will occur between 1 month to three years. Prepaid expenses &#x2013; current portion and long-term
portion of $&lt;span id="xdx_904_eus-gaap--PrepaidExpenseCurrent_iI_c20260630_zFUbdIac6CWl" title="Prepaid expenses, current"&gt;7,661,967&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--PrepaidExpenseNoncurrent_iI_c20260630_zsjY1VrbZVdf" title="Prepaid expenses, long-term portion"&gt;4,190,543&lt;/span&gt;, respectively, at June 30, 2026, consist primarily of costs paid for future services which will
occur between 6 months to three years. Prepaid expenses principally include prepayments in fully vested, non-forfeitable equity instruments
for general consulting, investor relations, and business advisory services, which are being amortized over the terms of their respective
agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</PPCB:PrepaidExpensesPolicyTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000848"
      unitRef="USD">7674443</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000850"
      unitRef="USD">2287540</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000852"
      unitRef="USD">7661967</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000854"
      unitRef="USD">4190543</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000856">&lt;p id="xdx_844_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zT593t9Jowi5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zYUeycbfDq6b"&gt;Property
and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred;
additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost
and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of
property and equipment is provided using the straight line method. The depreciable amount is the cost less its residual value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_ecustom--ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock_zBaeMU4e9QT9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated useful lives are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zCzv5ciYjbdf" style="display: none"&gt;SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 30%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery
    and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 70%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_z3rITwvWwfn7" title="Property plant and equipment, useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    &lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zIDkKACL4Nx6" title="Property plant and equipment, useful life"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_zmLYRMlOkNNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <PPCB:ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000858">&lt;p id="xdx_895_ecustom--ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock_zBaeMU4e9QT9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated useful lives are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zCzv5ciYjbdf" style="display: none"&gt;SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 30%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery
    and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 70%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_z3rITwvWwfn7" title="Property plant and equipment, useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    &lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zIDkKACL4Nx6" title="Property plant and equipment, useful life"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</PPCB:ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2026-09-30_us-gaap_MachineryAndEquipmentMember"
      id="Fact000860">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2026-09-30_us-gaap_FurnitureAndFixturesMember"
      id="Fact000862">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="From2026-07-01to2026-09-30" id="Fact000864">&lt;p id="xdx_845_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zD9Ju1lyQg0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zAGbhPuR53Id"&gt;Patents&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Patents
are stated at cost and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by
a regulatory agency. However, the Company will expense any patent costs as long as we are in the startup stage. Accordingly, as the Company&#x2019;s
products are not currently approved for market, all patent costs incurred from 2013 through September 30, 2026 were expensed immediately.
This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000866">&lt;p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zNrtgrpdIEk8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zZVK2xSFDQW4"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC 360-10, &#x201c;Long-lived assets,&#x201d; which include property and equipment and intangible assets, are reviewed
for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability
of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted
future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future
cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the
assets. Fair value is generally determined using the asset&#x2019;s expected future discounted cash flows or market value, if readily
determinable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:EmployeeStockOwnershipPlanESOPPolicy contextRef="From2026-07-01to2026-09-30" id="Fact000868">&lt;p id="xdx_849_eus-gaap--EmployeeStockOwnershipPlanESOPPolicy_zyhs7haEH6bd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zPTSDdkrxY43"&gt;Employee
Benefit/Liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liabilities
arising in respect of wages and salaries, accumulated annual leave, accumulated long service leave and any other employee benefits expected
to be settled within twelve months of the reporting date are measured based on the employee&#x2019;s remuneration rates applicable at
the reporting date. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to
be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve
months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EmployeeStockOwnershipPlanESOPPolicy>
    <PPCB:GoodsAndServicesTaxPolicyTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000870">&lt;p id="xdx_847_ecustom--GoodsAndServicesTaxPolicyTextBlock_z649QFpmFCE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zMt6saGLp4Hg"&gt;Australian
Goods and Services Tax (&#x201c;GST&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues,
expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive
of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPANC
BIOPHARMA, INC. AND SUBSIDIARY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities,
which are disclosed as operating cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2026 and June 30, 2026, the Company was owed $&lt;span id="xdx_909_ecustom--GoodsAndServicesTaxReceivableCurrent_iI_c20260930_z9DJoh9sr5U2" title="GST tax receivable"&gt;12,359&lt;/span&gt; and $&lt;span id="xdx_901_ecustom--GoodsAndServicesTaxReceivableCurrent_iI_c20260630_zGVXcXJdlUb2" title="GST tax receivable"&gt;13,694&lt;/span&gt;, respectively, from the Australian Taxation Office.
These amounts were fully collected subsequent to the balance sheet reporting dates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</PPCB:GoodsAndServicesTaxPolicyTextBlock>
    <PPCB:GoodsAndServicesTaxReceivableCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000872"
      unitRef="USD">12359</PPCB:GoodsAndServicesTaxReceivableCurrent>
    <PPCB:GoodsAndServicesTaxReceivableCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000874"
      unitRef="USD">13694</PPCB:GoodsAndServicesTaxReceivableCurrent>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000876">&lt;p id="xdx_84D_eus-gaap--DerivativesPolicyTextBlock_z9cjqIrvc3Yf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_ziHpic4jqkt3"&gt;Derivative
Instruments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
Topic 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt; (&#x201c;ASC Topic 815&#x201d;), establishes accounting and reporting standards for derivative
instruments and for hedging activities by requiring that all derivatives be recognized in the balance sheet and measured at fair value.
Gains or losses resulting from changes in the fair value of derivatives are recognized in earnings. On the date of conversion or payoff
of debt, the Company records the fair value of the conversion shares, removes the fair value of the related derivative liability, removes
any discounts and records a net gain or loss on debt extinguishment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <PPCB:ConvertibleNotesPolicyTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000878">&lt;p id="xdx_84E_ecustom--ConvertibleNotesPolicyTextBlock_zONSt1paMwoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zkb3kCzPWguc"&gt;Convertible
Notes With Variable Conversion Options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and
accrued interest may be converted, by the holder, into shares of the Company&#x2019;s common stock, par value $&lt;span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260930_zXlrXPsOqtfi" title="Common stock, par value"&gt;0.001&lt;/span&gt; per share (&#x201c;common
stock&#x201d;) at a fixed discount to the price of the common stock at or around the time of conversion. The Company treats these convertible
notes as stock settled debt under ASC 480, &#x201c;&lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;&#x201d; and measures the fair value of
the notes at the time of issuance, which is the result of the share price discount at the time of conversion and records the put premium
as interest expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</PPCB:ConvertibleNotesPolicyTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000880"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <PPCB:WarrantLiabilityPolicyTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000882">&lt;p id="xdx_84F_ecustom--WarrantLiabilityPolicyTextBlock_zgPo2emy80qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zhoIJvDpMQ0e"&gt;Warrant
Liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounted for the Series C warrants issued in November 2025, in accordance with the guidance contained in ASC 815 &#x201c;Derivatives
and Hedging&#x201d; whereby under that provision these warrants do not meet the criteria for equity treatment and must be recorded as
a liability. Accordingly, the Company classified these warrant instruments as liabilities at fair value and adjusted the instruments
to fair value at each reporting period. This liability was re-measured at each balance sheet date until the warrants were exercised or
expire, and any change in fair value were recognized in the Company&#x2019;s statement of operations. The fair value of these warrants
was estimated using a Monte Carlo simulation model. Such warrant classification was also subject to re-evaluation at each reporting period
(see Note 5).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</PPCB:WarrantLiabilityPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy contextRef="From2026-07-01to2026-09-30" id="Fact000884">&lt;p id="xdx_848_eus-gaap--StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_zS5ZlNoqHFX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_z2hZEmFtC8Al"&gt;Series
C Preferred Stock Subject to Possible Redemption&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounted for its Series C Convertible Preferred Stock subject to possible redemption in accordance with the guidance in ASC
Topic 480 &#x201c;Distinguishing Liabilities from Equity.&#x201d; Conditionally redeemable Series C Preferred stock that featured mandatory
redemption rights not solely within the Company&#x2019;s control was classified as temporary equity. The Company&#x2019;s Series C Preferred
stock features certain redemption rights that were considered to be outside of the Company&#x2019;s control and subject to occurrence
of uncertain future events. Accordingly, Series C preferred stock subject to possible redemption was presented at redemption value as
temporary equity, outside of the stockholders&#x2019; equity section of the Company&#x2019;s consolidated balance sheets (see Note 5).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000886">&lt;p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zdHl53FQLlmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_z6yvIvuBYWK4"&gt;Income
Taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.2pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the
United States Internal Revenue Service, respectively. The Company follows ASC 740 &#x201c;&lt;i&gt;Accounting for Income Taxes&lt;/i&gt;,&#x201d; when
accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred
income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets
and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the
periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce
deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or
minus the change during the period in deferred tax assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows ASC 740, Sections 25 through 60, &#x201c;&lt;i&gt;Accounting for Uncertainty in Income Taxes&lt;/i&gt;.&#x201d; These sections provide
detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial
statements. Tax positions must meet a &#x201c;more-likely-than-not&#x201d; recognition threshold at the effective date to be recognized
upon the adoption of ASC 740 and in subsequent periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2026-07-01to2026-09-30" id="Fact000888">&lt;p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zjFi5Hk3PMse" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zFgbRGEh63M2"&gt;Research
and Development Costs and Tax Credits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC 730-10, &lt;i&gt;&#x201c;Research and Development-Overall,&#x201d;&lt;/i&gt; research and development costs are expensed when incurred.
Total research and development costs for the three months ended September 30, 2026 and 2025 were $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20260701__20260930_zi0Nyfid35zj" title="Research and development costs"&gt;457,677&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20250701__20250930_ztjVqY9bRCT1" title="Research and development costs"&gt;60,201&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount
is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the
Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The
tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income
tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company&#x2019;s
net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate
is applied to that gross amount. The concession is recognized as a tax benefit, in operations, upon receipt.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPANC
BIOPHARMA, INC. AND SUBSIDIARY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000890"
      unitRef="USD">457677</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000892"
      unitRef="USD">60201</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2026-07-01to2026-09-30" id="Fact000894">&lt;p id="xdx_846_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zcc8lfNEKhPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zgKyhTDVcGib"&gt;Stock
Based Compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records stock-based compensation in accordance with ASC 718, &#x201c;&lt;i&gt;Stock Compensation&lt;/i&gt;&#x201d;. ASC 718 requires the fair
value of all stock-based employee compensation awarded to employees to be recorded as an expense over the shorter of the service period
or the vesting period. The Company values employee and non-employee stock-based compensation at fair value using the Black-Scholes Option
Pricing Model.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria
of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of
adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000896">&lt;p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zfIVbeTRZRGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_z6KiqhEgaiNg"&gt;Revenue
Recognition&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies ASC Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). ASC 606 establishes a single comprehensive
model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue
recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers
in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also
requires certain additional disclosures. Subject to these criteria, the Company intends to recognize revenue relating to royalties on
product sales in the period in which the sale occurs and the royalty term has begun.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:LegalCostsPolicyTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000898">&lt;p id="xdx_845_eus-gaap--LegalCostsPolicyTextBlock_zIoyRbOkqxsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zdsTAYeCWgV1"&gt;Legal
Expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
legal costs for litigation are charged to expense as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000900">&lt;p id="xdx_840_eus-gaap--LesseeLeasesPolicyTextBlock_zYUh2XROi4wj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zdlgVlybuVVl"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows ASC Topic 842, Leases (Topic 842) and applies the package of practical expedients, which permit it not to reassess under
the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company
elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less. Operating lease right of use assets (&#x201c;ROU&#x201d;)
represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value
of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company
uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future
payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general
and administrative expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000902">&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zxRXPqRZ7MVd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zr7MBZ4uKete"&gt;Basic
and Diluted Net Loss Per Common Share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period.
Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for
the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental
common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially
dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share
amounts for all periods presented are identical. The Company&#x2019;s CEO holds Series B Preferred Stock that, when combined, confers
upon him a majority vote, including regarding authorization of additional common shares and/or the authorization of a reverse split the
stock as considered necessary. Such securities are considered dilutive securities which were excluded from the computation since the
effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zUumyWbU1ACa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zYOxXlEVOUqk" style="display: none"&gt;SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Stock Warrants with no designations&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTjCdVO8d2eb" style="width: 14%; text-align: right" title="Warrants with no designations"&gt;120&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zRnM2pErScql" style="width: 14%; text-align: right" title="Warrants with no designations"&gt;121&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Series C Preferred Stock Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCPreferredStockWarrantsMember_zzt7TGKw9uql" style="text-align: right" title="Series C Preferred Stock Warrants"&gt;23,459,532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCPreferredStockWarrantsMember_zXIJvIUG9Cfk" style="text-align: right" title="Series C Preferred Stock Warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0912"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Convertible Series C Preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesCPreferredStockMember_ziSSrYnDtDT2" style="text-align: right" title="Convertible Series C Preferred stock"&gt;374,354&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesCPreferredStockMember_zsZRHPNWiU01" style="text-align: right" title="Convertible Series C Preferred stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Convertible Debt&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z7Un7sdmy6rb" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible Debt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0918"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zQuDbIxU20wl" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible Debt"&gt;514&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260701__20260930_zBYOxxetPR7l" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities"&gt;23,834,006&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250701__20250930_zAWcgptKlCHd" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities"&gt;635&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A6_zpAvYAnKl0Eg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000904">&lt;p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zUumyWbU1ACa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zYOxXlEVOUqk" style="display: none"&gt;SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Stock Warrants with no designations&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTjCdVO8d2eb" style="width: 14%; text-align: right" title="Warrants with no designations"&gt;120&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zRnM2pErScql" style="width: 14%; text-align: right" title="Warrants with no designations"&gt;121&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Series C Preferred Stock Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCPreferredStockWarrantsMember_zzt7TGKw9uql" style="text-align: right" title="Series C Preferred Stock Warrants"&gt;23,459,532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCPreferredStockWarrantsMember_zXIJvIUG9Cfk" style="text-align: right" title="Series C Preferred Stock Warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0912"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Convertible Series C Preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesCPreferredStockMember_ziSSrYnDtDT2" style="text-align: right" title="Convertible Series C Preferred stock"&gt;374,354&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesCPreferredStockMember_zsZRHPNWiU01" style="text-align: right" title="Convertible Series C Preferred stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Convertible Debt&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z7Un7sdmy6rb" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible Debt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0918"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zQuDbIxU20wl" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible Debt"&gt;514&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260701__20260930_zBYOxxetPR7l" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities"&gt;23,834,006&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250701__20250930_zAWcgptKlCHd" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities"&gt;635&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-07-012026-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000906"
      unitRef="Shares">120</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-07-012025-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000908"
      unitRef="Shares">121</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-07-012026-09-30_custom_SeriesCPreferredStockWarrantsMember"
      decimals="INF"
      id="Fact000910"
      unitRef="Shares">23459532</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-07-012026-09-30_custom_ConvertibleSeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000914"
      unitRef="Shares">374354</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-07-012025-09-30_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="Fact000920"
      unitRef="Shares">514</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-07-01to2026-09-30"
      decimals="INF"
      id="Fact000922"
      unitRef="Shares">23834006</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000924"
      unitRef="Shares">635</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000926">&lt;p id="xdx_843_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z9rVAdgjyScg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zD3mEK4MiIF8"&gt;Segment
Reporting&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses &#x201c;the management approach&#x201d; in determining reportable operating segments. Operating segments are defined as components
of an entity where discrete financial information is evaluated regularly by the chief operating decision maker (&#x201c;CODM&#x201d;).
The management approach considers the internal organization and reporting used by the Company&#x2019;s CODM for making operating decisions
and assessing performance as the source for determining the Company&#x2019;s reportable segments. All activities are related to the development
of cancer treatment and the Company has not commenced commercial operations or generated revenues to date. All activities are related
to the development of the cancer treatment and the Company has not commenced commercial operations or generated revenues to date. The
CODM is the chief executive officer of the Company, who reviews operating results and utilizes consolidated financial information, including
operating expenses, operating loss, and net loss as reported on the consolidated statements of operations, to make decisions about operating
decisions, allocate resources and assess performance for the entire Company. Consolidated net loss is our segment&#x2019;s primary measure
of loss. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets. The single segment
constitutes all the consolidated entity, and the accompanying consolidated financial statements and the notes to the accompanying consolidated
financial statements are representative of such amounts. For the three months ended September 30, 2026 and 2025, the Company operates
in &lt;span id="xdx_90D_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20260701__20260930_zxnYqhxgnTDc" title="Number of operating segments"&gt;&lt;span id="xdx_903_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20250701__20250930_z8ubGEx7qFV2" title="Number of operating segments"&gt;one&lt;/span&gt;&lt;/span&gt; operating segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPANC
BIOPHARMA, INC. AND SUBSIDIARY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2026-07-01to2026-09-30"
      decimals="INF"
      id="Fact000928"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000930"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2026-07-01to2026-09-30" id="Fact000932">&lt;p id="xdx_841_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_znw0JfKyWuxk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zxXNVmJM31E6"&gt;Reclassifications&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact
on the Company&#x2019;s previously reported financial position or results of operations or cash flows and relates to the presentation
of $&lt;span id="xdx_901_ecustom--CompensationAndRelatedTaxes_c20250701__20250930_znRydhFq1Mw6" title="Compensation and related taxes"&gt;110,002&lt;/span&gt;
compensation and related taxes and $&lt;span id="xdx_90A_eus-gaap--ProfessionalAndContractServicesExpense_c20250701__20250930_zndtCCq5R8Ul" title="Professional and consulting expenses"&gt;4,351,231&lt;/span&gt;
professional and consulting expenses being reclassified out of administration expenses and shown separately on the consolidated
statements of operations for the three months ended September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <PPCB:CompensationAndRelatedTaxes
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000934"
      unitRef="USD">110002</PPCB:CompensationAndRelatedTaxes>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000936"
      unitRef="USD">4351231</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000938">&lt;p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z1q1EWfhUDU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_z97sVWqA6zDi"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have reviewed the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;)
accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods.
We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that
any new or modified principles will have a material impact on the Company&#x2019;s reported financial position or operations in the near
term with the exception of those disclosed below. The applicability of any standard is subject to formal review of the Company&#x2019;s
financial management.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 4, 2024 the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (DISE) requiring additional disclosure of the
nature of expenses included in the income statement in response to longstanding requests from investors for more information about an
entity&#x2019;s expenses. This standard requires disclosures about specific types of expenses included in the expense captions presented
on the face of the income statement as well as disclosures about selling expenses. ASU 2024-03 applies to all public business entities
(PBEs) and is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods within annual reporting
periods beginning after December 15, 2027. Management does not believe the adoption of ASU 2024-03 will have a material impact on the
consolidated financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 8, 2025, the FASB issued ASU 2025-11 &#x2013; Interim Reporting (&#x201c;ASU 2025-11&#x201d;) which is intended to improve the
navigability of the guidance in ASC 270, Interim Reporting, and clarify when it applies. Under the amendments, an entity is subject to
ASC 270 if it provides interim financial statements and notes in accordance with GAAP. ASU 2025-11 also addresses the form and content
of such financial statements, interim disclosures requirements, and establishes a principle under which an entity must disclose events
since the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for interim reporting
periods within annual reporting periods beginning after December 15, 2027 and early adoption is permitted. The Company is currently evaluating
the impact the adoption of ASU 2025-11 may have on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 17, 2025, the FASB issued ASU 2025-12, Codification Improvements. The amendments in this update are to make other incremental
improvements to GAAP and facilitate codification updates for a broad range of Topics arising from technical corrections, unintended application
of the codification, clarifications, and other minor improvements. The resulting amendments are collectively referred to as Codification
improvements. ASU 2025-12 is effective for all entities for annual reporting periods beginning after December 15, 2026, and interim reporting
periods within those annual reporting periods. Management does not believe the adoption of ASU 2025-12 will have a material impact on
the consolidated financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000940">&lt;p id="xdx_80B_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zzVqPgiMonxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 &#x2013; &lt;span id="xdx_827_znYyT1z6RWLf"&gt;GOING CONCERN&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation
of the Company as a going concern. For the three months ended September 30, 2026, the Company had no revenues, had a net loss of $&lt;span id="xdx_903_eus-gaap--NetIncomeLoss_iN_di_c20260701__20260930_zabVPjAfr368" title="Net loss"&gt;8,588,159&lt;/span&gt;,
and had net cash used in operations of $&lt;span id="xdx_904_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pp0p0_di_c20260701__20260930_zYufjf38caf" title="Net cash used in operations"&gt;1,970,250&lt;/span&gt;. Additionally, as of September 30, 2026, the Company had accumulated deficit of $&lt;span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_di_c20260930_zHseYykNgNzi" title="Accumulated deficit"&gt;153,072,389&lt;/span&gt;.
It is management&#x2019;s opinion that these conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going
concern for a period of at least twelve months from the issue date of this Quarterly Report.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability
and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2026, the Company received proceeds of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromWarrantExercises_c20260801__20260831__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_zjVY3h9FKQn2" title="Proceeds from exercise of warrants"&gt;2,000,000&lt;/span&gt; from the exercise of Series C warrants (see Note 5).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Successful
completion of the Company&#x2019;s development program and, ultimately, the attainment of profitable operations are dependent upon future
events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company&#x2019;s patent applications,
obtaining additional sources of suitable and adequate financing and ultimately achieving a level of sales adequate to support the Company&#x2019;s
cost structure and business plan. The Company&#x2019;s ability to continue as a going concern is also dependent on its ability to further
develop and execute on its business plan. However, there can be no assurances that any or all of these endeavors will be successful.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPANC
BIOPHARMA, INC. AND SUBSIDIARY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000942"
      unitRef="USD">-8588159</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000944"
      unitRef="USD">-1970250</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000946"
      unitRef="USD">-153072389</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2026-08-012026-08-31_custom_SeriesCWarrantsMember"
      decimals="0"
      id="Fact000948"
      unitRef="USD">2000000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000950">&lt;p id="xdx_80D_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zjpb24PGgxl2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 &#x2013; &lt;span id="xdx_827_z9CvGY9CYu91"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_zEEvheDzPocj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consist of the following as of September 30, 2026 and June 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zHrljKqwEGY3" style="display: none"&gt;SCHEDULE OF PROPERTY PLANT AND EQUIPMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20260930_zuNlh6fd6i19" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
    30,&lt;br/&gt; 2026&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20260630_zoy9Hh0WKKcf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt;
2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzBVB_zsZhdkcvMbL8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Office equipment at cost&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;31,922&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;31,312&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzBVB_zSGyZrhtK6oj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(27,892&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(27,397&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzBVB_zuyvGNqOvkGe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total property, plant, and equipment&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,030&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,915&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zjy8EVP4x1Rf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense for the three months ended September 30, 2026 and 2025 was $&lt;span id="xdx_90F_eus-gaap--Depreciation_c20260701__20260930_z7Q8lix3DbO5" title="Depreciation"&gt;354&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--Depreciation_c20250701__20250930_zWo9pT1bw2Jd" title="Depreciation expense"&gt;125&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000952">&lt;p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_zEEvheDzPocj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consist of the following as of September 30, 2026 and June 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zHrljKqwEGY3" style="display: none"&gt;SCHEDULE OF PROPERTY PLANT AND EQUIPMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20260930_zuNlh6fd6i19" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
    30,&lt;br/&gt; 2026&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20260630_zoy9Hh0WKKcf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt;
2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzBVB_zsZhdkcvMbL8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Office equipment at cost&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;31,922&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;31,312&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzBVB_zSGyZrhtK6oj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(27,892&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(27,397&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzBVB_zuyvGNqOvkGe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total property, plant, and equipment&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,030&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,915&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000954"
      unitRef="USD">31922</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000955"
      unitRef="USD">31312</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000957"
      unitRef="USD">27892</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000958"
      unitRef="USD">27397</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000960"
      unitRef="USD">4030</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact000961"
      unitRef="USD">3915</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact000963"
      unitRef="USD">354</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000965"
      unitRef="USD">125</us-gaap:Depreciation>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact000967">&lt;p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zotbQj9qaGr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 &#x2013; &lt;span id="xdx_827_zGzxSYHNU0Jd"&gt;LOANS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Loans
payable - Related Party&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Between
November 2023 and May 2024, an institutional investor affiliated with one of our directors, Josef Zelinger, loaned the Company an aggregate
of $&lt;span id="xdx_906_eus-gaap--LoansPayableCurrent_iI_c20231130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zPj1gw2EJUg3" title="Loan payable"&gt;&lt;span id="xdx_90C_eus-gaap--LoansPayableCurrent_iI_c20240531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zziY253yJMg1" title="Loan payable"&gt;71,629&lt;/span&gt;&lt;/span&gt;. Additionally, in August 2024, the same affiliated institutional investor loaned the Company an amount of $&lt;span id="xdx_908_eus-gaap--LoansPayableCurrent_iI_pp0p0_uAUD_c20240831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z2pyCGSXWYH7" title="Loan payable"&gt;85,000&lt;/span&gt; AUD ($&lt;span id="xdx_90B_eus-gaap--LoansPayableCurrent_iI_pp0p0_uUSD_c20240831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zTdxULhwKGL5" title="Loan payable"&gt;57,639&lt;/span&gt;
USD). These loans were payable on demand and were non-interest bearing. In September 2025, the Company agreed to pay interest of &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zvvp8aoO1pG3" title="Debt instrument, interest rate"&gt;12&lt;/span&gt;%
per annum beginning from the funding date of these loans. The Company repaid $&lt;span id="xdx_90B_eus-gaap--RepaymentsOfDebt_c20260212__20260212__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zwCfd1bjCvCk" title="Repayment of loan"&gt;16,428&lt;/span&gt; USD including additional interest expense of $&lt;span id="xdx_905_eus-gaap--InterestPaid_c20260212__20260212__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z6UBc5zsuyF3" title="Interest expense paid"&gt;4,805&lt;/span&gt;
USD on February 12, 2026. The Company repaid $&lt;span id="xdx_908_eus-gaap--RepaymentsOfDebt_c20260428__20260428__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zYQa34jqgs25" title="Repayment of loan"&gt;16,188&lt;/span&gt; USD including interest expense of $&lt;span id="xdx_90C_eus-gaap--InterestPaid_c20260428__20260428__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zlvm42C1uyr6" title="Interest expense paid"&gt;4,793&lt;/span&gt; USD on April 28, 2026. Additionally, the
Company repaid the remaining principal balance of $&lt;span id="xdx_909_eus-gaap--RepaymentsOfDebt_c20260903__20260903__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zz6dAq8lhJL8" title="Repayment of loan"&gt;96,652&lt;/span&gt; USD and accrued interest of $&lt;span id="xdx_90E_eus-gaap--InterestPaid_c20260903__20260903__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z2KCBd7odWb5" title="Interest expense paid"&gt;26,991&lt;/span&gt; USD on September 3, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
August 1, 2024, the Company entered and closed a loan agreement with an institutional investor affiliated with one of our directors,
Josef Zelinger, pursuant to which the investor loaned the Company an aggregate principal amount of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_uAUD_c20240801__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zT0ITvcHDmoe" title="Aggregate principal amount"&gt;150,000&lt;/span&gt; AUD ($&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_uUSD_c20240801__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zh8NwqnJOef8" title="Aggregate principal amount"&gt;98,060&lt;/span&gt; USD). The Company
used the net proceeds for general working capital purposes. The maturity date of the loan is &lt;span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20240801__20240801__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z16889xeksui" title="Debt instrument maturity date"&gt;November 1, 2024&lt;/span&gt;, or sooner at the discretion
of the Company, and the loan bears an interest rate of &lt;span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240801__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zo2yeOZn2eMi" title="Debt instrument interest rate"&gt;12&lt;/span&gt;% per annum and default interest rate of &lt;span id="xdx_902_ecustom--DebtInstrumentInterestRateDefaultPercentage_iI_pid_dp_uPure_c20240801__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zyEDYFXaKw9c" title="Debt default interest rate"&gt;18&lt;/span&gt;% per annum. The Company has the
right to prepay in full at any time with no prepayment penalty. By mutual consent the amount can be repaid via the issuance of common
stock of the Company (upon uplisting on NASDAQ) and the strike price shall be at a &lt;span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20240801__20240801__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zjh6dRXwWOB5" title="Debt strike price percentage"&gt;35&lt;/span&gt;% discount to lowest daily balance of the five preceding
trading days. Such loan is past due and currently in default.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Between
November 2024 and December 2024, an institutional investor affiliated with one of our directors, Josef Zelinger, loaned the Company an
aggregate of $&lt;span id="xdx_908_eus-gaap--LoansPayableCurrent_iI_uAUD_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zKOk33DLdLlj" title="Loan payable"&gt;15,000&lt;/span&gt; AUD ($&lt;span id="xdx_904_eus-gaap--LoansPayableCurrent_iI_uUSD_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z7GB30r73DBf" title="Loan payable"&gt;9,731&lt;/span&gt; USD). These loans were payable on demand and were non-interest bearing. The Company repaid $&lt;span id="xdx_90E_eus-gaap--RepaymentsOfDebt_uAUD_c20250819__20250819__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z9HLSfbmIO3k" title="Repayment of loan"&gt;12,000&lt;/span&gt; AUD
($&lt;span id="xdx_907_eus-gaap--RepaymentsOfDebt_c20250819__20250819__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zpDDfNyrTRUk" title="Repayment of loan"&gt;7,774&lt;/span&gt; USD) of this loan including interest expense of $&lt;span id="xdx_90D_eus-gaap--InterestPaid_c20250819__20250819__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zIrtxsMYx014" title="Interest expense paid"&gt;653&lt;/span&gt; on August 19, 2025. In September 2025, the Company agreed to pay interest
of &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zOIsKe5Wq8u9" title="Debt instrument, interest rate"&gt;12&lt;/span&gt;% per annum beginning from the funding date of these loans. The Company repaid the remaining balance of $&lt;span id="xdx_90B_eus-gaap--RepaymentsOfDebt_uAUD_c20260212__20260212__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zgCXlnt3jJ1k" title="Repayment of loan"&gt;3,000&lt;/span&gt; AUD ($&lt;span id="xdx_90C_eus-gaap--RepaymentsOfDebt_c20260212__20260212__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z3LXqK4Ee7i3" title="Repayment of loan"&gt;1,957&lt;/span&gt; USD)
including additional interest expense of $&lt;span id="xdx_905_eus-gaap--InterestPaid_c20260212__20260212__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zeNsHxt2uT4d" title="Interest expense paid"&gt;319&lt;/span&gt; USD on February 12, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
December 3, 2024, the Company entered and closed a loan agreement with an institutional investor affiliated with one of our directors,
Josef Zelinger, pursuant to which the investor loaned the Company an aggregate principal amount of $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_uAUD_c20241203__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z9CPSdKtEwB4" title="Aggregate principal amount"&gt;175,000&lt;/span&gt; AUD ($&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_uUSD_c20241203__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zVscJU8fN62h" title="Aggregate principal amount"&gt;113,485&lt;/span&gt; USD). The Company
used the net proceeds for general working capital purposes. The term of the loan is four months or less (to be determined at the discretion
of the Company), with $&lt;span id="xdx_90B_eus-gaap--LoansPayable_iI_uAUD_c20250228__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zlOoNfzuw63c" title="Loans payable"&gt;70,000&lt;/span&gt; AUD was due on &lt;span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20241203__20241203__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zLtUxlK5W9F1" title="Debt instrument maturity date"&gt;February 28, 2025&lt;/span&gt;, and $&lt;span id="xdx_909_eus-gaap--LoansPayable_iI_uAUD_c20250402__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zg6dywmrIWpa" title="Loans payable"&gt;105,000&lt;/span&gt; AUD was due on April 2, 2025. The loan bears an interest
rate of &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241203__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zsDAGuCsGCO" title="Debt instrument interest rate"&gt;12&lt;/span&gt;% per annum and default interest rate of &lt;span id="xdx_90A_ecustom--DebtInstrumentInterestRateDefaultPercentage_iI_pid_dp_uPure_c20241203__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zrtW4dPMuGke" title="Debt default interest rate"&gt;18&lt;/span&gt;% per annum. Such loan is past due and currently in default.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2025, an institutional investor affiliated with one of our directors, Josef Zelinger, loaned the Company an aggregate of $&lt;span id="xdx_90D_eus-gaap--LoansPayableCurrent_iI_uAUD_c20250131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zmuhGGgC4DK4" title="Loan payable"&gt;25,000&lt;/span&gt;
AUD ($&lt;span id="xdx_908_eus-gaap--LoansPayableCurrent_iI_uUSD_c20250131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zzh3vBPJ6LGg" title="Loan payable"&gt;15,485&lt;/span&gt; USD). This loan bore no interest and was payable on demand. The Company fully repaid $&lt;span id="xdx_905_eus-gaap--RepaymentsOfDebt_uAUD_c20250819__20250819__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zAYiGNeJc784" title="Repaid loan amount"&gt;25,000&lt;/span&gt; AUD ($&lt;span id="xdx_904_eus-gaap--RepaymentsOfDebt_uUSD_c20250819__20250819__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zHmXuE2s4165" title="Repaid loan amount"&gt;15,485&lt;/span&gt; USD) including
additional interest expense of $&lt;span id="xdx_909_eus-gaap--InterestPaid_c20250819__20250819__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_ztQ7XBwRZZ83" title="Interest expense paid"&gt;1,169&lt;/span&gt; on August 19, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 12, 2025, the Company entered into and closed a loan agreement with an institutional investor affiliated with one of our directors,
Josef Zelinger, pursuant to which the investor loaned the Company an aggregate principal amount of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_uAUD_c20250412__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zDIAuhzX7Hyi" title="Aggregate principal amount"&gt;63,188&lt;/span&gt; AUD ($&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_uUSD_c20250412__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zIFpxG26FJj5" title="Aggregate principal amount"&gt;39,625&lt;/span&gt; USD). The Company
used the net proceeds for general working capital purposes. The maturity date was on &lt;span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20250412__20250412__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zLyZ2LmDiNK8" title="Debt instrument maturity date"&gt;June 30, 2025&lt;/span&gt;. The loan bore an interest rate of
&lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250412__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zxggxNCyL9D" title="Debt instrument interest rate"&gt;12&lt;/span&gt;% per annum and default interest rate of &lt;span id="xdx_905_ecustom--DebtInstrumentInterestRateDefaultPercentage_iI_pid_dp_uPure_c20250412__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zbqkDjfzT8Cf" title="Debt default interest rate"&gt;18&lt;/span&gt;% per annum. The Company fully repaid $&lt;span id="xdx_90D_eus-gaap--RepaymentsOfDebt_uAUD_c20250819__20250819__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zmrffHSb4yJ7" title="Repaid loan amount"&gt;63,188&lt;/span&gt; AUD ($&lt;span id="xdx_909_eus-gaap--RepaymentsOfDebt_uUSD_c20250819__20250819__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zQdlerVA8oM4" title="Repaid loan amount"&gt;39,625&lt;/span&gt; USD) including additional interest
expense of $&lt;span id="xdx_90C_eus-gaap--InterestPaid_c20250819__20250819__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zzqxc9JBRrP7" title="Interest expense paid"&gt;1,818&lt;/span&gt; on August 19, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 13, 2025, the Company entered into and closed a loan agreement with an institutional investor affiliated with one of our directors,
Josef Zelinger, pursuant to which the investor loaned the Company an aggregate principal amount of $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_uAUD_c20250613__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zjtcdOxlrial" title="Aggregate principal amount"&gt;15,000&lt;/span&gt; AUD ($&lt;span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_uUSD_c20250613__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zRIQP5e6NuBf" title="Aggregate principal amount"&gt;9,675&lt;/span&gt; USD). The Company
used the net proceeds for general working capital purposes. The maturity date was on &lt;span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20250613__20250613__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zoecpuUhNpW8" title="Debt instrument maturity date"&gt;June 30, 2025&lt;/span&gt;. The loan bore an interest rate of
&lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250613__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zqSPga4Gyu6e" title="Debt instrument interest rate"&gt;12&lt;/span&gt;% per annum and default interest rate of &lt;span id="xdx_90E_ecustom--DebtInstrumentInterestRateDefaultPercentage_iI_pid_dp_uPure_c20250613__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zu2Y4K16WVL6" title="Debt default interest rate"&gt;18&lt;/span&gt;% per annum. The Company fully repaid $&lt;span id="xdx_90C_eus-gaap--RepaymentsOfDebt_uAUD_c20250819__20250819__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zMyPHGwLQMch" title="Repaid loan amount"&gt;15,000&lt;/span&gt; AUD ($&lt;span id="xdx_90B_eus-gaap--RepaymentsOfDebt_uUSD_c20250819__20250819__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zaEqpaxdfv7d" title="Repaid loan amount"&gt;9,675&lt;/span&gt; USD) including additional interest
expense of $&lt;span id="xdx_90E_eus-gaap--InterestPaid_c20250819__20250819__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zqimXk3I3VV4" title="Interest expense paid"&gt;257&lt;/span&gt; on August 19, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Between
July 3, 2025 and August 14, 2025, an institutional investor affiliated with one of our directors, Josef Zelinger, loaned the Company
an aggregate of $&lt;span id="xdx_907_eus-gaap--LoansPayableCurrent_iI_uAUD_c20250703__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zXL2Fd3wft9b" title="Loan payable"&gt;&lt;span id="xdx_90A_eus-gaap--LoansPayableCurrent_iI_uAUD_c20250814__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zph6PYcmh4Jg" title="Loan payable"&gt;120,000&lt;/span&gt;&lt;/span&gt; AUD ($&lt;span id="xdx_90D_eus-gaap--LoansPayableCurrent_iI_uUSD_c20250703__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zaWbbTqQVhf7" title="Loan payable"&gt;&lt;span id="xdx_90D_eus-gaap--LoansPayableCurrent_iI_uUSD_c20250814__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zjzzoOATsnEj" title="Loan payable"&gt;78,249&lt;/span&gt;&lt;/span&gt; USD). These loans bore no interest and were payable on demand. The Company fully repaid these loans
between July 21, 2025 and August 19, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPANC
BIOPHARMA, INC. AND SUBSIDIARY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 5, 2023, the Company and an institutional investor affiliated with one of our directors, Josef Zelinger, entered into a letter agreement,
pursuant to which such investor loaned the Company an aggregate of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_uAUD_c20230705__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_zjJEgr9dB5Uc" title="Investor loan, value"&gt;230,000&lt;/span&gt; AUD ($&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_uUSD_c20230705__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_zUPifOMO4Ioi" title="Investor loan, value"&gt;153,256&lt;/span&gt; USD). Pursuant to such agreement, the term
of such loan is three (&lt;span id="xdx_902_eus-gaap--DebtInstrumentTerm_dtY_c20230705__20230705__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_zmtIP0pyf4pa" title="Term of agreement"&gt;3&lt;/span&gt;) years, ending on &lt;span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20230705__20230705__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_z2DtnVEjy4Qd" title="Debt instrument maturity date"&gt;July 5, 2026&lt;/span&gt;, with an interest rate of &lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230705__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_zWELZVJDXLhl" title="Debt instrument interest rate"&gt;10&lt;/span&gt;% to be paid monthly in arrears. In connection with
such loan, the Company issued &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230705__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8RPjIW2cMad" title="Warrants issued to purchase common stock"&gt;10&lt;/span&gt; warrants to purchase common stock to such investor immediately exercisable at an initial exercise price
of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230705__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXSAxXCU0Jgi" title="Warrants exercise price"&gt;15,000&lt;/span&gt; per share (subject to certain adjustments such as stock dividend, stock splits, subsequent right offering and pro-rata distribution)
with an expiry date of &lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230705__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKVgsCT6Hq78" title="Warrants expiry date"&gt;July 5, 2026&lt;/span&gt;. The Company accounted for the &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230705__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpoJNUYKmwFi" title="Warrants issued to purchase common stock"&gt;10&lt;/span&gt; warrants issued with this loan payable as debt discount by using
the relative fair value method. The total debt discount which is equivalent to the relative fair value of the warrants of $&lt;span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20230705__20230705__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zflpJA4NbGRa" title="Fair value adjustment of warrants"&gt;141,084&lt;/span&gt; was
based on a fair value determination using a Black-Scholes model with the following assumptions: stock price at valuation date of $&lt;span id="xdx_901_eus-gaap--FairValueAdjustmentOfWarrants_c20230705__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zMdfXV3f2bgc" title="Stock valuation price per share"&gt;178,500&lt;/span&gt;
based on the closing price of common stock at date of grant, exercise price of $&lt;span id="xdx_90D_eus-gaap--WarrantExercisePriceIncrease_c20230705__20230705__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zOOn4CPuqapd" title="Warrant exercise price"&gt;15,000&lt;/span&gt;, dividend yield of &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dc_uPure_c20230705__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zNQLfhvWXtDe" title="Measurement input"&gt;zero&lt;/span&gt;, expected term of &lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230705__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_zViX3AkB3hR6" title="Maturity term"&gt;3.00&lt;/span&gt;,
a risk-free rate of &lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230705__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_zsU3cVS5rgy1" title="Measurement input"&gt;4.59&lt;/span&gt;%, and expected volatility of &lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230705__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_zGE6xe8VA65d" title="Measurement input"&gt;268&lt;/span&gt;%. The debt discount shall be amortized over the term of this loan. A portion
of the proceeds of such loan were used to repay an outstanding balance of approximately $&lt;span id="xdx_900_eus-gaap--RepaymentsOfConvertibleDebt_c20240701__20250630__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_zUct5pNhrX3e" title="Repayment of convertible debt"&gt;143,000&lt;/span&gt; due on a convertible note held by a
third-party investor which had been in default. Amortization of debt discount for the three months ended September 30, 2026 and 2025
was $&lt;span id="xdx_905_eus-gaap--AmortizationOfDebtDiscountPremium_c20260701__20260930__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_zsQdnYRj1ECf" title="Amortization of debt discounts"&gt;644&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--AmortizationOfDebtDiscountPremium_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_zhuWj4F8XY65" title="Amortization of debt discount"&gt;11,843&lt;/span&gt;, respectively. The total principal outstanding under this loan, net of discount was $&lt;span id="xdx_902_eus-gaap--LoansPayable_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_zQTW7phJzTKf" title="Loans payable"&gt;152,612&lt;/span&gt; ($&lt;span id="xdx_90C_eus-gaap--DebtInstrumentCarryingAmount_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_zQGJqvIAleHg" title="Principal outstanding"&gt;153,256&lt;/span&gt; principal
and remaining unamortized debt discount of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_z3V3om4wmZud" title="Unamortized debt discount"&gt;644&lt;/span&gt;) as of June 30, 2026 and has been reclassified as a short-term loan. The total principal
outstanding under this loan was $&lt;span id="xdx_905_eus-gaap--LoansPayable_iI_c20260930__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_zvMLTQAkE5D8" title="Loans payable"&gt;153,256&lt;/span&gt; and remaining debt discount of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260930__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_zILDvNNrzmbl" title="Unamortized debt discount"&gt;0&lt;/span&gt; as of September 30, 2026 and has been included in loans payable
&#x2013; related parties, net of discount as reflected in the accompanying condensed consolidated balance sheet. Such loan is past due and currently in default.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
remaining balance of all the above loans payable &#x2013; related parties, net of discount amounted to $&lt;span id="xdx_90F_eus-gaap--LoansPayableCurrent_iI_c20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zzWpxTELJs98" title="Loan payable"&gt;364,801&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--LoansPayableCurrent_iI_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zIRnB3pr8569" title="Loan payable"&gt;460,809&lt;/span&gt; as of September
30, 2026 and June 30, 2026, respectively. Accrued interest for all of the above loans payable &#x2013; related parties as of September
30, 2026 and June 30, 2026 was $&lt;span id="xdx_90B_eus-gaap--InterestPayableCurrent_iI_c20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zKGvT8s9kPy5" title="Interest payable"&gt;118,927&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--InterestPayableCurrent_iI_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z1ksge2CjsT" title="Accrued interest"&gt;128,318&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Loans
Payable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
October 3, 2019, the Company entered into a securities purchase agreement with Crown Bridge Partners, LLC (&#x201c;Crown Bridge&#x201d;),
pursuant to which Crown Bridge purchased a convertible promissory note from the Company (the &#x201c;Crown Bridge Note&#x201d;), which
had a remaining principal balance of $&lt;span id="xdx_904_eus-gaap--ConvertibleDebt_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--CrownBridgePartnersLLCMember_zoN7ccQg5Ro1" title="Convertible debt"&gt;0&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ConvertibleDebt_iI_c20250630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--CrownBridgePartnersLLCMember_zORuyz2A3aya" title="Convertible debt"&gt;65,280&lt;/span&gt; as of June 30, 2026 and 2025, respectively. The maturity date of the Crown Bridge
Note was October 3, 2020 and was past due. The Crown Bridge Note bore interest at a default interest rate of &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20191003__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--CrownBridgePartnersLLCMember_zhp2YJ7pRIX1" title="Debt instrument interest rate stated percentage"&gt;15&lt;/span&gt;% per annum. In August
2022, the SEC filed a complaint against Crown Bridge due to its violation of Section 15(a)(1) of the Securities Exchange Act of 1934,
as amended (the &#x201c;Exchange Act&#x201d;). Crown Bridge agreed to surrender all conversion rights in its currently held convertible
notes, including the Crown Bridge Note. Consequently, during fiscal year 2023, the Company reclassified the remaining principal balance
of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20250630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--CrownBridgePartnersLLCMember_zKjfuF7mLDW7" title="Debt instrument face amount"&gt;65,280&lt;/span&gt; from a convertible note into a loan payable which is the principal balance at June 30, 2025. The total accrued interest from
this loan amounted to $&lt;span id="xdx_90D_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260930__dei--LegalEntityAxis__custom--CrownBridgePartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_z1MBwHrGpKeh" title="Accrued interest"&gt;&lt;span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20250930__dei--LegalEntityAxis__custom--CrownBridgePartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_ztWsoCbx9wbe" title="Accrued interest"&gt;0&lt;/span&gt;&lt;/span&gt; as of September 30, 2026 and June 30, 2026, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 7, 2026, the Company entered into an Exchange Agreement with Crown Bridge and issued &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20260107__20260107__dei--LegalEntityAxis__custom--CrownBridgePartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_z6GleOq159L4" title="Number of common stock issued"&gt;1,579&lt;/span&gt; shares of common stock in exchange
for the total outstanding balance of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20260107__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__dei--LegalEntityAxis__custom--CrownBridgePartnersLLCMember_zcqaaw6sccGc" title="Principal amount"&gt;65,280&lt;/span&gt; and accrued interest of $&lt;span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260107__dei--LegalEntityAxis__custom--CrownBridgePartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zUSzITVcobzb" title="Accrued interest"&gt;60,484&lt;/span&gt;. Those shares were valued at approximately $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20260107__dei--LegalEntityAxis__custom--CrownBridgePartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zAVPLYafctg1" title="Conversion price per share"&gt;127&lt;/span&gt; per share
or $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20260107__20260107__dei--LegalEntityAxis__custom--CrownBridgePartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_z18BCmJj39Q5" title="Value of common stock issued"&gt;200,000&lt;/span&gt;, being the closing price of the stock on the date of grant, resulting in a loss on extinguishment of debt at the time of
exchange of $&lt;span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20260107__20260107__dei--LegalEntityAxis__custom--CrownBridgePartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zrdei2aWqYt9" title="Loss on extinguishment of debt"&gt;74,236&lt;/span&gt;. Accordingly, the remaining principal balance and accrued interest at September 30, 2026 and June 30, 2026 is $&lt;span id="xdx_903_eus-gaap--LoansPayable_iI_c20260930__dei--LegalEntityAxis__custom--CrownBridgePartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zrZA03ePeDA9" title="Loans payable"&gt;&lt;span id="xdx_904_eus-gaap--LoansPayable_iI_c20260630__dei--LegalEntityAxis__custom--CrownBridgePartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zGvCkLcLKoQc" title="Loans payable"&gt;0&lt;/span&gt;&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Loans
in default&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loans
payable &#x2013; related party for total principal amount of $&lt;span id="xdx_904_eus-gaap--LoansPayableCurrent_iI_c20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--LoansInDefaultMember_zqrwEHjp3wqg" title="Loan payable"&gt;364,801&lt;/span&gt; and accrued interest of $&lt;span id="xdx_908_eus-gaap--InterestPayableCurrent_iI_c20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--LoansInDefaultMember_zgmDZC6JZUb1" title="Interest payable"&gt;118,928&lt;/span&gt;, which includes interest accruing
at the default interest rate at &lt;span id="xdx_90C_ecustom--DebtInstrumentInterestRateDefaultPercentage_iI_pid_dp_uPure_c20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--LoansInDefaultMember_z0MicYdEaek7" title="Debt default interest rate"&gt;18&lt;/span&gt;% with maturity dates between November 2024 and April 2025, were in default as of September 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2023-11-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000969"
      unitRef="USD">71629</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2024-05-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000971"
      unitRef="USD">71629</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2024-08-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000973"
      unitRef="AUD">85000</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2024-08-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000975"
      unitRef="USD">57639</us-gaap:LoansPayableCurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2025-09-30_us-gaap_RelatedPartyMember"
      decimals="INF"
      id="Fact000977"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2026-02-122026-02-12_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000979"
      unitRef="USD">16428</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestPaid
      contextRef="From2026-02-122026-02-12_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000981"
      unitRef="USD">4805</us-gaap:InterestPaid>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2026-04-282026-04-28_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000983"
      unitRef="USD">16188</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestPaid
      contextRef="From2026-04-282026-04-28_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000985"
      unitRef="USD">4793</us-gaap:InterestPaid>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2026-09-032026-09-03_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000987"
      unitRef="USD">96652</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestPaid
      contextRef="From2026-09-032026-09-03_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000989"
      unitRef="USD">26991</us-gaap:InterestPaid>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-08-01_custom_LoanAgreementMember"
      decimals="0"
      id="Fact000991"
      unitRef="AUD">150000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-08-01_custom_LoanAgreementMember"
      decimals="0"
      id="Fact000993"
      unitRef="USD">98060</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-08-012024-08-01_custom_LoanAgreementMember"
      id="Fact000995">2024-11-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-08-01_custom_LoanAgreementMember"
      decimals="INF"
      id="Fact000997"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <PPCB:DebtInstrumentInterestRateDefaultPercentage
      contextRef="AsOf2024-08-01_custom_LoanAgreementMember"
      decimals="INF"
      id="Fact000999"
      unitRef="Pure">0.18</PPCB:DebtInstrumentInterestRateDefaultPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="From2024-08-012024-08-01_custom_LoanAgreementMember"
      decimals="INF"
      id="Fact001001"
      unitRef="Pure">0.35</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2024-12-31_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001003"
      unitRef="AUD">15000</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2024-12-31_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001005"
      unitRef="USD">9731</us-gaap:LoansPayableCurrent>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2025-08-192025-08-19_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001007"
      unitRef="AUD">12000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2025-08-192025-08-19_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001009"
      unitRef="USD">7774</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestPaid
      contextRef="From2025-08-192025-08-19_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001011"
      unitRef="USD">653</us-gaap:InterestPaid>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2025-09-30_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact001013"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2026-02-122026-02-12_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001015"
      unitRef="AUD">3000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2026-02-122026-02-12_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001017"
      unitRef="USD">1957</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestPaid
      contextRef="From2026-02-122026-02-12_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001019"
      unitRef="USD">319</us-gaap:InterestPaid>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-12-03_custom_LoanAgreementMember"
      decimals="0"
      id="Fact001021"
      unitRef="AUD">175000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-12-03_custom_LoanAgreementMember"
      decimals="0"
      id="Fact001023"
      unitRef="USD">113485</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LoansPayable
      contextRef="AsOf2025-02-28_custom_LoanAgreementMember"
      decimals="0"
      id="Fact001025"
      unitRef="AUD">70000</us-gaap:LoansPayable>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-12-032024-12-03_custom_LoanAgreementMember"
      id="Fact001027">2025-02-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LoansPayable
      contextRef="AsOf2025-04-02_custom_LoanAgreementMember"
      decimals="0"
      id="Fact001029"
      unitRef="AUD">105000</us-gaap:LoansPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-12-03_custom_LoanAgreementMember"
      decimals="INF"
      id="Fact001031"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <PPCB:DebtInstrumentInterestRateDefaultPercentage
      contextRef="AsOf2024-12-03_custom_LoanAgreementMember"
      decimals="INF"
      id="Fact001033"
      unitRef="Pure">0.18</PPCB:DebtInstrumentInterestRateDefaultPercentage>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2025-01-31_srt_DirectorMember"
      decimals="0"
      id="Fact001035"
      unitRef="AUD">25000</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2025-01-31_srt_DirectorMember"
      decimals="0"
      id="Fact001037"
      unitRef="USD">15485</us-gaap:LoansPayableCurrent>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2025-08-192025-08-19_srt_DirectorMember"
      decimals="0"
      id="Fact001039"
      unitRef="AUD">25000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2025-08-192025-08-19_srt_DirectorMember"
      decimals="0"
      id="Fact001041"
      unitRef="USD">15485</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestPaid
      contextRef="From2025-08-192025-08-19_srt_DirectorMember"
      decimals="0"
      id="Fact001043"
      unitRef="USD">1169</us-gaap:InterestPaid>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-04-12_custom_LoanAgreementMember_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001045"
      unitRef="AUD">63188</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-04-12_custom_LoanAgreementMember_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001047"
      unitRef="USD">39625</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2025-04-122025-04-12_custom_LoanAgreementMember_us-gaap_InvestorMember"
      id="Fact001049">2025-06-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2025-04-12_custom_LoanAgreementMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact001051"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <PPCB:DebtInstrumentInterestRateDefaultPercentage
      contextRef="AsOf2025-04-12_custom_LoanAgreementMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact001053"
      unitRef="Pure">0.18</PPCB:DebtInstrumentInterestRateDefaultPercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2025-08-192025-08-19_custom_LoanAgreementMember_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001055"
      unitRef="AUD">63188</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2025-08-192025-08-19_custom_LoanAgreementMember_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001057"
      unitRef="USD">39625</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestPaid
      contextRef="From2025-08-192025-08-19_custom_LoanAgreementMember_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001059"
      unitRef="USD">1818</us-gaap:InterestPaid>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-06-13_custom_LoanAgreementMember"
      decimals="0"
      id="Fact001061"
      unitRef="AUD">15000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-06-13_custom_LoanAgreementMember"
      decimals="0"
      id="Fact001063"
      unitRef="USD">9675</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2025-06-132025-06-13_custom_LoanAgreementMember"
      id="Fact001065">2025-06-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2025-06-13_custom_LoanAgreementMember"
      decimals="INF"
      id="Fact001067"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <PPCB:DebtInstrumentInterestRateDefaultPercentage
      contextRef="AsOf2025-06-13_custom_LoanAgreementMember"
      decimals="INF"
      id="Fact001069"
      unitRef="Pure">0.18</PPCB:DebtInstrumentInterestRateDefaultPercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2025-08-192025-08-19_custom_LoanAgreementMember"
      decimals="0"
      id="Fact001071"
      unitRef="AUD">15000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2025-08-192025-08-19_custom_LoanAgreementMember"
      decimals="0"
      id="Fact001073"
      unitRef="USD">9675</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestPaid
      contextRef="From2025-08-192025-08-19_custom_LoanAgreementMember"
      decimals="0"
      id="Fact001075"
      unitRef="USD">257</us-gaap:InterestPaid>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2025-07-03_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001077"
      unitRef="AUD">120000</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2025-08-14_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001079"
      unitRef="AUD">120000</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2025-07-03_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001081"
      unitRef="USD">78249</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2025-08-14_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001083"
      unitRef="USD">78249</us-gaap:LoansPayableCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-07-05_custom_LetterAgreementMember"
      decimals="0"
      id="Fact001085"
      unitRef="AUD">230000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-07-05_custom_LetterAgreementMember"
      decimals="0"
      id="Fact001087"
      unitRef="USD">153256</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2023-07-052023-07-05_custom_LetterAgreementMember"
      id="Fact001089">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2023-07-052023-07-05_custom_LetterAgreementMember"
      id="Fact001091">2026-07-05</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-07-05_custom_LetterAgreementMember"
      decimals="INF"
      id="Fact001093"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-07-05_custom_LetterAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001095"
      unitRef="Shares">10</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-05_custom_LetterAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001097"
      unitRef="USDPShares">15000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-07-05_custom_LetterAgreementMember_us-gaap_WarrantMember"
      id="Fact001099">2026-07-05</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-07-05_custom_LetterAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001101"
      unitRef="Shares">10</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-07-052023-07-05_custom_LetterAgreementMember_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001103"
      unitRef="USD">141084</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2023-07-052023-07-05_custom_LetterAgreementMember_us-gaap_WarrantMember_us-gaap_MeasurementInputExercisePriceMember"
      decimals="INF"
      id="Fact001107"
      unitRef="USDPShares">15000</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-07-05_custom_LetterAgreementMember_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001109"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-07-05_us-gaap_MeasurementInputExpectedTermMember_us-gaap_WarrantMember_custom_LetterAgreementMember"
      id="Fact001111">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-07-05_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_WarrantMember_custom_LetterAgreementMember"
      decimals="INF"
      id="Fact001113"
      unitRef="Pure">4.59</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-07-05_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_WarrantMember_custom_LetterAgreementMember"
      decimals="INF"
      id="Fact001115"
      unitRef="Pure">268</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2024-07-012025-06-30_custom_LetterAgreementMember"
      decimals="0"
      id="Fact001117"
      unitRef="USD">143000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2026-07-012026-09-30_custom_LetterAgreementMember"
      decimals="0"
      id="Fact001119"
      unitRef="USD">644</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2025-07-012025-09-30_custom_LetterAgreementMember"
      decimals="0"
      id="Fact001121"
      unitRef="USD">11843</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:LoansPayable
      contextRef="AsOf2026-06-30_custom_LetterAgreementMember"
      decimals="0"
      id="Fact001123"
      unitRef="USD">152612</us-gaap:LoansPayable>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2026-06-30_custom_LetterAgreementMember"
      decimals="0"
      id="Fact001125"
      unitRef="USD">153256</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2026-06-30_custom_LetterAgreementMember"
      decimals="0"
      id="Fact001127"
      unitRef="USD">644</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LoansPayable
      contextRef="AsOf2026-09-30_custom_LetterAgreementMember"
      decimals="0"
      id="Fact001129"
      unitRef="USD">153256</us-gaap:LoansPayable>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2026-09-30_custom_LetterAgreementMember"
      decimals="0"
      id="Fact001131"
      unitRef="USD">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001133"
      unitRef="USD">364801</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2026-06-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001135"
      unitRef="USD">460809</us-gaap:LoansPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001137"
      unitRef="USD">118927</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2026-06-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001139"
      unitRef="USD">128318</us-gaap:InterestPayableCurrent>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2026-06-30_custom_SecuritiesPurchaseAgreementMember_custom_CrownBridgePartnersLLCMember"
      decimals="0"
      id="Fact001141"
      unitRef="USD">0</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2025-06-30_custom_SecuritiesPurchaseAgreementMember_custom_CrownBridgePartnersLLCMember"
      decimals="0"
      id="Fact001143"
      unitRef="USD">65280</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2019-10-03_custom_SecuritiesPurchaseAgreementMember_custom_CrownBridgePartnersLLCMember"
      decimals="INF"
      id="Fact001145"
      unitRef="Pure">0.15</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-06-30_custom_SecuritiesPurchaseAgreementMember_custom_CrownBridgePartnersLLCMember"
      decimals="0"
      id="Fact001147"
      unitRef="USD">65280</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2026-09-30_custom_CrownBridgePartnersLLCMember_custom_ExchangeAgreementMember"
      decimals="0"
      id="Fact001149"
      unitRef="USD">0</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2025-09-30_custom_CrownBridgePartnersLLCMember_custom_ExchangeAgreementMember"
      decimals="0"
      id="Fact001151"
      unitRef="USD">0</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2026-01-072026-01-07_custom_CrownBridgePartnersLLCMember_custom_ExchangeAgreementMember"
      decimals="INF"
      id="Fact001153"
      unitRef="Shares">1579</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-01-07_custom_ExchangeAgreementMember_custom_CrownBridgePartnersLLCMember"
      decimals="0"
      id="Fact001155"
      unitRef="USD">65280</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2026-01-07_custom_ExchangeAgreementMember_custom_CrownBridgePartnersLLCMember"
      decimals="0"
      id="Fact001157"
      unitRef="USD">60484</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2026-01-07_custom_ExchangeAgreementMember_custom_CrownBridgePartnersLLCMember"
      decimals="INF"
      id="Fact001159"
      unitRef="USDPShares">127</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2026-01-072026-01-07_custom_CrownBridgePartnersLLCMember_custom_ExchangeAgreementMember"
      decimals="0"
      id="Fact001161"
      unitRef="USD">200000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-01-072026-01-07_custom_CrownBridgePartnersLLCMember_custom_ExchangeAgreementMember"
      decimals="0"
      id="Fact001163"
      unitRef="USD">74236</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LoansPayable
      contextRef="AsOf2026-09-30_custom_CrownBridgePartnersLLCMember_custom_ExchangeAgreementMember"
      decimals="0"
      id="Fact001165"
      unitRef="USD">0</us-gaap:LoansPayable>
    <us-gaap:LoansPayable
      contextRef="AsOf2026-06-30_custom_CrownBridgePartnersLLCMember_custom_ExchangeAgreementMember"
      decimals="0"
      id="Fact001167"
      unitRef="USD">0</us-gaap:LoansPayable>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember_custom_LoansInDefaultMember"
      decimals="0"
      id="Fact001169"
      unitRef="USD">364801</us-gaap:LoansPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember_custom_LoansInDefaultMember"
      decimals="0"
      id="Fact001171"
      unitRef="USD">118928</us-gaap:InterestPayableCurrent>
    <PPCB:DebtInstrumentInterestRateDefaultPercentage
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember_custom_LoansInDefaultMember"
      decimals="INF"
      id="Fact001173"
      unitRef="Pure">0.18</PPCB:DebtInstrumentInterestRateDefaultPercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact001175">&lt;p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z9dnADXXID25" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5 - &lt;span id="xdx_82A_zAFDFFlOBJw7"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Reverse
Stock Split&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2026, the Company received written consent in lieu of a meeting by the holders of a majority of the voting power of the Company&#x2019;s
outstanding capital stock as of March 2026 and the Company&#x2019;s Board of Directors approving such actions as are necessary for the
Company to proceed to, and the Company accordingly intends to, effectuate and execute a reverse stock split of &lt;span id="xdx_90A_eus-gaap--StockholdersEquityReverseStockSplit_c20260301__20260331_z7JrfUFy0W29" title="Reverse stock split description"&gt;the Company&#x2019;s issued and outstanding shares of common stock at a ratio of one post-split share per twenty-five pre-split shares (1:25)&lt;/span&gt; (the &#x201c;May 2026
Reverse Stock Split&#x201d;). The Reverse Stock Split became effective as of May 18, 2026. Proportional adjustments for the May 2026 Reverse
Stock Split were made to the Company&#x2019;s outstanding stock options, warrants and equity incentive plans.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2026, the Company received written consent in lieu of a meeting by the holders of a majority of the voting power of the Company&#x2019;s
outstanding capital stock as of October 2026 and the Company&#x2019;s Board of Directors approving such actions as are necessary for the
Company to proceed to effectuate and execute a reverse stock split of &lt;span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20261001__20261031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zttvVbPoL1ea" title="Reverse stock split description"&gt;the Company&#x2019;s issued and outstanding shares of common stock
at a ratio of one post-split share per ten pre-split shares (1:10) (the &#x201c;Reverse Stock Split&#x201d;)&lt;/span&gt;. The Reverse Stock Split became
effective as of October 26, 2026. Proportional adjustments for the Reverse Stock Split were made to the Company&#x2019;s outstanding stock
options, warrants and equity incentive plans.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
share and per-share data and amounts have been retroactively adjusted as of the earliest period presented in the consolidated financial
statements to reflect the reverse stock splits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPANC
BIOPHARMA, INC. AND SUBSIDIARY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Series
A Preferred Stock&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Of
the total preferred shares authorized, &lt;span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zm61YR7VUtL8" title="Preferred stock, shares authorized"&gt;500,000&lt;/span&gt; had been designated as Series A Preferred Stock (&#x201c;Series A Preferred Stock&#x201d;),
pursuant to the Certificate of Designation for the Series A Preferred Stock filed with the Secretary of State of the State of Delaware
on December 9, 2014. There were &lt;span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_do_c20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zDmBT9jY6bI6" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWIk7sMhTBNl" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_do_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4GtcgRGk4S1" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zpTuoT3vpc5g" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares of Series A Preferred Stock issued and outstanding as of September 30, 2026 and June 30, 2026
for both periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Series
B Preferred Stock&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to a certificate of designation filed with the Secretary of State of the State of Delaware on June 16, 2015, five shares of preferred
stock have been designated as Series B Preferred Stock, par value $&lt;span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_z9qFtnwzGEqc" title="Preferred stock, par value"&gt;0.01&lt;/span&gt; per share, of the Company (&#x201c;Series B Preferred Stock&#x201d;).
Each holder of shares of Series B Preferred Stock is entitled to voting power equivalent to the number of votes equal to the total number
of shares of common stock outstanding as of the record date for the determination of stockholders entitled to vote at each meeting of
stockholders of the Company and entitled to vote on all matters submitted or required to be submitted to a vote of the stockholders of
the Company. &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_c20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zB7iaR3egBVe" title="Preferred stock shares issued"&gt;&lt;span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zu9zpNIz5JAi" title="Preferred stock shares outstanding"&gt;&lt;span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pid_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWhBOFE0j0Ul" title="Preferred stock shares issued"&gt;&lt;span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zDfbqFYK2iBj" style="display: none" title="Preferred stock shares outstanding"&gt;1&lt;/span&gt;One&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; share of Series B Preferred Stock is issued and outstanding as of September 30, 2026 and June 30, 2026. Mr. Nathanielsz,
the Company&#x2019;s Chief Executive Officer, directly beneficially owns such &lt;span id="xdx_90A_eus-gaap--InvestmentOwnedBalanceShares_iI_c20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_ztVFftfL4436" title="Preferred stock, shares owned"&gt;one&lt;/span&gt; share of Series B Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharesIssued_iI_pid_do_c20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCrr7uJcaRCe" title="Shares issued"&gt;&lt;span id="xdx_90A_eus-gaap--SharesIssued_iI_pid_do_c20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zlFPcCx9954d" title="Shares issued"&gt;&lt;span id="xdx_90E_eus-gaap--SharesIssued_iI_pid_do_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3ES5oGo1909" title="Shares issued"&gt;&lt;span id="xdx_90B_eus-gaap--SharesIssued_iI_pid_do_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUgcBGyGxbal" title="Shares issued"&gt;No&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
additional shares of Series A Preferred Stock or Series B Preferred Stock were issued as of September 30, 2026 and June 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Convertible
Series C Preferred Stock and Series C Warrants&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 4, 2025 (the &#x201c;Closing Date&#x201d;), the Company completed a private placement pursuant to a Securities Purchase Agreement
with Hexstone Capital LLC (&#x201c;Hexstone&#x201d;). At closing, Hexstone purchased &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20251104__20251104__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--HexstoneCapitalLLCMember_zHangruta1i4" title="Shares issued"&gt;100&lt;/span&gt; shares of Series C Preferred Stock (the &#x201c;Initial
Preferred Shares&#x201d;), par value $&lt;span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20251104__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--HexstoneCapitalLLCMember_zocYEoi0Tqfd" title="Preferred stock par value"&gt;0.01&lt;/span&gt;, with a stated value of $&lt;span id="xdx_905_ecustom--PreferredStockStatedValuePerShare_iI_pid_c20251104__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--HexstoneCapitalLLCMember_zulOIuvuthC2" title="Preferred stock stated value"&gt;10,000&lt;/span&gt; per share, for total gross proceeds of $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueOther_c20251104__20251104__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--HexstoneCapitalLLCMember_zFrioCx6vFDi" title="Stock issued in private placement, value"&gt;1,000,099&lt;/span&gt;. The Company
paid legal fees of $&lt;span id="xdx_905_eus-gaap--LegalFees_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--HexstoneCapitalLLCMember_zuAHuT4YQKl4" title="Legal fees paid"&gt;50,000&lt;/span&gt; related to this private placement and was recorded as deemed dividend during the year ended June 30, 2026
due to the temporary equity classification as noted below. In connection with the transaction, the Company also issued warrants to purchase
up to &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251104__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--HexstoneCapitalLLCMember_zQ1t9478M2nj" title="Warrants issued convertible into shares"&gt;9,900&lt;/span&gt; additional shares of Series C Preferred Stock. Each warrant is exercisable for one share of Series C Preferred Stock at an
exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251104__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--HexstoneCapitalLLCMember_zXpsw5VkyTO5" title="Warrant exercise price"&gt;10,000&lt;/span&gt; per share (subject to equitable adjustments by the Company relating to stock-splits, reclassifications, combination,
extraordinary distributions and similar events) and expires two years from issuance. The Series C Preferred Stock and warrants were issued
in a private placement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series C Preferred Stock shall have a stated value of $&lt;span id="xdx_905_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20251104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HexstoneCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zAxn8lGachc8" title="Preferred stock liquidation value per share"&gt;10,000&lt;/span&gt; per share and liquidation value equal to the greater of (A) &lt;span id="xdx_903_ecustom--PreferredStockStatedValuePercentage_pid_dp_c20251104__20251104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HexstoneCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z0lPInwRoFS8" title="Preferred stock stated value percentage"&gt;100&lt;/span&gt;% of stated
value of such Series C Preferred Stock and (B) the amount per share such holder would receive if such holder converted into Common Stock
immediately prior to the date of such payment. The holder of Series C Preferred Stock shall have a dividend rate of &lt;span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20251104__20251104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HexstoneCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zecHhJWIsDl8" title="Preferred stock dividend rate"&gt;0&lt;/span&gt;%. However, the
dividend rate shall automatically be increased to ten percent (&lt;span id="xdx_909_ecustom--DividendRateAnnualIncreasePercentage_pid_dp_c20251104__20251104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HexstoneCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zsMYVBdLtfgb" title="Annual increased dividend rate"&gt;10.0&lt;/span&gt;%) per annum upon any bankruptcy triggering event as defined in the
Certificate of Designation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
any time after the initial issuance date, each share of Series C Preferred Stock shall be convertible into shares of common stock of
the Company by the holder thereof by dividing the stated amount of each share of Series C Preferred Stock of $&lt;span id="xdx_909_ecustom--PreferredStockConversionPrice_iI_pid_c20251104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HexstoneCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z1yRQsGaA1Sl" title="Preferred stock, conversion price"&gt;10,000&lt;/span&gt; by the conversion
price. The conversion price shall be the lesser of the fixed conversion price of $&lt;span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20251104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HexstoneCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zwo66Q2Z24ri" title="Fixed conversion price"&gt;125.00&lt;/span&gt; per share or 85% (or 70% if the common stock
is suspended from trading on or delisted from the principal market at any time after the initial issuance date (whether or not subsequently
cured)), or, in the case of the Initial Preferred Shares) of the of the lowest trading price of the Common Stock during the period beginning
on the day the holder sends a conversion notice to the Company and ending on the trading day on which the aggregate dollar volume of
the Company&#x2019;s common stock exceeds the product of the conversion amount set forth on the applicable conversion notice multiplied
by seven (7) after the applicable holder receives the shares of common stock issuable upon conversion of the Series C Preferred Stock,
subject to a five (5) trading day minimum (such period, the &#x201c;Conversion Measuring Period&#x201d;); provided, however, that each
day on which (i) the Common Stock has been suspended for trading on all Eligible Markets, (ii) Conversion Shares cannot be sold by the
Holder because of violation of Section 32 by the Company, or (iii) Conversion Shares are not delivered after the Share Delivery Deadline,
that day&#x2019;s dollar volume shall be excluded from the calculation of the total aggregate dollar volume of the Conversion Measuring
Period. All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification
or similar transaction that proportionately decreases or increases the Common Stock during such Conversion Measuring Period; provided
further that in no event shall the Conversion Price be lower than the initial Floor Price of $&lt;span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20251104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HexstoneCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zJila0Bpm9M4" title="Fixed conversion price"&gt;125.00&lt;/span&gt; subject to adjustment per the Board&#x2019;s
discretion. In February 2026, the floor price was adjusted to a new floor price of $&lt;span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20260228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HexstoneCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zyJ9XjAFufb" title="Fixed conversion price"&gt;12.50&lt;/span&gt;. In May 2026, the floor price was readjusted
to $&lt;span id="xdx_90A_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20260531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HexstoneCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zbIfKqaAm2A4" title="Fixed conversion price"&gt;0.50&lt;/span&gt; after the reverse stock split. As of September 30, 2026, the effective floor price is $&lt;span id="xdx_902_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HexstoneCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zfXGVacnhEki" title="Fixed conversion price"&gt;0.50&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subject
to the limitations specified in the Certificate of Designation, holders of Series C Preferred Stock shall have the right to vote on all
matters presented to the stockholders for approval together with the shares of Common Stock, voting together as a single class, on an
&#x201c;as converted&#x201d; basis using the conversion price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--PreferredStockConversionBasisForBankruptcy_pid_c20251104__20251104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HexstoneCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zbCkwVEZEkL7" title="Preferred stock, conversion basis for bankruptcy"&gt;Upon
any bankruptcy triggering event, the Company were to immediately redeem, in cash, each of the Series C Preferred Stock then outstanding
at a redemption price equal to the applicable triggering event redemption price. Each of the Series C Preferred Stock subject to redemption
by the Company were to be redeemed by the Company at a price equal to the greater of (i) the product of (A) the conversion amount to
be redeemed multiplied by (B) the redemption premium of 110% and (ii) the product of (X) the conversion rate with respect to the conversion
amount in effect multiplied by (Y) the product of (1) the redemption premium of 110% multiplied by (2) the VWAP of the Common Stock on
any trading day during the period commencing on the date immediately preceding such triggering event and ending on the trading date prior
to the date the Company makes the entire payment required to be made. On May 5, 2026, the Company filed a certificate of amendment of
certificate of designations of Series C Convertible Preferred Stock whereby amongst other things, the Company removed the mandatory redemption
upon any bankruptcy triggering event (the &#x201c;May 5, 2026 Amended Series C Designation&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--InvestmentMaturityDescription_pid_c20260505__20260505__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HexstoneCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zNDJrg4D05uc" title="Maturity description"&gt;Although
the Series C Preferred Stock does not have a fixed maturity date and is not mandatorily redeemable on a specified date, the contingent
mandatory redemption feature upon a bankruptcy triggering event was considered a conditional obligation to transfer assets outside the
Company&#x2019;s control. Accordingly, the Company determined that under ASC 480, the Series C Preferred Stock was initially treated as
temporary equity until the May 5, 2026 Amended Series C Designation. Upon issuance of the Series C Preferred Stock, the Company allocated
the fair value of $117,754 to the Series C Preferred and subsequent accretion to redemption value at issuance date. Accordingly, during
fiscal year 2026, the Company accreted $882,246 to redemption value along with the $50,000 in offering costs and was recorded as deemed
dividend totaling $932,246 which was charged to additional paid in capital in the absence of retained earnings in the Company. On May
5, 2026, the date the Series C designation was amended, there were 100 shares of Series C Preferred Stock at that time with a redemption
value of $1,000,000 and was reclassified from temporary equity to permanent equity&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPANC
BIOPHARMA, INC. AND SUBSIDIARY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
due to delayed filing and declaration of effectiveness relative to the deadlines defined in the Registration Rights Agreement in connection
with this Securities Purchase Agreement, the Company accrued a registration rights penalty amounting to $&lt;span id="xdx_908_ecustom--RegistrationRightsPenaltyAmount_c20250701__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HexstoneCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zR3J4tGgXOh6" title="Registration rights penalty amount"&gt;6,000&lt;/span&gt;, which is payable in &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250701__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HexstoneCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zj5utOlyBFhc" title="Shares of common stock"&gt;400&lt;/span&gt;
shares of the Company&#x2019;s common stock to Hexstone and was included in accrued expenses and other payables on the accompanying consolidated
balance sheets as of June 30, 2026 and a corresponding other expense during the fiscal year June 30, 2026. As of September 30, 2026,
the Company revalued such &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260701__20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HexstoneCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zwnxbBOcCMTd" title="Shares of common stock"&gt;400&lt;/span&gt; shares and the value amounted to $&lt;span id="xdx_90E_ecustom--RegistrationRightsPenaltyAmount_c20260701__20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HexstoneCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zdykiubywWf6" title="Registration rights penalty amount"&gt;1,976&lt;/span&gt; and was included in accrued expenses and other payables on the
accompanying condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Series
C Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had previously accounted for the &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251104__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--HexstoneCapitalLLCMember_zXEHSzCcv237" title="Warrants issued convertible into shares"&gt;9,900&lt;/span&gt; warrants issued on November 4, 2025, in accordance with the guidance contained in ASC
815 &#x201c;Derivatives and Hedging&#x201d; whereby under that provision these warrants did not meet the criteria for equity treatment
and were recorded as a liability since the host instrument itself (Series C Preferred Stock) was classified as temporary equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
initial valuation of the &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251104__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--HexstoneCapitalLLCMember_z9GgjsOxVPRl" title="Warrants issued convertible into shares"&gt;9,900&lt;/span&gt; warrants was valued at $&lt;span id="xdx_903_ecustom--InitialFairValueOfWarrantLiabilityUponIssuance_c20251104__20251104__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--HexstoneCapitalLLCMember_zsrRdCPZLzT6" title="Initial fair value of warrants"&gt;882,345&lt;/span&gt; on November 4, 2025 and was recorded at fair value as of each reporting
date with the change in fair value reported within other income in the accompanying consolidated statements of operations as &#x201c;Change
in fair value of warrant liability&#x201d; until the warrants are exercised, expired or other facts and circumstances lead the warrant
liability to be reclassified to stockholders&#x2019; equity which occurred on May 5, 2026 due to the May 5, 2026 Amended Series C Designation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilized a Monte Carlo Simulation model to estimate the fair values of the &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251104__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--MonteCarloMember_zJBxnjmRaVBb" title="Warrants issued convertible into shares"&gt;9,900&lt;/span&gt; warrants, which incorporated significant inputs
that were not observable in the market, and thus represents a Level 3 measurement as defined in ASC 820. The unobservable inputs utilized
for measuring the fair value of the contingent consideration reflected management&#x2019;s own assumptions about the assumptions that
market participants would use in valuing the contingent consideration. The total fair value of the warrant liability on May 5, 2026 of
$&lt;span id="xdx_90D_ecustom--InitialFairValueOfWarrantLiabilityUponIssuance_c20260505__20260505__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--MonteCarloMember_zfmDAr4nuSrk" title="Initial fair value of warrants"&gt;973,115&lt;/span&gt; was reclassified into additional paid in capital during fiscal year 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Series
C Preferred Stock Conversions&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2026, the Company issued an aggregate of &lt;span id="xdx_900_eus-gaap--ConversionOfStockSharesIssued1_c20260801__20260831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhJhy8y79pxk" title="Number of shares issued upon conversion"&gt;220,466&lt;/span&gt; shares of its common stock as a result of the conversion of &lt;span id="xdx_90A_eus-gaap--ConversionOfStockSharesConverted1_c20260801__20260831__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zq5Ya90RrcKk" title="Preferred stock converted"&gt;200&lt;/span&gt; shares of Series
C Preferred stock during such period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2026, the Company issued an aggregate of &lt;span id="xdx_901_eus-gaap--ConversionOfStockSharesIssued1_pid_c20260901__20260930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6rDAmF4eP24" title="Number of shares issued upon conversion"&gt;32,800&lt;/span&gt; shares of its common stock and recorded common stock issuable of &lt;span id="xdx_908_ecustom--CommonStockIssuableShares_iI_c20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zZbKsG2qU9a9" title="Common stock issuable, shares"&gt;64,972&lt;/span&gt; shares
as a result of the conversion of &lt;span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20260901__20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z36SNLijr6Wd" title="Preferred stock converted"&gt;50&lt;/span&gt; shares of Series C Preferred stock during such period. The common stock issuable of &lt;span id="xdx_904_eus-gaap--SharesIssued_iI_pid_c20261031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMsvGtlt4iyb" title="Shares issued for common stock issuable"&gt;64,972&lt;/span&gt; shares
were issued in October 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Issuance
of Series C Preferred Stock upon exercise of Series C Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2026, the Company issued an aggregate of &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20260801__20260831__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_za0iNgF6jyF7" title="Shares issued upon exercise of warrants"&gt;200&lt;/span&gt; shares of Series C preferred stock upon the exercise of &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260831__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zmeLuf6WOjMe" title="Warrants exercised"&gt;200&lt;/span&gt; Series C Warrants with
an exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260831__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zvfbIvQPBmIg" title="Warrant exercise price per share"&gt;10,000&lt;/span&gt; per share and received aggregate gross proceeds of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromWarrantExercises_c20260801__20260831__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_z1ZTZ1RWqtGb" title="Proceeds from exercise of warrants"&gt;2,000,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were &lt;span&gt;&lt;span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_c20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zoKtitYGUOdg" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zAIXVFmpo2d6" title="Preferred stock, shares outstanding"&gt;150&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares of Series C Preferred Stock issued and outstanding as of September 30, 2026 with a redemption value amounted to $&lt;span id="xdx_90F_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_c20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zEQNb1npdEhl" title="Preferred stock, redemption value"&gt;1,500,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Issuance
of common stock for common stock issuable&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Between
July 2026 and August 2026, the Company issued an aggregate of &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260701__20260831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqJ2yrrqL4Bf" title="Number of shares issued"&gt;48,763&lt;/span&gt; shares of its common stock for common stock issuable as of June
30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Issuance
of common stock issued for services&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 24, 2026, the Company issued an aggregate of &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20260724__20260724__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKXL99Pyl8W3" title="Stock issued"&gt;350,000&lt;/span&gt; shares of common stock to certain officers, an employee, directors and consultants
for services rendered in July 2026. Those shares were valued at approximately $&lt;span id="xdx_905_eus-gaap--SharePrice_iI_pid_c20260724__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zE3xIwl715Tj" title="Share price per share"&gt;13.7&lt;/span&gt; per share or $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20260724__20260724__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyhlf3t0Swkj" title="Value of shares issued for services"&gt;4,795,000&lt;/span&gt;, being the closing price
of the stock on the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock-based
expense for prepaid (stock-based) services&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
fiscal year 2025, the Company issued an aggregate of &lt;span&gt;&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240701__20250630__srt--TitleOfIndividualAxis__custom--ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqW0xXWsFHcd" title="Issuance of common stock for services, shares"&gt;8,100&lt;/span&gt;&lt;/span&gt; shares of fully vested, non-forfeitable common stock to various consultants
for consulting, investor relations and business advisory services with service terms ranging from &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dtM_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember__srt--RangeAxis__srt--MinimumMember_z2BZzr5DX8Of" title="Service term"&gt;6&lt;/span&gt; months to &lt;span&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dtY_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember__srt--RangeAxis__srt--MaximumMember_zEwN3o6LSq71" style="display: none" title="Service term"&gt;3&lt;/span&gt;three years&lt;/span&gt;. Those shares
were valued at a weighted average price of approximately $&lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember_zDaOLIDueUai" title="Share issued price per share"&gt;2,900&lt;/span&gt; (ranging from $&lt;span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember__srt--TitleOfIndividualAxis__custom--ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember_zUgwmeYLSDUd" title="Share issued price per share"&gt;1,750&lt;/span&gt; to $&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember__srt--TitleOfIndividualAxis__custom--ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember_z9pfZEDlZ5T7" title="Share issued price per share"&gt;3,750&lt;/span&gt;) or $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember_z7IXWhNjIxp" title="Issuance of common stock for services, value"&gt;23,881,110&lt;/span&gt;, being the closing prices
of the stock on each respective date of grants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
fiscal year 2026, the Company issued an additional &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250701__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember_z5mbGoylje5j" title="Number of shares issued for services"&gt;30,000&lt;/span&gt; shares of fully vested, non-forfeitable common stock to various consultants
for consulting, investor relations and business advisory services related to existing &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dtY_c20250701__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember_z99C7IJeUoT3" title="Service term"&gt;3&lt;/span&gt;-year consulting agreements dated between January
2025 and March 2025. Those shares were valued at approximately $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember_zSgAGFV5a0Ve" title="Share issued price per share"&gt;35&lt;/span&gt; per share or $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250701__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember_zxgzuIeBuWD7" title="Value of shares issued for services"&gt;1,050,000&lt;/span&gt;, being the closing price of the stock on the
date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended September 30, 2026 and 2025, the Company recorded total stock-based compensation of $&lt;span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20260701__20260930__srt--TitleOfIndividualAxis__custom--ConsultingInvestorRelationsAndBusinessAdvisoryServicesOneMember_z55gi6JZrJU2" title="Stock-based compensation"&gt;1,931,989&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20250701__20250930__srt--TitleOfIndividualAxis__custom--ConsultingInvestorRelationsAndBusinessAdvisoryServicesOneMember_za8olR7lcm7c" title="Stock-based compensation"&gt;3,024,605&lt;/span&gt;,
respectively, related to the above transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
June 30, 2026, the Company recorded prepaid (stock based) expense &#x2013; current portion of $&lt;span id="xdx_904_eus-gaap--PrepaidExpenseCurrent_iI_c20260630__srt--TitleOfIndividualAxis__custom--ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember_zAz56t1Yex3b" title="Prepaid expenses, current portion"&gt;7,620,846&lt;/span&gt; and prepaid (stock based) expense
&#x2013; long-term portion of $&lt;span id="xdx_90A_eus-gaap--PrepaidExpenseNoncurrent_iI_c20260630__srt--TitleOfIndividualAxis__custom--ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember_zijKHG9WgIZ" title="Prepaid expenses, long-term portion"&gt;4,190,543&lt;/span&gt; to be amortized over the terms of the respective agreements. At September 30, 2026, the Company
recorded prepaid (stock based) expense &#x2013; current portion of $&lt;span id="xdx_905_eus-gaap--PrepaidExpenseCurrent_iI_c20260930__srt--TitleOfIndividualAxis__custom--ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember_z5AxOoWahzk9" title="Prepaid stock based expenses, current portion"&gt;7,591,860&lt;/span&gt; and prepaid (stock based) expense &#x2013; long-term portion
of $&lt;span id="xdx_908_eus-gaap--PrepaidExpenseNoncurrent_iI_c20260930__srt--TitleOfIndividualAxis__custom--ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember_zxWZTKnUC3X8" title="Prepaid expenses stock based, long-term portion"&gt;2,287,540&lt;/span&gt; related to fiscal year 2025 and 2026 issuances to be amortized over the terms of the respective agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPANC
BIOPHARMA, INC. AND SUBSIDIARY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Treasury
Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Between
July 2026 and August 2026, the Company repurchased &lt;span id="xdx_902_eus-gaap--StockRepurchasedDuringPeriodShares_c20260701__20260831__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zuJ4Jz2hYDIk" title="Number of shares repurchased"&gt;&lt;span&gt;&lt;span&gt;320,031&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares of its common stock under the Repurchase Plan for an aggregate purchase
price of approximately $&lt;span id="xdx_90A_eus-gaap--StockRepurchasedDuringPeriodValue_c20260701__20260831__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zreugp9WzpRf" title="Value of shares repurchased"&gt;499,000&lt;/span&gt;, at an average purchase price of $&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20260831__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zlrDN3xyYHLl"&gt;1.56&lt;/span&gt; per share. The shares repurchased are recorded as treasury stock
at cost and presented as a reduction of stockholders&#x2019; equity in the Company&#x2019;s condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Restricted
Stock Units&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to employment agreements dated in May 2019, the Company granted de minimis restricted stock unit (after the Reverse Stock Split) to the
Company&#x2019;s Chief Executive Officer and Chief Scientific Officer. Such restricted stock units are subject to vesting terms as defined
in the employment agreements. Such restricted stock units were valued at the fair value of approximately $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20190501__20190531__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zei5d0TX8Zh" title="Restricted stock units, value"&gt;497,240&lt;/span&gt; based on the quoted
trading price on the date of grant. There were $&lt;span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20260930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z550NsD69LA" title="Unrecognized restricted stock units expense"&gt;&lt;span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhUnczqEPEUg" title="Unrecognized restricted stock units expense"&gt;248,620&lt;/span&gt;&lt;/span&gt; unrecognized restricted stock units expense as of September 30, 2026 and June
30, 2026. A de minimis amount of unvested restricted stock units which are subject to various performance conditions have not yet been
met and have not yet vested as of September 30, 2026 to which the above amount of $&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_iI_c20260930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm6csPtaSPo" title="Restricted stock units not yet vested"&gt;248,620&lt;/span&gt; relates to.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Stock
Warrants:&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zI0dvux9wlWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes warrant activity for the three months ended September 30, 2026:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zIUi6o5xTlvj" style="display: none"&gt;SUMMARY OF WARRANT ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price Per Share&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Outstanding at June 30, 2026 &#x2013; no warrant designation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20260701__20260930_z8sht09gs4C5" style="width: 14%; text-align: right" title="Number of Warrants, Outstanding, Balance"&gt;121&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageOutstanding_iS_pid_c20260701__20260930_z4eM5eLLemwb" style="width: 14%; text-align: right" title="Weighted Average Price Per Share, Outstanding, Balance"&gt;1,248&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Outstanding at June 30, 2026 - Series C preferred stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_pid_c20260701__20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zt3S1shDKzo5" style="text-align: right" title="Number of Series C Preferred stock warrants, Outstanding, Balance"&gt;9,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceOutstanding_pid_c20260701__20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zmmVeL0WOA6i" style="text-align: right" title="Weighted Average Price Per Share, Outstanding preferred stock warrants"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Exercised &#x2013; Series C preferred stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20260701__20260930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zjLIFuqA6mj" style="text-align: right" title="Number of Warrants, Exercised"&gt;(200&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExercised_pid_c20260701__20260930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zxKD836Fpzml" style="text-align: right" title="Weighted Average Price Per Share, Exercised"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20260701__20260930_zPRuMVGsramj" style="text-align: right" title="Number of Warrants, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1362"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceForfeited_pid_c20260701__20260930_zsxWEcUY3W75" style="text-align: right" title="Weighted Average Price Per Share, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1364"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20260701__20260930_zDurmV8V62q9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Expired"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExpired_pid_c20260701__20260930_za1T4nK6s8vd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Price Per Share, Expired"&gt;150,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Outstanding at September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20260701__20260930_zFMNK55a3mTk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Outstanding, Balance"&gt;9,520&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageOutstanding_iE_pid_c20260701__20260930_zZOjIXuG6mEd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Price Per Share, Outstanding, Balance"&gt;9,886.55&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Exercisable at September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20260701__20260930_zcnHLIkPU101" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Exercisable, Balance"&gt;9,520&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisable_iE_pid_c20260701__20260930_zSyX4BoNGhbe" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Price Per Share, Exercisable, Balance"&gt;9,886.55&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Outstanding and Exercisable:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Weighted average remaining contractual term&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260701__20260930_z9VQy1sNiGd4" title="Weighted average remaining contractual term"&gt;1.13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Aggregate intrinsic value &lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20260701__20260930_z5iuIiv1zA7i" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1380"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zXn3vHQQ7tIh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2026-03-012026-03-31" id="Fact001177">the Company&#x2019;s issued and outstanding shares of common stock at a ratio of one post-split share per twenty-five pre-split shares (1:25)</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2026-10-012026-10-31_us-gaap_SubsequentEventMember"
      id="Fact001179">the Company&#x2019;s issued and outstanding shares of common stock
at a ratio of one post-split share per ten pre-split shares (1:10) (the &#x201c;Reverse Stock Split&#x201d;)</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-09-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001181"
      unitRef="Shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-09-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001183"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-09-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001185"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-06-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001187"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-06-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001189"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-09-30_us-gaap_SeriesBPreferredStockMember_custom_MrNathanielszMember"
      decimals="INF"
      id="Fact001191"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-09-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001193"
      unitRef="Shares">1</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001195"
      unitRef="Shares">1</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-06-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001197"
      unitRef="Shares">1</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001199"
      unitRef="Shares">1</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-09-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001203"
      unitRef="Shares">0</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-09-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001205"
      unitRef="Shares">0</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-06-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001207"
      unitRef="Shares">0</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-06-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001209"
      unitRef="Shares">0</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-11-042025-11-04_us-gaap_SeriesCPreferredStockMember_custom_HexstoneCapitalLLCMember"
      decimals="INF"
      id="Fact001211"
      unitRef="Shares">100</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-11-04_us-gaap_SeriesCPreferredStockMember_custom_HexstoneCapitalLLCMember"
      decimals="INF"
      id="Fact001213"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <PPCB:PreferredStockStatedValuePerShare
      contextRef="AsOf2025-11-04_us-gaap_SeriesCPreferredStockMember_custom_HexstoneCapitalLLCMember"
      decimals="INF"
      id="Fact001215"
      unitRef="USDPShares">10000</PPCB:PreferredStockStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-11-042025-11-04_us-gaap_SeriesCPreferredStockMember_custom_HexstoneCapitalLLCMember"
      decimals="0"
      id="Fact001217"
      unitRef="USD">1000099</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:LegalFees
      contextRef="From2025-11-042025-11-04_custom_HexstoneCapitalLLCMember"
      decimals="0"
      id="Fact001219"
      unitRef="USD">50000</us-gaap:LegalFees>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-11-04_us-gaap_SeriesCPreferredStockMember_custom_HexstoneCapitalLLCMember"
      decimals="INF"
      id="Fact001221"
      unitRef="Shares">9900</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-11-04_us-gaap_SeriesCPreferredStockMember_custom_HexstoneCapitalLLCMember"
      decimals="INF"
      id="Fact001223"
      unitRef="USDPShares">10000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2025-11-04_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001225"
      unitRef="USDPShares">10000</us-gaap:PreferredStockLiquidationPreference>
    <PPCB:PreferredStockStatedValuePercentage
      contextRef="From2025-11-042025-11-04_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001227"
      unitRef="Pure">1</PPCB:PreferredStockStatedValuePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-11-042025-11-04_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001229"
      unitRef="Pure">0</us-gaap:PreferredStockDividendRatePercentage>
    <PPCB:DividendRateAnnualIncreasePercentage
      contextRef="From2025-11-042025-11-04_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001231"
      unitRef="Pure">0.100</PPCB:DividendRateAnnualIncreasePercentage>
    <PPCB:PreferredStockConversionPrice
      contextRef="AsOf2025-11-04_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001233"
      unitRef="USD">10000</PPCB:PreferredStockConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2025-11-04_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001235"
      unitRef="USDPShares">125.00</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2025-11-04_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001237"
      unitRef="USDPShares">125.00</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2026-02-28_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001239"
      unitRef="USDPShares">12.50</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2026-05-31_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001241"
      unitRef="USDPShares">0.50</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2026-09-30_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001243"
      unitRef="USDPShares">0.50</us-gaap:PreferredStockConvertibleConversionPrice>
    <PPCB:PreferredStockConversionBasisForBankruptcy
      contextRef="From2025-11-042025-11-04_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember"
      id="Fact001245">Upon
any bankruptcy triggering event, the Company were to immediately redeem, in cash, each of the Series C Preferred Stock then outstanding
at a redemption price equal to the applicable triggering event redemption price. Each of the Series C Preferred Stock subject to redemption
by the Company were to be redeemed by the Company at a price equal to the greater of (i) the product of (A) the conversion amount to
be redeemed multiplied by (B) the redemption premium of 110% and (ii) the product of (X) the conversion rate with respect to the conversion
amount in effect multiplied by (Y) the product of (1) the redemption premium of 110% multiplied by (2) the VWAP of the Common Stock on
any trading day during the period commencing on the date immediately preceding such triggering event and ending on the trading date prior
to the date the Company makes the entire payment required to be made. On May 5, 2026, the Company filed a certificate of amendment of
certificate of designations of Series C Convertible Preferred Stock whereby amongst other things, the Company removed the mandatory redemption
upon any bankruptcy triggering event (the &#x201c;May 5, 2026 Amended Series C Designation&#x201d;).</PPCB:PreferredStockConversionBasisForBankruptcy>
    <PPCB:InvestmentMaturityDescription
      contextRef="From2026-05-052026-05-05_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember"
      id="Fact001247">Although
the Series C Preferred Stock does not have a fixed maturity date and is not mandatorily redeemable on a specified date, the contingent
mandatory redemption feature upon a bankruptcy triggering event was considered a conditional obligation to transfer assets outside the
Company&#x2019;s control. Accordingly, the Company determined that under ASC 480, the Series C Preferred Stock was initially treated as
temporary equity until the May 5, 2026 Amended Series C Designation. Upon issuance of the Series C Preferred Stock, the Company allocated
the fair value of $117,754 to the Series C Preferred and subsequent accretion to redemption value at issuance date. Accordingly, during
fiscal year 2026, the Company accreted $882,246 to redemption value along with the $50,000 in offering costs and was recorded as deemed
dividend totaling $932,246 which was charged to additional paid in capital in the absence of retained earnings in the Company. On May
5, 2026, the date the Series C designation was amended, there were 100 shares of Series C Preferred Stock at that time with a redemption
value of $1,000,000 and was reclassified from temporary equity to permanent equity</PPCB:InvestmentMaturityDescription>
    <PPCB:RegistrationRightsPenaltyAmount
      contextRef="From2025-07-012026-06-30_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact001249"
      unitRef="USD">6000</PPCB:RegistrationRightsPenaltyAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-012026-06-30_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001251"
      unitRef="Shares">400</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-07-012026-09-30_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001253"
      unitRef="Shares">400</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <PPCB:RegistrationRightsPenaltyAmount
      contextRef="From2026-07-012026-09-30_custom_HexstoneCapitalLLCMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact001255"
      unitRef="USD">1976</PPCB:RegistrationRightsPenaltyAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-11-04_us-gaap_SeriesCPreferredStockMember_custom_HexstoneCapitalLLCMember"
      decimals="INF"
      id="Fact001257"
      unitRef="Shares">9900</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-11-04_us-gaap_SeriesCPreferredStockMember_custom_HexstoneCapitalLLCMember"
      decimals="INF"
      id="Fact001259"
      unitRef="Shares">9900</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <PPCB:InitialFairValueOfWarrantLiabilityUponIssuance
      contextRef="From2025-11-042025-11-04_us-gaap_SeriesCPreferredStockMember_custom_HexstoneCapitalLLCMember"
      decimals="0"
      id="Fact001261"
      unitRef="USD">882345</PPCB:InitialFairValueOfWarrantLiabilityUponIssuance>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-11-04_us-gaap_SeriesCPreferredStockMember_custom_MonteCarloMember"
      decimals="INF"
      id="Fact001263"
      unitRef="Shares">9900</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <PPCB:InitialFairValueOfWarrantLiabilityUponIssuance
      contextRef="From2026-05-052026-05-05_us-gaap_SeriesCPreferredStockMember_custom_MonteCarloMember"
      decimals="0"
      id="Fact001265"
      unitRef="USD">973115</PPCB:InitialFairValueOfWarrantLiabilityUponIssuance>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2026-08-012026-08-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001267"
      unitRef="Shares">220466</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2026-08-012026-08-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001269"
      unitRef="Shares">200</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2026-09-012026-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001271"
      unitRef="Shares">32800</us-gaap:ConversionOfStockSharesIssued1>
    <PPCB:CommonStockIssuableShares
      contextRef="AsOf2026-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001273"
      unitRef="Shares">64972</PPCB:CommonStockIssuableShares>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2026-09-012026-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001275"
      unitRef="Shares">50</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-10-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001277"
      unitRef="Shares">64972</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2026-08-012026-08-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001279"
      unitRef="Shares">200</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2026-08-31_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001281"
      unitRef="Shares">200</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-08-31_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001283"
      unitRef="USDPShares">10000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2026-08-012026-08-31_custom_SeriesCWarrantsMember103576656"
      decimals="0"
      id="Fact001285"
      unitRef="USD">2000000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001287"
      unitRef="Shares">150</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001289"
      unitRef="Shares">150</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2026-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact001291"
      unitRef="USD">1500000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-07-012026-08-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001293"
      unitRef="Shares">48763</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2026-07-242026-07-24_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001295"
      unitRef="Shares">350000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharePrice
      contextRef="AsOf2026-07-24_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001297"
      unitRef="USDPShares">13.7</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2026-07-242026-07-24_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001299"
      unitRef="USD">4795000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-07-012025-06-30_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001301"
      unitRef="Shares">8100</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember_srt_MinimumMember"
      id="Fact001303">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember_srt_MaximumMember"
      id="Fact001305">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember"
      decimals="INF"
      id="Fact001307"
      unitRef="USDPShares">2900</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember_srt_MinimumMember_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember"
      decimals="INF"
      id="Fact001309"
      unitRef="USDPShares">1750</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember_srt_MaximumMember_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember"
      decimals="INF"
      id="Fact001311"
      unitRef="USDPShares">3750</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-07-012025-06-30_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001313"
      unitRef="USD">23881110</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-07-012026-06-30_us-gaap_CommonStockMember_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember"
      decimals="INF"
      id="Fact001315"
      unitRef="Shares">30000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="From2025-07-012026-06-30_us-gaap_CommonStockMember_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember"
      id="Fact001317">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2026-06-30_us-gaap_CommonStockMember_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember"
      decimals="INF"
      id="Fact001319"
      unitRef="USDPShares">35</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-07-012026-06-30_us-gaap_CommonStockMember_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember"
      decimals="0"
      id="Fact001321"
      unitRef="USD">1050000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2026-07-012026-09-30_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesOneMember"
      decimals="0"
      id="Fact001323"
      unitRef="USD">1931989</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-07-012025-09-30_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesOneMember"
      decimals="0"
      id="Fact001325"
      unitRef="USD">3024605</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2026-06-30_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember"
      decimals="0"
      id="Fact001327"
      unitRef="USD">7620846</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="AsOf2026-06-30_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember"
      decimals="0"
      id="Fact001329"
      unitRef="USD">4190543</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2026-09-30_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember"
      decimals="0"
      id="Fact001331"
      unitRef="USD">7591860</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="AsOf2026-09-30_custom_ConsultingInvestorRelationsAndBusinessAdvisoryServicesMember"
      decimals="0"
      id="Fact001333"
      unitRef="USD">2287540</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2026-07-012026-08-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact001335"
      unitRef="Shares">320031</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2026-07-012026-08-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact001337"
      unitRef="USD">499000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2026-08-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact001338"
      unitRef="USDPShares">1.56</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="From2019-05-012019-05-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001340"
      unitRef="USD">497240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="AsOf2026-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001342"
      unitRef="USD">248620</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="AsOf2026-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001344"
      unitRef="USD">248620</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="AsOf2026-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001346"
      unitRef="USD">248620</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact001348">&lt;p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zI0dvux9wlWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes warrant activity for the three months ended September 30, 2026:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zIUi6o5xTlvj" style="display: none"&gt;SUMMARY OF WARRANT ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price Per Share&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Outstanding at June 30, 2026 &#x2013; no warrant designation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20260701__20260930_z8sht09gs4C5" style="width: 14%; text-align: right" title="Number of Warrants, Outstanding, Balance"&gt;121&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageOutstanding_iS_pid_c20260701__20260930_z4eM5eLLemwb" style="width: 14%; text-align: right" title="Weighted Average Price Per Share, Outstanding, Balance"&gt;1,248&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Outstanding at June 30, 2026 - Series C preferred stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_pid_c20260701__20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zt3S1shDKzo5" style="text-align: right" title="Number of Series C Preferred stock warrants, Outstanding, Balance"&gt;9,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceOutstanding_pid_c20260701__20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zmmVeL0WOA6i" style="text-align: right" title="Weighted Average Price Per Share, Outstanding preferred stock warrants"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Exercised &#x2013; Series C preferred stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20260701__20260930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zjLIFuqA6mj" style="text-align: right" title="Number of Warrants, Exercised"&gt;(200&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExercised_pid_c20260701__20260930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zxKD836Fpzml" style="text-align: right" title="Weighted Average Price Per Share, Exercised"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20260701__20260930_zPRuMVGsramj" style="text-align: right" title="Number of Warrants, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1362"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceForfeited_pid_c20260701__20260930_zsxWEcUY3W75" style="text-align: right" title="Weighted Average Price Per Share, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1364"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20260701__20260930_zDurmV8V62q9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Expired"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExpired_pid_c20260701__20260930_za1T4nK6s8vd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Price Per Share, Expired"&gt;150,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Outstanding at September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20260701__20260930_zFMNK55a3mTk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Outstanding, Balance"&gt;9,520&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageOutstanding_iE_pid_c20260701__20260930_zZOjIXuG6mEd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Price Per Share, Outstanding, Balance"&gt;9,886.55&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Exercisable at September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20260701__20260930_zcnHLIkPU101" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Exercisable, Balance"&gt;9,520&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisable_iE_pid_c20260701__20260930_zSyX4BoNGhbe" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Price Per Share, Exercisable, Balance"&gt;9,886.55&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Outstanding and Exercisable:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Weighted average remaining contractual term&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260701__20260930_z9VQy1sNiGd4" title="Weighted average remaining contractual term"&gt;1.13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Aggregate intrinsic value &lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20260701__20260930_z5iuIiv1zA7i" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1380"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2026-06-30"
      decimals="INF"
      id="Fact001350"
      unitRef="Shares">121</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <PPCB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageOutstanding
      contextRef="AsOf2026-06-30"
      decimals="INF"
      id="Fact001352"
      unitRef="USDPShares">1248</PPCB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther
      contextRef="From2026-07-012026-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001354"
      unitRef="Shares">9600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther>
    <PPCB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceOutstanding
      contextRef="From2026-07-012026-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001356"
      unitRef="USDPShares">10000</PPCB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001358"
      unitRef="Shares">-200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <PPCB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExercised
      contextRef="From2026-07-012026-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001360"
      unitRef="USDPShares">10000</PPCB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2026-07-01to2026-09-30"
      decimals="INF"
      id="Fact001366"
      unitRef="Shares">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <PPCB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExpired
      contextRef="From2026-07-01to2026-09-30"
      decimals="INF"
      id="Fact001368"
      unitRef="USDPShares">150000</PPCB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact001370"
      unitRef="Shares">9520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <PPCB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageOutstanding
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact001372"
      unitRef="USDPShares">9886.55</PPCB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageOutstanding>
    <PPCB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact001374"
      unitRef="Shares">9520</PPCB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <PPCB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisable
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact001376"
      unitRef="USDPShares">9886.55</PPCB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisable>
    <PPCB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2026-07-01to2026-09-30" id="Fact001378">P1Y1M17D</PPCB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact001382">&lt;p id="xdx_807_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zwKWPmEwnmo1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6 &#x2013; &lt;span id="xdx_82B_zllfNrDjyBm"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Legal
Matters &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 9, 2025, &lt;span id="xdx_90C_eus-gaap--LossContingencyDamagesSought_c20251209__20251209__us-gaap--LossContingenciesByNatureOfContingencyAxis__us-gaap--IndemnificationGuaranteeMember_zr3gLgJpJYCa" title="Damages sought for breach of agreement"&gt;the Company was served with a complaint (the &#x201c;Complaint&#x201d;) filed in the Superior Court of the State Delaware
by an investment firm (the &#x201c;Investment Firm&#x201d;). In the Complaint, the Investment Firm alleges breach of an engagement agreement
dated August 3, 2025 (the &#x201c;Engagement Agreement&#x201d;) between the Company and the Investment Firm and argued that the Company
owed the Investment Firm a $15,000 deal deposit fee for entering into the Engagement Agreement and a $250,000 break fee for not completing
an equity financing with the Investment Firm&lt;/span&gt;. On January 15, 2026, the Company filed an answer to the Complaint with the Superior Court
of the State of Delaware and intended to vigorously defend the action. Other than as described above, there is no other action, suit,
or proceeding by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the
executive officers of our Company or our subsidiary, threatened against or affecting our Company, our Common Stock, our subsidiary or
of our companies or our subsidiary&#x2019;s officers or directors in their capacities as such, in which an adverse decision could have
a material adverse effect.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2026, the Company entered into a settlement agreement and release with the Investment Firm pursuant to which the both parties
agreed to resolve the disputed claims above, in exchange for dismissal and complete release of all claims, the Company agrees to: (i)
make a cash payment of $&lt;span id="xdx_90C_eus-gaap--RepaymentsOfOtherDebt_c20260601__20260630__dei--LegalEntityAxis__custom--HelenaPartnersIncMember_z7uLALJpze09" title="Settlement payment"&gt;75,000&lt;/span&gt; to the Investment Firm; and (ii) issue common shares to the Investment Firm shares which, on the date
of issuance, have an aggregate value of $&lt;span id="xdx_90C_eus-gaap--RepaymentsOfOtherDebt_c20260601__20260630__dei--LegalEntityAxis__custom--HelenaPartnersIncMember_z86VMYQDqzE4" title="Settlement payment"&gt;75,000&lt;/span&gt; (the &#x201c;Settlement Payment&#x201d;) During fiscal year 2026, the Company recorded
$&lt;span id="xdx_904_ecustom--SettlementExpenses_c20250701__20260630__dei--LegalEntityAxis__custom--HelenaPartnersIncMember_zkh7QK13aRUb" title="Settlement expenses"&gt;150,000&lt;/span&gt; in settlement expenses. In July 2026, the Company paid $&lt;span id="xdx_90C_eus-gaap--RepaymentsOfOtherDebt_c20260601__20260630__dei--LegalEntityAxis__custom--HelenaPartnersIncMember_zCpU7DiOAstk" title="Settlement payment"&gt;75,000&lt;/span&gt; and issued &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260601__20260630__dei--LegalEntityAxis__custom--HelenaPartnersIncMember_z3Uf4ylG3sul" title="Shares issued"&gt;5,129&lt;/span&gt; shares of the Company&#x2019;s common stock valued
at $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260601__20260630__dei--LegalEntityAxis__custom--HelenaPartnersIncMember_zkazhOTr2J56" title="Shares issued value"&gt;75,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;IRS
Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of its requirement for having a foreign operating subsidiary, the Company is required to file an informational Form 5471 to the
Internal Revenue Service (the &#x201c;IRS&#x201d;), which is a form that explains the nature of the relationship between the foreign subsidiary
and the parent company. From 2012 through the 2014, the Company did not file this form in a timely manner. As a result of the non-timely
filings, the Company incurred a penalty from the IRS in the amount of $&lt;span id="xdx_909_ecustom--PenaltyAmount_c20260701__20260930__us-gaap--AwardDateAxis__custom--From2012ThroughThe2014Member_z9uMRmqYUwP5" title="Litigation penalty amount"&gt;10,000&lt;/span&gt; per year, or $&lt;span id="xdx_90F_ecustom--PenaltyAmount_c20260701__20260930_z78wuHm4io2d" title="Total litigation penalty amount"&gt;30,000&lt;/span&gt; in total, plus accrued interest, such
penalty and interest having been accrued and is included in the accrued expenses and other payable figure on the September 30, 2026 and
June 30, 2026 consolidated balance sheets. The Company recorded the penalties for all three years during the year ended June 30, 2018.
The Company is current on all subsequent filings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPANC
BIOPHARMA, INC. AND SUBSIDIARY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Operating
Agreements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2009, the Company entered into a commercialization agreement with the University of Bath (UK) (the &#x201c;UK University&#x201d;),
whereby the Company and the UK University co-owned the intellectual property relating to the Company&#x2019;s pro-enzyme formulations.
In June 2012, the Company and the UK University entered into an assignment and amendment whereby the Company assumed full ownership of
the intellectual property, while agreeing to pay royalties of &lt;span id="xdx_900_ecustom--OperatingLeasesIncomeStatementRevenuePercentage_pid_dp_c20120601__20120630__us-gaap--TypeOfArrangementAxis__us-gaap--RoyaltyAgreementTermsMember_zfGfPqRzMYQe" title="Operating leases income statement revenue percentage"&gt;2&lt;/span&gt;% of net revenues to the UK University. Additionally, the Company agreed
to pay &lt;span id="xdx_90F_ecustom--OperatingLeasesIncomeStatementRevenuePercentage_pid_dp_uPure_c20120601__20120630__us-gaap--TypeOfArrangementAxis__us-gaap--LicenseAgreementTermsMember_z3uGR7LQovU9" title="Operating leases income statement revenue percentage"&gt;5&lt;/span&gt;% of each and every license agreement subscribed for. The contract is cancellable at any time by either party. To date, no amounts
are owed under the agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Collaboration
Agreement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 13, 2018, the Company entered into a two-year collaboration agreement with the University of Ja&#xe9;n (the &#x201c;University&#x201d;)
to provide certain research services to the Company. In consideration of such services, the Company agreed to pay the University approximately
&lt;span id="xdx_907_ecustom--PaymentForServices_uEUR_c20180913__20180913__us-gaap--TypeOfArrangementAxis__custom--OneYearCollaborationAgreementMember_z8nOrkKFfAba" title="Payment for services"&gt;52,000&lt;/span&gt; Euros ($&lt;span id="xdx_90C_ecustom--PaymentForServices_c20180913__20180913__us-gaap--TypeOfArrangementAxis__custom--OneYearCollaborationAgreementMember_zAUouaBBqXDd" title="Payment for services"&gt;59,508&lt;/span&gt; USD) in year one and a maximum of &lt;span id="xdx_90D_ecustom--PaymentForServices_uEUR_c20180913__20180913__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember_zjB0s8rhoqna" title="Payment for services"&gt;40,000&lt;/span&gt; Euros ($&lt;span id="xdx_908_ecustom--PaymentForServices_c20180913__20180913__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember_zgUQZ6JZX2i" title="Payment for services"&gt;45,775&lt;/span&gt; USD) in year two. Additionally, in exchange for full ownership
of the intellectual property, the Company agreed to pay royalties of &lt;span id="xdx_905_ecustom--RoyaltyPercentage_pid_dp_uPure_c20180913__20180913__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember_zxJnav9osYQ2" title="Royalty percentage"&gt;2&lt;/span&gt;% of net revenues to the University.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 1, 2020, the Company entered into another two-year collaboration agreement with the University to provide certain research services
to the Company. In consideration of such services, the Company agreed to pay the University approximately &lt;span id="xdx_909_ecustom--PaymentForServices_uEUR_c20201001__20201001__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember_zf7uWm03l8ye" title="Payment for services"&gt;30,000&lt;/span&gt; Euros ($&lt;span id="xdx_907_ecustom--PaymentForServices_c20201001__20201001__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember_zjakVsoTrSW3" title="Payment for services"&gt;35,145&lt;/span&gt; USD),
which were paid in four installment payment of &lt;span id="xdx_90C_ecustom--PaymentForServices_uEUR_c20201101__20201130__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember__us-gaap--AwardDateAxis__custom--InstallmentOneMember_zdfGf5g9MMGc" title="Payment for services"&gt;5,000&lt;/span&gt; Euros in November 2020, &lt;span id="xdx_909_ecustom--PaymentForServices_uEUR_c20210301__20210331__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember__us-gaap--AwardDateAxis__custom--InstallmentTwoMember_zmcCo6tlQMDe" title="Payment for services"&gt;5,000&lt;/span&gt; Euros ($&lt;span id="xdx_903_ecustom--PaymentForServices_c20210301__20210331__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember__us-gaap--AwardDateAxis__custom--InstallmentTwoMember_zGJSGyEAOW35" title="Payment for services"&gt;5,858&lt;/span&gt;) in March 2021, &lt;span id="xdx_908_ecustom--PaymentForServices_uEUR_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember__us-gaap--AwardDateAxis__custom--InstallmentThreeMember_z36QPkGwMuj9" title="Payment for services"&gt;10,000&lt;/span&gt; Euros ($&lt;span id="xdx_90A_ecustom--PaymentForServices_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember__us-gaap--AwardDateAxis__custom--InstallmentThreeMember_zYhafxtxeoY6" title="Payment for services"&gt;11,715&lt;/span&gt;)
in December 2021 and &lt;span id="xdx_908_ecustom--PaymentForServices_uEUR_c20220901__20220930__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember__us-gaap--AwardDateAxis__custom--InstallmentFourMember_zbo7JpJa3TCb" title="Payment for services"&gt;10,000&lt;/span&gt; Euros ($&lt;span id="xdx_900_ecustom--PaymentForServices_c20220901__20220930__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember__us-gaap--AwardDateAxis__custom--InstallmentFourMember_zLy1fagBmZG1" title="Payment for services"&gt;11,715&lt;/span&gt;) in September 2022. Additionally, the University agreed to hire and train a doctoral student
for this project and the Company agreed to pay the University &lt;span id="xdx_902_ecustom--PaymentForServices_uEUR_c20201001__20201001__dei--LegalEntityAxis__custom--UniversityOfJaenMember_zFNS3cEkLl81" title="Payment for services"&gt;25,837&lt;/span&gt; Euros ($&lt;span id="xdx_905_ecustom--PaymentForServices_c20201001__20201001__dei--LegalEntityAxis__custom--UniversityOfJaenMember_zFD7Cq6gyJO6" title="Payment for services"&gt;30,268&lt;/span&gt; USD). In exchange for full ownership of the intellectual
property, the Company agreed to pay royalties of &lt;span id="xdx_905_ecustom--RoyaltiesPercentage_pid_dp_uPure_c20201001__20201001_zDqXWCY8gDrc" title="Royalties percentage"&gt;2&lt;/span&gt;% of net revenues to the University.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 27, 2022, the Company entered into a two-year research agreement with the University to provide certain research and experiment
services to the Company. One of the Company&#x2019;s Scientific Advisory Board is the lead joint researcher of the University. In exchange
for full ownership of the intellectual property, the Company agreed to pay royalties of &lt;span id="xdx_906_ecustom--RoyaltyPercentage_pid_dp_uPure_c20220727__20220727__dei--LegalEntityAxis__custom--UniversityOfJaenMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAgreementMember_zX5eHvXywhcj" title="Royalty percentage"&gt;1&lt;/span&gt;% of net revenues each to two members of the
Scientific Advisory Board. In consideration of such services, the Company agreed to pay the University approximately &lt;span id="xdx_905_ecustom--PaymentForServices_uEUR_c20220727__20220727__dei--LegalEntityAxis__custom--UniversityOfJaenMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAgreementMember_z7y8dVqJpQd" title="Payment for services"&gt;53,200&lt;/span&gt; Euros ($&lt;span id="xdx_903_ecustom--PaymentForServices_c20220727__20220727__dei--LegalEntityAxis__custom--UniversityOfJaenMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAgreementMember_zwcvFN0gWI1c" title="Payment for services"&gt;53,806&lt;/span&gt;
USD) payable as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
&lt;span id="xdx_90E_ecustom--PaymentForServices_uEUR_c20220801__20220831__us-gaap--AwardDateAxis__custom--InstallmentOneMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAgreementMember_zAWLQsTFalE7" title="Payment for services"&gt;18,200&lt;/span&gt; Euros ($&lt;span id="xdx_903_ecustom--PaymentForServices_c20220801__20220831__us-gaap--AwardDateAxis__custom--InstallmentOneMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAgreementMember_zzlZ9SlJXZ5c" title="Payment for services"&gt;18,407&lt;/span&gt; USD) upon execution (paid in August 2022),&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
&lt;span id="xdx_90C_ecustom--PaymentForServices_uEUR_c20220901__20220930__us-gaap--AwardDateAxis__custom--InstallmentTwoMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAgreementMember_z2U2O4TndwR2" title="Payment for services"&gt;8,000&lt;/span&gt; Euros ($&lt;span id="xdx_906_ecustom--PaymentForServices_c20220901__20220930__us-gaap--AwardDateAxis__custom--InstallmentTwoMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAgreementMember_zlMPgzR81XGi" title="Payment for services"&gt;8,091&lt;/span&gt; USD) in September 2022 (paid in September 2025),&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
&lt;span id="xdx_905_ecustom--PaymentForServices_uEUR_c20221201__20221231__us-gaap--AwardDateAxis__custom--InstallmentThreeMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAgreementMember_zVZixDAJ9ko3" title="Payment for services"&gt;7,000&lt;/span&gt; Euros ($&lt;span id="xdx_909_ecustom--PaymentForServices_c20221201__20221231__us-gaap--AwardDateAxis__custom--InstallmentThreeMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAgreementMember_zl2dKrWpTzVb" title="Payment for services"&gt;7,080&lt;/span&gt; USD) in December 2022 (paid in September 2025),&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
&lt;span id="xdx_90D_ecustom--PaymentForServices_uEUR_c20230301__20230331__us-gaap--AwardDateAxis__custom--InstallmentFourMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAgreementMember_z9TBzdPStDt1" title="Payment for services"&gt;10,000&lt;/span&gt; Euros ($&lt;span id="xdx_90D_ecustom--PaymentForServices_c20230301__20230331__us-gaap--AwardDateAxis__custom--InstallmentFourMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAgreementMember_zSkJQ9ECztNk" title="Payment for services"&gt;10,114&lt;/span&gt; USD) in March 2023 (paid in October 2025), and&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
&lt;span id="xdx_90A_ecustom--PaymentForServices_uEUR_c20230701__20230731__us-gaap--AwardDateAxis__custom--InstallmentFiveMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAgreementMember_zesedClHtu58" title="Payment for services"&gt;10,000&lt;/span&gt; Euros ($&lt;span id="xdx_901_ecustom--PaymentForServices_c20230701__20230731__us-gaap--AwardDateAxis__custom--InstallmentFiveMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAgreementMember_zu2JjmpqEvc4" title="Payment for services"&gt;10,114&lt;/span&gt; USD) in July 2023 (paid in October 2025).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
commencement date for the experiments was on September 1, 2022, and the length of time for completion was 24 months. A doctoral thesis
was completed in December 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2026, the Company entered into another two-year collaboration agreement with the University of Ja&#xe9;n and the University of
Granada (the &#x201c;Universities&#x201d;) to provide certain research services to the Company. In consideration of such services, the
Company agreed to pay the Universities for research services of approximately &lt;span id="xdx_90A_ecustom--PaymentForServices_uEUR_c20260301__20260331__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember__us-gaap--AwardDateAxis__custom--YearOneMember_z0yGASCsn2Z8" title="Payment for services"&gt;100,000&lt;/span&gt; Euros ($&lt;span id="xdx_901_ecustom--PaymentForServices_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember__us-gaap--AwardDateAxis__custom--YearOneMember_zWE6Xs0e8jb2" title="Payment for services"&gt;115,900&lt;/span&gt; USD) in year one and &lt;span id="xdx_902_ecustom--PaymentForServices_uEUR_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember__us-gaap--AwardDateAxis__custom--YearTwoMember_z4K2WvvIadNa" title="Payment for services"&gt;102,800&lt;/span&gt; Euros
($&lt;span id="xdx_90D_ecustom--PaymentForServices_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember__us-gaap--AwardDateAxis__custom--YearTwoMember_zr5aXYgsRey7" title="Payment for services"&gt;119,145&lt;/span&gt; USD) in year two, as well as, personnel compensation of approximately &lt;span id="xdx_905_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_uEUR_c20260301__20260331__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember_znGgG9BxORfa" title="Compensation amount"&gt;80,000&lt;/span&gt; Euros or $&lt;span id="xdx_903_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20260301__20260331__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember_zKOMQlDOT1M5" title="Compensation amount"&gt;92,720&lt;/span&gt; USD (&lt;span id="xdx_908_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_uEUR_c20260201__20260228__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember_z2fozu44YQpa" title="Compensation amount"&gt;40,000&lt;/span&gt; Euros paid in February
2026, &lt;span id="xdx_904_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_uEUR_c20261231__20261231__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zUM8pnhBxjA2" title="Compensation amount"&gt;20,000&lt;/span&gt; Euros payable in December 2026, and &lt;span id="xdx_909_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_uEUR_c20270601__20270630__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zEy3yNuF6hbh" title="Compensation amount"&gt;20,000&lt;/span&gt; Euros in June 2027). In exchange for full ownership of the intellectual property,
the Company agreed to pay royalties of &lt;span id="xdx_90C_ecustom--RoyaltyPercentage_pid_dp_uPure_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--TwoYearCollaborationAgreementMember_zaoeUUOTGAla" title="Royalty percentage"&gt;5&lt;/span&gt;% of net revenues to each University.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
consideration for the research services, the Company agreed to pay the Universities &lt;span id="xdx_906_ecustom--PaymentForServices_uEUR_c20260101__20260331__dei--LegalEntityAxis__custom--UniversityOfJaenMember_zNdzAOlXKM58" title="Payment for services"&gt;202,800&lt;/span&gt; Euros ($&lt;span id="xdx_90C_ecustom--PaymentForServices_c20260101__20260331__dei--LegalEntityAxis__custom--UniversityOfJaenMember_zdHtYeXjwB45" title="Payment for services"&gt;235,045&lt;/span&gt; USD) payable as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
&lt;span id="xdx_900_ecustom--PaymentForServices_uEUR_c20260601__20260630__us-gaap--AwardDateAxis__custom--InstallmentOneMember_zEyxO7aWUCT8" title="Payment for services"&gt;34,000&lt;/span&gt; Euros ($&lt;span id="xdx_907_ecustom--PaymentForServices_c20260601__20260630__us-gaap--AwardDateAxis__custom--InstallmentOneMember_zhQtMpqPv0Ba" title="Payment for services"&gt;39,406&lt;/span&gt; USD) 3&lt;sup&gt;rd&lt;/sup&gt; Month from date of execution in June 2026 (paid in April 2026),&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
&lt;span id="xdx_906_ecustom--PaymentForServices_uEUR_c20260701__20260731__us-gaap--AwardDateAxis__custom--InstallmentTwoMember_zdka2xjBfOzf" title="Payment for services"&gt;41,800&lt;/span&gt; Euros ($&lt;span id="xdx_902_ecustom--PaymentForServices_c20260701__20260731__us-gaap--AwardDateAxis__custom--InstallmentTwoMember_zf2VsISeJFq4" title="Payment for services"&gt;48,446&lt;/span&gt; USD) in July 2026 (paid in September 2026),&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
&lt;span id="xdx_90F_ecustom--PaymentForServices_uEUR_c20260901__20260930__us-gaap--AwardDateAxis__custom--InstallmentThreeMember_z7pukZcISdwc" title="Payment for services"&gt;30,000&lt;/span&gt; Euros ($&lt;span id="xdx_900_ecustom--PaymentForServices_c20260901__20260930__us-gaap--AwardDateAxis__custom--InstallmentThreeMember_zAqXLyFuDo1g" title="Payment for services"&gt;34,770&lt;/span&gt; USD) in September 2026,&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
&lt;span id="xdx_901_ecustom--PaymentForServices_uEUR_c20270101__20270131__us-gaap--AwardDateAxis__custom--InstallmentFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUjm2FQuewki" title="Payment for services"&gt;40,000&lt;/span&gt; Euros ($&lt;span id="xdx_90B_ecustom--PaymentForServices_c20270101__20270131__us-gaap--AwardDateAxis__custom--InstallmentFourMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_znoH7s2d4gaa" title="Payment for services"&gt;46,360&lt;/span&gt; USD) in January 2027,&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
&lt;span id="xdx_901_ecustom--PaymentForServices_uEUR_c20270501__20270530__us-gaap--AwardDateAxis__custom--InstallmentFiveMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4M72KN5UWRg" title="Payment for services"&gt;30,000&lt;/span&gt; Euros ($&lt;span id="xdx_907_ecustom--PaymentForServices_c20270501__20270530__us-gaap--AwardDateAxis__custom--InstallmentFiveMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_z2h8gKFYPE3f" title="Payment for services"&gt;34,770&lt;/span&gt; USD) in May 2027, and&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
&lt;span id="xdx_90D_ecustom--PaymentForServices_uEUR_c20270901__20270930__us-gaap--AwardDateAxis__custom--InstallmentSixMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zM7QTlNU8TJ5" title="Payment for services"&gt;27,000&lt;/span&gt; Euros ($&lt;span id="xdx_90A_ecustom--PaymentForServices_c20270901__20270930__us-gaap--AwardDateAxis__custom--InstallmentSixMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zHmIgAVVL9aj" title="Payment for services"&gt;31,293&lt;/span&gt; USD) in September 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2026 and June 30, 2026, the Company has $&lt;span id="xdx_903_ecustom--UnreimbursedLabFees_iI_c20260930_zyDabTSsO9Wc" title="Unreimbursed lab fees"&gt;&lt;span id="xdx_902_ecustom--UnreimbursedLabFees_iI_c20260630_z9xBwBfbBv9l" title="Unreimbursed lab fees"&gt;0&lt;/span&gt;&lt;/span&gt; balance due to the University for unreimbursed lab fees for both periods.
As of September 30, 2026 and June 30, 2026, there are no royalty fees owed to the University.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Consulting
Agreements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 14, 2025, the Company entered into an underwriting agreement with D. Boral Capital, LLC, as representative (the
&#x201c;Representative&#x201d;) of the underwriters in connection with a public offering of the Company&#x2019;s common stock. On
January 23, 2026, the Company entered into a settlement agreement and release with the Representative pursuant to which the Company
agreed that, during the 360-day period following the public offering (the &#x201c;Lock-up Period&#x201d;), it would not, without the
prior consent of the Representative, offer or sell any securities or file any registration statement with the Commission relating to
the offering of any shares (as defined in the Lock-up Agreement executed with the Representative). Under the terms of the settlement
agreement, the Company agreed to pay the Representative an initial settlement amount of $&lt;span id="xdx_901_ecustom--ProceedsFromSettlementAmount_c20260123__20260123__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zBsxk2JWZSLe" title="Settlement amount"&gt;50,000&lt;/span&gt;,
as well as &lt;span id="xdx_904_ecustom--PercentageOfSettlement_iI_pid_dp_c20260123__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_z4uP3Lsu6PBc" title="Settlement percentage"&gt;4&lt;/span&gt;%
of the gross proceeds received from any additional closings. During the three months ended September 30, 2026 and 2025, the Company
paid $&lt;span id="xdx_905_ecustom--SettlementExpense_c20260701__20260930__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zT2VFrVia4Oa" title="Settlement expense"&gt;20,000&lt;/span&gt;, as part of the 4% obligation, and $&lt;span id="xdx_90A_ecustom--SettlementExpense_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zLbS2fBwKx3j" title="Settlement expense"&gt;0&lt;/span&gt;,
respectively, and has been recorded in settlement expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPANC
BIOPHARMA, INC. AND SUBSIDIARY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Operating
Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 4, 2025, the Company entered in a &lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20250504__us-gaap--TypeOfArrangementAxis__custom--NewOneYearOperatingLeaseAgreementMember_zKI7XIVL9Ggd" style="display: none" title="Lessee operating lease term"&gt;1&lt;/span&gt;one-year lease agreement with North Horizon Pty Ltd., a related party, for a monthly rent of $&lt;span id="xdx_901_eus-gaap--PaymentsForRent_uAUD_c20250504__20250504__us-gaap--TypeOfArrangementAxis__custom--NewOneYearOperatingLeaseAgreementMember_zTqRABXGRftf" title="Payments for rent"&gt;3,300&lt;/span&gt;
AUD or $&lt;span id="xdx_909_eus-gaap--PaymentsForRent_uUSD_c20250504__20250504__us-gaap--TypeOfArrangementAxis__custom--NewOneYearOperatingLeaseAgreementMember_zNjmpigfxxGg" title="Payments for rent"&gt;2,127&lt;/span&gt; USD (depending on exchange rate) per month plus taxes with an option to renew the lease for an additional two-year term.
On May 4, 2025, the Company recorded right-of-use assets of $&lt;span id="xdx_901_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20250504_z7gwVUJLL7H6" title="Operating lease right of use asset"&gt;62,126&lt;/span&gt; and total lease liabilities of $&lt;span id="xdx_907_eus-gaap--OperatingLeaseLiability_iI_c20250504_zIhKm1f0FpQc" title="Operating lease liabilities"&gt;62,126&lt;/span&gt; based on an incremental borrowing
rate of &lt;span id="xdx_90D_ecustom--IncrementalBorrowingRate_pid_dp_uPure_c20250504__20250504_zkgK6m5RTGN" title="Incremental borrowing rate"&gt;12&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_ecustom--ScheduleOfRightUseOfAssetTableTextBlock_zeAiEJIEYVal" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ROU
is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zGNPXafYKgk9" style="display: none"&gt;SCHEDULE OF RIGHT OF USE ASSET&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20260930_z6jLP2nU33ih" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
30,&lt;br/&gt;
2026&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20260630_zWn9PEdovFZk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt;
2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--OperatingLeaseRightOfUseAssets_iI_maOLROUzZkA_zcDoLWBGgKZ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Office lease&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;68,339&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;68,339&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AccumulatedReduction_iNI_di_msOLROUzZkA_zQzAPsg9ENYd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(33,353&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(27,549&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_mtOLROUzZkA_zqe2YPAH7Yc5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Right-of-use asset, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;34,986&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;40,790&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zqu8xPVDaSu2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zfrlVfI3qn6h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
Lease liabilities are summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zj5kXOYPavv9" style="display: none"&gt;SCHEDULE OF OPERATING LEASE LIABILITY&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20260930_zR97yKbH8tI9" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
30,&lt;br/&gt;
2026&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20260630_zIESv5yC0vB9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt;
2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--OfficeLeaseLiability_iI_pp0p0_z8QwhPMTqn1d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Office lease&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;68,339&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;68,339&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ReductionOfLeaseLiability_iNI_di_zitjcIHIELQi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Reduction of lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25,598&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,032&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zOE6VpcWgJgl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Less: office lease, current portion&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(25,731&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(24,489&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zVF9DUXlzFri" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Long term portion of lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17,010&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23,818&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zRKOKiDcvE07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z3YRud2NhyCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Remaining
future minimum lease payments under non-cancelable operating lease at September 30, 2026 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;span id="xdx_8B4_z1gtlHZjkwie" style="display: none"&gt;SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20260930_z0YKI6BQUxi7" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zPjZHxoYYAs7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;Fiscal Year 2026- remainder&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;7,223&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zqbGGbeNFqLd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Fiscal Year 2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,857&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zVHFPMa5LXQb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fiscal Year 2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,113&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zo4W3OCDQYi1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,452&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iTI_zQDqkNseChz8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;42,741&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zQnPvhe3HAIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average remaining lease term for the operating lease is &lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260930_zWnSwmxiQtel" title="Weighted average remaining lease term"&gt;1.52&lt;/span&gt; years as of September 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyDamagesSought
      contextRef="From2025-12-092025-12-09_us-gaap_IndemnificationGuaranteeMember"
      id="Fact001384">the Company was served with a complaint (the &#x201c;Complaint&#x201d;) filed in the Superior Court of the State Delaware
by an investment firm (the &#x201c;Investment Firm&#x201d;). In the Complaint, the Investment Firm alleges breach of an engagement agreement
dated August 3, 2025 (the &#x201c;Engagement Agreement&#x201d;) between the Company and the Investment Firm and argued that the Company
owed the Investment Firm a $15,000 deal deposit fee for entering into the Engagement Agreement and a $250,000 break fee for not completing
an equity financing with the Investment Firm</us-gaap:LossContingencyDamagesSought>
    <us-gaap:RepaymentsOfOtherDebt
      contextRef="From2026-06-012026-06-30_custom_HelenaPartnersIncMember"
      decimals="0"
      id="Fact001386"
      unitRef="USD">75000</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:RepaymentsOfOtherDebt
      contextRef="From2026-06-012026-06-30_custom_HelenaPartnersIncMember"
      decimals="0"
      id="Fact001388"
      unitRef="USD">75000</us-gaap:RepaymentsOfOtherDebt>
    <PPCB:SettlementExpenses
      contextRef="From2025-07-012026-06-30_custom_HelenaPartnersIncMember"
      decimals="0"
      id="Fact001390"
      unitRef="USD">150000</PPCB:SettlementExpenses>
    <us-gaap:RepaymentsOfOtherDebt
      contextRef="From2026-06-012026-06-30_custom_HelenaPartnersIncMember"
      decimals="0"
      id="Fact001392"
      unitRef="USD">75000</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-06-012026-06-30_custom_HelenaPartnersIncMember"
      decimals="INF"
      id="Fact001394"
      unitRef="Shares">5129</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-06-012026-06-30_custom_HelenaPartnersIncMember"
      decimals="0"
      id="Fact001396"
      unitRef="USD">75000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <PPCB:PenaltyAmount
      contextRef="From2026-07-012026-09-30_custom_From2012ThroughThe2014Member"
      decimals="0"
      id="Fact001398"
      unitRef="USD">10000</PPCB:PenaltyAmount>
    <PPCB:PenaltyAmount
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact001400"
      unitRef="USD">30000</PPCB:PenaltyAmount>
    <PPCB:OperatingLeasesIncomeStatementRevenuePercentage
      contextRef="From2012-06-012012-06-30_us-gaap_RoyaltyAgreementTermsMember"
      decimals="INF"
      id="Fact001402"
      unitRef="Pure">0.02</PPCB:OperatingLeasesIncomeStatementRevenuePercentage>
    <PPCB:OperatingLeasesIncomeStatementRevenuePercentage
      contextRef="From2012-06-012012-06-30_us-gaap_LicenseAgreementTermsMember"
      decimals="INF"
      id="Fact001404"
      unitRef="Pure">0.05</PPCB:OperatingLeasesIncomeStatementRevenuePercentage>
    <PPCB:PaymentForServices
      contextRef="From2018-09-132018-09-13_custom_OneYearCollaborationAgreementMember"
      decimals="0"
      id="Fact001406"
      unitRef="EUR">52000</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2018-09-132018-09-13_custom_OneYearCollaborationAgreementMember"
      decimals="0"
      id="Fact001408"
      unitRef="USD">59508</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2018-09-132018-09-13_custom_TwoYearCollaborationAgreementMember"
      decimals="0"
      id="Fact001410"
      unitRef="EUR">40000</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2018-09-132018-09-13_custom_TwoYearCollaborationAgreementMember"
      decimals="0"
      id="Fact001412"
      unitRef="USD">45775</PPCB:PaymentForServices>
    <PPCB:RoyaltyPercentage
      contextRef="From2018-09-132018-09-13_custom_TwoYearCollaborationAgreementMember"
      decimals="INF"
      id="Fact001414"
      unitRef="Pure">0.02</PPCB:RoyaltyPercentage>
    <PPCB:PaymentForServices
      contextRef="From2020-10-012020-10-01_custom_TwoYearCollaborationAgreementMember"
      decimals="0"
      id="Fact001416"
      unitRef="EUR">30000</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2020-10-012020-10-01_custom_TwoYearCollaborationAgreementMember"
      decimals="0"
      id="Fact001418"
      unitRef="USD">35145</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2020-11-012020-11-30_custom_TwoYearCollaborationAgreementMember_custom_InstallmentOneMember"
      decimals="0"
      id="Fact001420"
      unitRef="EUR">5000</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2021-03-012021-03-31_custom_TwoYearCollaborationAgreementMember_custom_InstallmentTwoMember"
      decimals="0"
      id="Fact001422"
      unitRef="EUR">5000</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2021-03-012021-03-31_custom_TwoYearCollaborationAgreementMember_custom_InstallmentTwoMember"
      decimals="0"
      id="Fact001424"
      unitRef="USD">5858</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2021-12-012021-12-31_custom_TwoYearCollaborationAgreementMember_custom_InstallmentThreeMember"
      decimals="0"
      id="Fact001426"
      unitRef="EUR">10000</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2021-12-012021-12-31_custom_TwoYearCollaborationAgreementMember_custom_InstallmentThreeMember"
      decimals="0"
      id="Fact001428"
      unitRef="USD">11715</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2022-09-012022-09-30_custom_TwoYearCollaborationAgreementMember_custom_InstallmentFourMember"
      decimals="0"
      id="Fact001430"
      unitRef="EUR">10000</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2022-09-012022-09-30_custom_TwoYearCollaborationAgreementMember_custom_InstallmentFourMember"
      decimals="0"
      id="Fact001432"
      unitRef="USD">11715</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2020-10-012020-10-01_custom_UniversityOfJaenMember"
      decimals="0"
      id="Fact001434"
      unitRef="EUR">25837</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2020-10-012020-10-01_custom_UniversityOfJaenMember"
      decimals="0"
      id="Fact001436"
      unitRef="USD">30268</PPCB:PaymentForServices>
    <PPCB:RoyaltiesPercentage
      contextRef="From2020-10-012020-10-01"
      decimals="INF"
      id="Fact001438"
      unitRef="Pure">0.02</PPCB:RoyaltiesPercentage>
    <PPCB:RoyaltyPercentage
      contextRef="From2022-07-272022-07-27_custom_UniversityOfJaenMember_custom_ResearchAgreementMember"
      decimals="INF"
      id="Fact001440"
      unitRef="Pure">0.01</PPCB:RoyaltyPercentage>
    <PPCB:PaymentForServices
      contextRef="From2022-07-272022-07-27_custom_UniversityOfJaenMember_custom_ResearchAgreementMember"
      decimals="0"
      id="Fact001442"
      unitRef="EUR">53200</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2022-07-272022-07-27_custom_UniversityOfJaenMember_custom_ResearchAgreementMember"
      decimals="0"
      id="Fact001444"
      unitRef="USD">53806</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2022-08-012022-08-31_custom_InstallmentOneMember_custom_ResearchAgreementMember"
      decimals="0"
      id="Fact001446"
      unitRef="EUR">18200</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2022-08-012022-08-31_custom_InstallmentOneMember_custom_ResearchAgreementMember"
      decimals="0"
      id="Fact001448"
      unitRef="USD">18407</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2022-09-012022-09-30_custom_InstallmentTwoMember_custom_ResearchAgreementMember"
      decimals="0"
      id="Fact001450"
      unitRef="EUR">8000</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2022-09-012022-09-30_custom_InstallmentTwoMember_custom_ResearchAgreementMember"
      decimals="0"
      id="Fact001452"
      unitRef="USD">8091</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2022-12-012022-12-31_custom_InstallmentThreeMember_custom_ResearchAgreementMember"
      decimals="0"
      id="Fact001454"
      unitRef="EUR">7000</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2022-12-012022-12-31_custom_InstallmentThreeMember_custom_ResearchAgreementMember"
      decimals="0"
      id="Fact001456"
      unitRef="USD">7080</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2023-03-012023-03-31_custom_InstallmentFourMember_custom_ResearchAgreementMember"
      decimals="0"
      id="Fact001458"
      unitRef="EUR">10000</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2023-03-012023-03-31_custom_InstallmentFourMember_custom_ResearchAgreementMember"
      decimals="0"
      id="Fact001460"
      unitRef="USD">10114</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2023-07-012023-07-31_custom_InstallmentFiveMember_custom_ResearchAgreementMember"
      decimals="0"
      id="Fact001462"
      unitRef="EUR">10000</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2023-07-012023-07-31_custom_InstallmentFiveMember_custom_ResearchAgreementMember"
      decimals="0"
      id="Fact001464"
      unitRef="USD">10114</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2026-03-012026-03-31_custom_TwoYearCollaborationAgreementMember_custom_YearOneMember"
      decimals="0"
      id="Fact001466"
      unitRef="EUR">100000</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2026-01-012026-03-31_custom_TwoYearCollaborationAgreementMember_custom_YearOneMember"
      decimals="0"
      id="Fact001468"
      unitRef="USD">115900</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2026-01-012026-03-31_custom_TwoYearCollaborationAgreementMember_custom_YearTwoMember"
      decimals="0"
      id="Fact001470"
      unitRef="EUR">102800</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2026-01-012026-03-31_custom_TwoYearCollaborationAgreementMember_custom_YearTwoMember"
      decimals="0"
      id="Fact001472"
      unitRef="USD">119145</PPCB:PaymentForServices>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2026-03-012026-03-31_custom_TwoYearCollaborationAgreementMember"
      decimals="0"
      id="Fact001474"
      unitRef="EUR">80000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2026-03-012026-03-31_custom_TwoYearCollaborationAgreementMember"
      decimals="0"
      id="Fact001476"
      unitRef="USD">92720</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2026-02-012026-02-28_custom_TwoYearCollaborationAgreementMember"
      decimals="0"
      id="Fact001478"
      unitRef="EUR">40000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2026-12-312026-12-31_custom_TwoYearCollaborationAgreementMember_srt_ScenarioForecastMember"
      decimals="0"
      id="Fact001480"
      unitRef="EUR">20000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2027-06-012027-06-30_custom_TwoYearCollaborationAgreementMember_srt_ScenarioForecastMember"
      decimals="0"
      id="Fact001482"
      unitRef="EUR">20000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <PPCB:RoyaltyPercentage
      contextRef="From2026-01-012026-03-31_custom_TwoYearCollaborationAgreementMember"
      decimals="INF"
      id="Fact001484"
      unitRef="Pure">0.05</PPCB:RoyaltyPercentage>
    <PPCB:PaymentForServices
      contextRef="From2026-01-012026-03-31_custom_UniversityOfJaenMember"
      decimals="0"
      id="Fact001486"
      unitRef="EUR">202800</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2026-01-012026-03-31_custom_UniversityOfJaenMember"
      decimals="0"
      id="Fact001488"
      unitRef="USD">235045</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2026-06-012026-06-30_custom_InstallmentOneMember"
      decimals="0"
      id="Fact001490"
      unitRef="EUR">34000</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2026-06-012026-06-30_custom_InstallmentOneMember"
      decimals="0"
      id="Fact001492"
      unitRef="USD">39406</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2026-07-012026-07-31_custom_InstallmentTwoMember"
      decimals="0"
      id="Fact001494"
      unitRef="EUR">41800</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2026-07-012026-07-31_custom_InstallmentTwoMember"
      decimals="0"
      id="Fact001496"
      unitRef="USD">48446</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2026-09-012026-09-30_custom_InstallmentThreeMember"
      decimals="0"
      id="Fact001498"
      unitRef="EUR">30000</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2026-09-012026-09-30_custom_InstallmentThreeMember"
      decimals="0"
      id="Fact001500"
      unitRef="USD">34770</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2027-01-012027-01-31_custom_InstallmentFourMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001502"
      unitRef="EUR">40000</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2027-01-012027-01-31_custom_InstallmentFourMember_srt_ScenarioForecastMember"
      decimals="0"
      id="Fact001504"
      unitRef="USD">46360</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2027-05-012027-05-30_custom_InstallmentFiveMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001506"
      unitRef="EUR">30000</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2027-05-012027-05-30_custom_InstallmentFiveMember_srt_ScenarioForecastMember"
      decimals="0"
      id="Fact001508"
      unitRef="USD">34770</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2027-09-012027-09-30_custom_InstallmentSixMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001510"
      unitRef="EUR">27000</PPCB:PaymentForServices>
    <PPCB:PaymentForServices
      contextRef="From2027-09-012027-09-30_custom_InstallmentSixMember_srt_ScenarioForecastMember"
      decimals="0"
      id="Fact001512"
      unitRef="USD">31293</PPCB:PaymentForServices>
    <PPCB:UnreimbursedLabFees
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001514"
      unitRef="USD">0</PPCB:UnreimbursedLabFees>
    <PPCB:UnreimbursedLabFees
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001516"
      unitRef="USD">0</PPCB:UnreimbursedLabFees>
    <PPCB:ProceedsFromSettlementAmount
      contextRef="From2026-01-232026-01-23_custom_UnderwritingAgreementMember"
      decimals="0"
      id="Fact001518"
      unitRef="USD">50000</PPCB:ProceedsFromSettlementAmount>
    <PPCB:PercentageOfSettlement
      contextRef="AsOf2026-01-23_custom_UnderwritingAgreementMember"
      decimals="INF"
      id="Fact001520"
      unitRef="Pure">0.04</PPCB:PercentageOfSettlement>
    <PPCB:SettlementExpense
      contextRef="From2026-07-012026-09-30_custom_UnderwritingAgreementMember"
      decimals="0"
      id="Fact001522"
      unitRef="USD">20000</PPCB:SettlementExpense>
    <PPCB:SettlementExpense
      contextRef="From2025-07-012025-09-30_custom_UnderwritingAgreementMember"
      decimals="0"
      id="Fact001524"
      unitRef="USD">0</PPCB:SettlementExpense>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="AsOf2025-05-04_custom_NewOneYearOperatingLeaseAgreementMember"
      id="Fact001526">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:PaymentsForRent
      contextRef="From2025-05-042025-05-04_custom_NewOneYearOperatingLeaseAgreementMember"
      decimals="0"
      id="Fact001528"
      unitRef="AUD">3300</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2025-05-042025-05-04_custom_NewOneYearOperatingLeaseAgreementMember"
      decimals="0"
      id="Fact001530"
      unitRef="USD">2127</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-05-04"
      decimals="0"
      id="Fact001532"
      unitRef="USD">62126</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-05-04"
      decimals="0"
      id="Fact001534"
      unitRef="USD">62126</us-gaap:OperatingLeaseLiability>
    <PPCB:IncrementalBorrowingRate
      contextRef="From2025-05-042025-05-04"
      decimals="INF"
      id="Fact001536"
      unitRef="Pure">0.12</PPCB:IncrementalBorrowingRate>
    <PPCB:ScheduleOfRightUseOfAssetTableTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact001538">&lt;p id="xdx_894_ecustom--ScheduleOfRightUseOfAssetTableTextBlock_zeAiEJIEYVal" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ROU
is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zGNPXafYKgk9" style="display: none"&gt;SCHEDULE OF RIGHT OF USE ASSET&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20260930_z6jLP2nU33ih" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
30,&lt;br/&gt;
2026&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20260630_zWn9PEdovFZk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt;
2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--OperatingLeaseRightOfUseAssets_iI_maOLROUzZkA_zcDoLWBGgKZ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Office lease&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;68,339&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;68,339&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AccumulatedReduction_iNI_di_msOLROUzZkA_zQzAPsg9ENYd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(33,353&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(27,549&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_mtOLROUzZkA_zqe2YPAH7Yc5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Right-of-use asset, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;34,986&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;40,790&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</PPCB:ScheduleOfRightUseOfAssetTableTextBlock>
    <PPCB:OperatingLeaseRightOfUseAssets
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001540"
      unitRef="USD">68339</PPCB:OperatingLeaseRightOfUseAssets>
    <PPCB:OperatingLeaseRightOfUseAssets
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001541"
      unitRef="USD">68339</PPCB:OperatingLeaseRightOfUseAssets>
    <PPCB:AccumulatedReduction
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001543"
      unitRef="USD">33353</PPCB:AccumulatedReduction>
    <PPCB:AccumulatedReduction
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001544"
      unitRef="USD">27549</PPCB:AccumulatedReduction>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001546"
      unitRef="USD">34986</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001547"
      unitRef="USD">40790</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact001549">&lt;p id="xdx_897_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zfrlVfI3qn6h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
Lease liabilities are summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zj5kXOYPavv9" style="display: none"&gt;SCHEDULE OF OPERATING LEASE LIABILITY&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20260930_zR97yKbH8tI9" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
30,&lt;br/&gt;
2026&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20260630_zIESv5yC0vB9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt;
2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--OfficeLeaseLiability_iI_pp0p0_z8QwhPMTqn1d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Office lease&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;68,339&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;68,339&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ReductionOfLeaseLiability_iNI_di_zitjcIHIELQi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Reduction of lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25,598&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,032&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zOE6VpcWgJgl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Less: office lease, current portion&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(25,731&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(24,489&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zVF9DUXlzFri" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Long term portion of lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17,010&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23,818&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <PPCB:OfficeLeaseLiability
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001551"
      unitRef="USD">68339</PPCB:OfficeLeaseLiability>
    <PPCB:OfficeLeaseLiability
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001552"
      unitRef="USD">68339</PPCB:OfficeLeaseLiability>
    <PPCB:ReductionOfLeaseLiability
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001554"
      unitRef="USD">25598</PPCB:ReductionOfLeaseLiability>
    <PPCB:ReductionOfLeaseLiability
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001555"
      unitRef="USD">20032</PPCB:ReductionOfLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001557"
      unitRef="USD">25731</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001558"
      unitRef="USD">24489</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001560"
      unitRef="USD">17010</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001561"
      unitRef="USD">23818</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact001563">&lt;p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z3YRud2NhyCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Remaining
future minimum lease payments under non-cancelable operating lease at September 30, 2026 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;span id="xdx_8B4_z1gtlHZjkwie" style="display: none"&gt;SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20260930_z0YKI6BQUxi7" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zPjZHxoYYAs7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;Fiscal Year 2026- remainder&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;7,223&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zqbGGbeNFqLd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Fiscal Year 2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,857&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zVHFPMa5LXQb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fiscal Year 2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,113&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zo4W3OCDQYi1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,452&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iTI_zQDqkNseChz8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;42,741&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001565"
      unitRef="USD">7223</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001567"
      unitRef="USD">29857</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001569"
      unitRef="USD">10113</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001571"
      unitRef="USD">4452</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001573"
      unitRef="USD">42741</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2026-09-30" id="Fact001575">P1Y6M7D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact001577">&lt;p id="xdx_80A_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zIoniGl90KGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7 &#x2013; &lt;span id="xdx_82C_zZ24w0ffoLP2"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since
its inception, the Company has conducted transactions with its directors and entities related to such directors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Lease
Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
May 5, 2016, the Company entered into an agreement for the lease of its principal executive offices with North Horizon Pty Ltd., a related
party, of which Mr. Nathanielsz, our CEO, CFO and a director, and his wife are owners and directors. The lease had a &lt;span id="xdx_904_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20160505__dei--LegalEntityAxis__custom--NorthHorizonPtyLtdMember_zzzD53UXPd7" style="display: none"&gt;5&lt;/span&gt;five-year term and
provided for annual rental payments of $&lt;span id="xdx_907_ecustom--LeasesRentExpenseMinimumRentals_uAUD_c20160505__20160505__dei--LegalEntityAxis__custom--NorthHorizonPtyLtdMember_zieijmXCkEge" title="Annual rental payments"&gt;39,600&lt;/span&gt; AUD or $&lt;span id="xdx_907_ecustom--LeasesRentExpenseMinimumRentals_c20160505__20160505__dei--LegalEntityAxis__custom--NorthHorizonPtyLtdMember_zxwPtaLo3e6e" title="Annual rental payments"&gt;28,325&lt;/span&gt; USD, which includes $&lt;span id="xdx_90E_ecustom--GoodsAndServiceTax_uAUD_c20160505__20160505__dei--LegalEntityAxis__custom--NorthHorizonPtyLtdMember_zFSu1PXBUeIb" title="Goods and service tax"&gt;3,600&lt;/span&gt; AUD or $&lt;span id="xdx_908_ecustom--GoodsAndServiceTax_c20160505__20160505__dei--LegalEntityAxis__custom--NorthHorizonPtyLtdMember_z3W4tIIH1yqg" title="Goods and service tax"&gt;2,575&lt;/span&gt; USD of goods and service tax for
total payments of $&lt;span id="xdx_903_ecustom--LeasesFutureMinimumPaymentsDue_iI_uAUD_c20160505__dei--LegalEntityAxis__custom--NorthHorizonPtyLtdMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NathanielszMember_zWHSQifge06l" title="Rent amount"&gt;198,000&lt;/span&gt; AUD or $&lt;span id="xdx_90B_ecustom--LeasesFutureMinimumPaymentsDue_iI_c20160505__dei--LegalEntityAxis__custom--NorthHorizonPtyLtdMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NathanielszMember_zQvePf1ef7df" title="Rent amount"&gt;141,629&lt;/span&gt; USD during the term of the lease. &lt;span id="xdx_901_eus-gaap--LesseeOperatingLeaseDescription_c20160505__20160505_zLF7kLm8SOhc"&gt;Such lease expired in May 2021 and was renewed for another
one-year term from May 2021 to May 2022.&lt;/span&gt; On May 4, 2022, the Company entered into a three-year&lt;span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20220504__us-gaap--TypeOfArrangementAxis__custom--NewThreeYearOperatingLeaseAgreementMember_zyS4yIk4he4b" style="display: none" title="Lessee operating lease term"&gt;3&lt;/span&gt; lease agreement with North Horizon Pty
Ltd. for a monthly rent of $&lt;span id="xdx_90E_eus-gaap--PaymentsForRent_uAUD_c20220504__20220504__us-gaap--TypeOfArrangementAxis__custom--ThreeYearOperatingLeaseAgreementMember__dei--LegalEntityAxis__custom--NorthHorizonPtyLtdMember_zUNL8zdUXSn" title="Payments for rent"&gt;3,000&lt;/span&gt; AUD or $&lt;span id="xdx_905_eus-gaap--PaymentsForRent_c20220504__20220504__us-gaap--TypeOfArrangementAxis__custom--ThreeYearOperatingLeaseAgreementMember__dei--LegalEntityAxis__custom--NorthHorizonPtyLtdMember_zoOorblsvHr9" title="Payments for rent"&gt;2,176&lt;/span&gt; USD (depending on exchange rate) per month plus taxes. On May 4, 2025, the Company renewed
for another one-year lease agreement with North Horizon Pty Ltd., a related party, for a monthly rent of $&lt;span id="xdx_90D_eus-gaap--PaymentsForRent_uAUD_c20250504__20250504__us-gaap--TypeOfArrangementAxis__custom--OneYearOperatingLeaseAgreementMember__dei--LegalEntityAxis__custom--NorthHorizonPtyLtdMember_z026o2glRm2a" title="Payments for rent"&gt;3,300&lt;/span&gt; AUD or $&lt;span id="xdx_907_eus-gaap--PaymentsForRent_uUSD_c20250504__20250504__us-gaap--TypeOfArrangementAxis__custom--OneYearOperatingLeaseAgreementMember__dei--LegalEntityAxis__custom--NorthHorizonPtyLtdMember_zUxG7RKPLrqk" title="Payments for rent"&gt;2,127&lt;/span&gt; USD (depending
on exchange rate) per month plus taxes with an option to renew the lease for an additional two-year term (See Note 6). As of September
30, 2026 and June 30, 2026, total rent payable of $&lt;span id="xdx_90E_ecustom--RentPayable_iI_uAUD_c20260930_zbOSi42FHwu3" title="Rent payable"&gt;119,159&lt;/span&gt; AUD ($&lt;span id="xdx_90B_ecustom--RentPayable_iI_uUSD_c20260930_zk9KDXVveJqc" title="Rent payable"&gt;82,804&lt;/span&gt; USD) and $&lt;span id="xdx_90E_ecustom--RentPayable_iI_uAUD_c20260630_zPKkwllqHwrf" title="Rent payable"&gt;119,159&lt;/span&gt; AUD ($&lt;span id="xdx_90F_ecustom--RentPayable_iI_uUSD_c20260630_zWUuYdUB50ch" title="Rent payable"&gt;82,363&lt;/span&gt; USD), respectively, was included
in accrued expenses in the accompanying condensed consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rent
expense under the lease was $&lt;span id="xdx_90D_eus-gaap--PaymentsForRent_c20260701__20260930_za4OLUgPOR0j" title="Payments for rent"&gt;9,523&lt;/span&gt; USD and $&lt;span id="xdx_90F_eus-gaap--PaymentsForRent_c20250701__20250930_zU2C9fcyrRH5" title="Payments for rent"&gt;14,789&lt;/span&gt; USD during the three months ended September 30, 2026 and 2025, respectively, reflected
as occupancy expenses in the accompanying condensed consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Loans
payable - Related Party&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company repaid the remaining balance of $&lt;span id="xdx_906_eus-gaap--RepaymentsOfDebt_uUSD_c20260903__20260903__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zXFMwo2tqm7h" title="Repayment of loan"&gt;96,652&lt;/span&gt; USD including interest expense of $&lt;span id="xdx_906_eus-gaap--InterestPaid_c20260903__20260903__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSB13qvxe7ll" title="Interest expense paid"&gt;26,991&lt;/span&gt; USD of loans payable &#x2013; related party
on September 3, 2026 (see Note 4).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPANC
BIOPHARMA, INC. AND SUBSIDIARY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
remaining balance of all loans payable &#x2013; related parties, net of discount amounted to $&lt;span id="xdx_909_eus-gaap--LoansPayableCurrent_iI_c20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z3ziGYPrCy2h" title="Loan payable"&gt;364,801&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--LoansPayableCurrent_iI_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z23bMLQMIMol" title="Loan payable"&gt;460,809&lt;/span&gt; as of September 30,
2026 and June 30, 2026, respectively. Accrued interest for all loans payable &#x2013; related parties as of September 30, 2026 and June
30, 2026 was $&lt;span id="xdx_904_eus-gaap--InterestPayableCurrent_iI_c20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zF6p8UxAymJ4" title="Accrued interest"&gt;118,927&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--InterestPayableCurrent_iI_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zk8lvkDYQ4E9" title="Accrued interest"&gt;128,318&lt;/span&gt;, respectively (see Note 4).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Employment
and Services Agreements with Management&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company and Mr. Nathanielsz entered into an employment agreement as of February 25, 2015 (the &#x201c;Nathanielsz Employment Agreement&#x201d;)
setting forth the terms and conditions of Mr. Nathanielsz&#x2019;s employment as the Company&#x2019;s President and Chief Executive Officer.
The Nathanielsz Employment Agreement was scheduled to expire on &lt;span id="xdx_903_eus-gaap--RelatedPartyTransactionDate_dd_c20150225__20150225__us-gaap--TypeOfArrangementAxis__custom--NathanielszEmploymentAgreementMember_zLlR2xtEp1ta" title="Expired date"&gt;February 25, 2019&lt;/span&gt;; however, the term of the Nathanielsz Employment Agreement
automatically renews for successive one-year periods unless either party provides 30 days&#x2019; prior written notice of his or its intent
not to renew. The Nathanielsz Employment Agreement continues in effect as amended on October 26, 2022 (see below). The Nathanielsz Employment
Agreement provides Mr. Nathanielsz with a base salary of $&lt;span id="xdx_906_ecustom--BaseSalaryPerMonth_uAUD_c20150225__20150225__us-gaap--TypeOfArrangementAxis__custom--NathanielszEmploymentAgreementMember_z6Ru5pyh0K6h" title="Base salary per month"&gt;25,000&lt;/span&gt; AUD per month ($&lt;span id="xdx_900_eus-gaap--SalariesAndWages_uAUD_c20150225__20150225__us-gaap--TypeOfArrangementAxis__custom--NathanielszEmploymentAgreementMember_z8AKzdkq82xl" title="Annual salary"&gt;300,000&lt;/span&gt; AUD annually or $&lt;span id="xdx_908_eus-gaap--SalariesAndWages_c20150225__20150225__us-gaap--TypeOfArrangementAxis__custom--NathanielszEmploymentAgreementMember_zBO5mn0V4K63" title="Annual salary"&gt;205,680&lt;/span&gt; USD) and a monthly
contribution to Mr. Nathanielsz&#x2019;s pension equal to &lt;span id="xdx_908_ecustom--PercentageOfPensionOfMonthlySalary_pid_dp_uPure_c20150225__20150225__us-gaap--TypeOfArrangementAxis__custom--NathanielszEmploymentAgreementMember_zuhdfaqJo7mf" title="Percentage of pension of monthly salary"&gt;9.5&lt;/span&gt;% of his monthly salary. Mr. Nathanielsz has the ability to convert any accrued
but unpaid salary into common stock at the end of each fiscal year at a conversion price to be determined by Mr. Nathanielsz and the
Company, which will in no event be lower than par value or higher than the closing bid price on the date of conversion. Pursuant to the
Nathanielsz Employment Agreement, Mr. Nathanielsz is entitled to an annual discretionary bonus in an amount up to &lt;span id="xdx_907_ecustom--PercentageOfBonusOfAnnualBaseSalary_pid_dp_c20150225__20150225__us-gaap--TypeOfArrangementAxis__custom--NathanielszEmploymentAgreementMember__srt--RangeAxis__srt--MaximumMember_zhhT7ck6qLje" title="Percentage of bonus of annual base salary"&gt;200&lt;/span&gt;% of his annual
base salary, which bonus shall be determined by the Company&#x2019;s board of directors based upon the performance of the Company. On
March 16, 2018, the Company&#x2019;s board of directors approved an increase of Mr. Nathanielsz&#x2019;s annual base salary from $&lt;span id="xdx_90A_eus-gaap--SalariesAndWages_uAUD_c20180316__20180316__us-gaap--TypeOfArrangementAxis__custom--NathanielszEmploymentAgreementMember__srt--RangeAxis__srt--MinimumMember_zmeGAkWoJKud" title="Annual salary"&gt;300,000&lt;/span&gt;
AUD ($&lt;span id="xdx_909_eus-gaap--SalariesAndWages_c20180316__20180316__us-gaap--TypeOfArrangementAxis__custom--NathanielszEmploymentAgreementMember__srt--RangeAxis__srt--MinimumMember_zRNKotzCRL3g" title="Annual salary"&gt;205,680&lt;/span&gt; USD) to $&lt;span id="xdx_90D_eus-gaap--SalariesAndWages_uAUD_c20180316__20180316__us-gaap--TypeOfArrangementAxis__custom--NathanielszEmploymentAgreementMember__srt--RangeAxis__srt--MaximumMember_z7f29VH2gmhd" title="Annual salary"&gt;400,000&lt;/span&gt; AUD ($&lt;span id="xdx_90B_eus-gaap--SalariesAndWages_c20180316__20180316__us-gaap--TypeOfArrangementAxis__custom--NathanielszEmploymentAgreementMember__srt--RangeAxis__srt--MaximumMember_zBh69lR2tm6j" title="Annual salary"&gt;274,240&lt;/span&gt; USD), effective February 2018. On August 1, 2022, the Company&#x2019;s board of directors
approved an increase of Mr. Nathanielsz&#x2019;s annual base salary from $&lt;span id="xdx_90A_eus-gaap--SalariesAndWages_uAUD_c20220801__20220801__us-gaap--TypeOfArrangementAxis__custom--NathanielszEmploymentAgreementMember__srt--RangeAxis__srt--MinimumMember_zu58l4kxVYe1" title="Annual salary"&gt;400,000&lt;/span&gt; AUD ($&lt;span id="xdx_900_eus-gaap--SalariesAndWages_c20220801__20220801__us-gaap--TypeOfArrangementAxis__custom--NathanielszEmploymentAgreementMember__srt--RangeAxis__srt--MinimumMember_zdz1hBW3AE73" title="Annual salary"&gt;309,313&lt;/span&gt; USD) to $&lt;span id="xdx_903_eus-gaap--SalariesAndWages_uAUD_c20220801__20220801__us-gaap--TypeOfArrangementAxis__custom--NathanielszEmploymentAgreementMember__srt--RangeAxis__srt--MaximumMember_zuKIE1FwrNG4" title="Annual salary"&gt;600,000&lt;/span&gt; AUD ($&lt;span id="xdx_90B_eus-gaap--SalariesAndWages_c20220801__20220801__us-gaap--TypeOfArrangementAxis__custom--NathanielszEmploymentAgreementMember__srt--RangeAxis__srt--MaximumMember_zjwZxwkDQZj9" title="Annual salary"&gt;414,900&lt;/span&gt; USD), effective
July 1, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr.
Nathanielsz&#x2019;s wife, Sylvia Nathanielsz, was a non-executive, part-time employee of the Company since October 2015. Effective October
17, 2025, Mr. Nathanielsz&#x2019;s wife, Sylvia Nathanielsz, became the finance and operations manager of the Company. Consequently, Mrs.
Nathanielsz&#x2019;s annual salary increased from $&lt;span id="xdx_902_eus-gaap--SalariesAndWages_uAUD_c20251017__20251017__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrsNathanielszMember__srt--RangeAxis__srt--MinimumMember_zpSKm9m3n9M8" title="Annual salary"&gt;120,000&lt;/span&gt; AUD ($&lt;span id="xdx_90E_eus-gaap--SalariesAndWages_c20251017__20251017__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrsNathanielszMember__srt--RangeAxis__srt--MinimumMember_z60Xrl2RDXs9" title="Annual salary"&gt;80,904&lt;/span&gt; USD) to $&lt;span id="xdx_902_eus-gaap--SalariesAndWages_uAUD_c20251017__20251017__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrsNathanielszMember__srt--RangeAxis__srt--MaximumMember_z5XN43F3uRB2" title="Annual salary"&gt;150,000&lt;/span&gt; AUD ($&lt;span id="xdx_908_eus-gaap--SalariesAndWages_c20251017__20251017__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrsNathanielszMember__srt--RangeAxis__srt--MaximumMember_zi4QqLHpqt4b" title="Annual salary"&gt;103,680&lt;/span&gt; USD) and is entitled to customary
benefits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 12, 2021, the Board approved a bonus of $&lt;span id="xdx_900_eus-gaap--OfficersCompensation_c20210812__20210812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zs0L01pjBag2" title="Officers compensation"&gt;177,840&lt;/span&gt; USD. A total of $&lt;span id="xdx_907_ecustom--PaymentsForBonus_uAUD_c20200701__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_z5uOtlmz5Xwj" title="Bonus payable"&gt;221,890&lt;/span&gt; AUD ($&lt;span id="xdx_90B_ecustom--PaymentsForBonus_c20200701__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zUC935OKZEY2" title="Bonus payable"&gt;166,418&lt;/span&gt; USD) in payments were made against the
bonuses during the year ended June 30, 2021 resulting in a remaining balance of $&lt;span id="xdx_909_ecustom--BonusPayable_iI_pp0p0_uAUD_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zCHPq3rrY5T4" title="Bonus payable"&gt;422,610&lt;/span&gt; AUD ($&lt;span id="xdx_90B_ecustom--BonusPayable_iI_pp0p0_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zeBQpdwUsZNj" title="Bonus payable"&gt;316,957&lt;/span&gt; USD) bonus payable as of June
30, 2021. On August 12, 2021, pursuant to the Cancellation Agreement, Mr. Nathanielsz agreed to cancel $&lt;span id="xdx_903_eus-gaap--OfficersCompensation_c20210812__20210812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zksqHoOBTgPj" title="Officers compensation"&gt;177,840&lt;/span&gt; of the bonus payable
in exchange for &lt;span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210812__20210812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zUtDlpp6lN4i" title="Debt conversion, converted instrument, shares issued"&gt;4&lt;/span&gt; shares of the Company&#x2019;s Common Stock. On August 1, 2022, the Board approved a bonus of $&lt;span id="xdx_909_eus-gaap--OfficersCompensation_uAUD_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zqFtHECcJKu7" title="Officers compensation"&gt;140,000&lt;/span&gt; AUD or $&lt;span id="xdx_90A_eus-gaap--OfficersCompensation_c20220801__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zmRUMCIgQ5fj" title="Officers compensation"&gt;96,810&lt;/span&gt;
USD. A total of $&lt;span id="xdx_90D_ecustom--PaymentsForBonus_uAUD_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zWEZgLnyybV1" title="Bonus payable"&gt;25,000&lt;/span&gt; AUD ($&lt;span id="xdx_908_ecustom--PaymentsForBonus_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zeSEBR16U521" title="Bonus payable"&gt;16,070&lt;/span&gt; USD) in payments were made in respect of the bonuses during fiscal year 2024. In January 2024, the
Board approved a bonus of $&lt;span id="xdx_905_eus-gaap--OfficersCompensation_uAUD_c20240101__20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zb12ObcNcnIi" title="Officers compensation"&gt;150,000&lt;/span&gt; AUD or $&lt;span id="xdx_905_eus-gaap--OfficersCompensation_c20240101__20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zfo6DjSUqFk" title="Officers compensation"&gt;102,195&lt;/span&gt; USD. In June 2025, the Board approved a bonus of $&lt;span id="xdx_90B_eus-gaap--OfficersCompensation_uAUD_c20250601__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zBxQPC2kCq42" title="Officers compensation"&gt;198,000&lt;/span&gt; AUD or $&lt;span id="xdx_902_eus-gaap--OfficersCompensation_c20250601__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zYC7ipZp5a16" title="Officers compensation"&gt;130,106&lt;/span&gt; USD resulting
in a remaining balance of $&lt;span id="xdx_90B_ecustom--BonusPayable_iI_uAUD_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zxQ6xO8IcDUc" title="Remaining bonus amount"&gt;415,540&lt;/span&gt; AUD ($&lt;span id="xdx_900_ecustom--BonusPayable_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zzBjbeY8URc4" title="Remaining bonus amount"&gt;273,051&lt;/span&gt; USD) bonus payable as of June 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
bonus payments of $&lt;span id="xdx_90B_ecustom--PaymentsForBonus_uAUD_c20250701__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zEaVLQHJEBh8" title="Bonus payable"&gt;172,939&lt;/span&gt; AUD ($&lt;span id="xdx_90A_ecustom--PaymentsForBonus_c20250701__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_z3cEVWeAbSul" title="Bonus payable"&gt;115,247&lt;/span&gt; USD) were made during the year June 30, 2026. In fiscal year 2026, the Board approved a bonus
of $&lt;span id="xdx_901_eus-gaap--OfficersCompensation_uAUD_c20250701__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zVhjlV93bnT5" title="Officers compensation"&gt;330,000&lt;/span&gt; AUD or $&lt;span id="xdx_907_eus-gaap--OfficersCompensation_uUSD_c20250701__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zh5Dfcynmj12" title="Bonus approved"&gt;228,096&lt;/span&gt; USD resulting in a remaining balance of $&lt;span id="xdx_906_ecustom--BonusPayable_iI_pp0p0_uAUD_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zcLowGPTbPc9" title="Remaining balance of bonus payable"&gt;572,664&lt;/span&gt; AUD ($&lt;span id="xdx_906_ecustom--BonusPayable_iI_pp0p0_uUSD_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zJvsDsMxAW15" title="Remaining balance of bonus payable"&gt;395,825&lt;/span&gt; USD) bonus payable as of June 30, 2026 which
was included in accrued expenses in the accompanying condensed consolidated balance sheet. Total bonus payments of $&lt;span id="xdx_908_ecustom--PaymentsForBonus_uAUD_c20260701__20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zqHzts91lLt5" title="Bonus payable"&gt;112,664&lt;/span&gt; AUD ($&lt;span id="xdx_906_ecustom--PaymentsForBonus_c20260701__20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_z5aajgE7H8c4" title="Bonus paid"&gt;79,574&lt;/span&gt;
USD) were made during the three months ended September 30, 2026, resulting in a remaining balance of $&lt;span id="xdx_90A_ecustom--BonusPayable_pp0p0_uAUD_c20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_ztuWYKnznUx3" title="Remaining balance of bonus payable"&gt;460,000&lt;/span&gt; AUD ($&lt;span id="xdx_906_ecustom--BonusPayable_pp0p0_uUSD_c20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_znu9QUOdo368" title="Remaining balance of bonus payable"&gt;319,251&lt;/span&gt; USD) bonus
payable as of September 30, 2026 which was included in accrued expenses in the accompanying condensed consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Amended
and Restated Employment Agreement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 14, 2019 (the &#x201c;Effective Date&#x201d;), the Company entered into an Amended and Restated Employment Agreement (the &#x201c;Employment
Agreement&#x201d;) with Mr. Nathanielsz for a term of &lt;span id="xdx_90A_ecustom--AgreementTerm_dc_c20190514__20190514__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrKenyonMember_zVg50zNbxY55" title="Agreement term"&gt;three years&lt;/span&gt;, subject to automatic one-year renewals, at an annual salary of $&lt;span id="xdx_90F_eus-gaap--SalariesAndWages_uAUD_c20190514__20190514__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zkPI7e4CKHp" title="Annual salary"&gt;400,000&lt;/span&gt;
AUD ($&lt;span id="xdx_90B_eus-gaap--SalariesAndWages_c20190514__20190514__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNathanielszMember_zMIiMo9FXEl1" title="Annual salary"&gt;309,313&lt;/span&gt; USD). Pursuant to the Employment Agreement, Mr. Nathanielsz was granted options to purchase a de minimis share of common
stock (the &#x201c;Nathanielsz Options&#x201d;), de minimis restricted stock units of the Company (the &#x201c;Initial Nathanielsz RSUs&#x201d;),
and an additional de minimis restricted stock units of the Company (the &#x201c;Additional Nathanielsz RSUs&#x201d;). Such options and
restricted stock units were granted pursuant to the 2019 Plan approved by the Board on the Effective Date. The Nathanielsz Options have
a term of 10 years from the date of grant. The Nathanielsz Options and Additional Nathanielsz RSU&#x2019;s are subject to vesting periods
pursuant to the Employment Agreement. There are de minimis vested options and restricted stock units that are considered issuable as
of September 30, 2026 and June 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 26, 2022, the Company entered into an Amended and Restated Employment Agreement (the &#x201c;Amended Agreement&#x201d;) with Mr.
Nathanielsz, effective as of July 1, 2022, (the &#x201c;2022 Effective Date&#x201d;). The Amended Agreement provides Mr. Nathanielsz with
a base salary of $&lt;span id="xdx_904_eus-gaap--SalariesAndWages_uAUD_c20221026__20221026__us-gaap--TypeOfArrangementAxis__custom--NathanielszEmploymentAgreementMember_zk1W6S4Gl9Ya" title="Annual salary"&gt;600,000&lt;/span&gt; AUD ($&lt;span id="xdx_905_eus-gaap--SalariesAndWages_c20221026__20221026__us-gaap--TypeOfArrangementAxis__custom--NathanielszEmploymentAgreementMember_zruawTk0bBu" title="Annual salary"&gt;414,900&lt;/span&gt; USD) per annum. The Company has also agreed to pay Mr. Nathanielsz an annual discretionary bonus
in an amount up to &lt;span id="xdx_905_ecustom--PercentageOfBonusOfAnnualBaseSalary_pid_dp_uPure_c20240701__20250630__us-gaap--TypeOfArrangementAxis__custom--NathanielszEmploymentAgreementMember__srt--RangeAxis__srt--MaximumMember_znBNplwuISh1" title="Percentage of bonus of annual base salary"&gt;100&lt;/span&gt;% of his annual base salary, reduced from &lt;span id="xdx_900_ecustom--PercentageOfBonusOfAnnualBaseSalary_pid_dp_uPure_c20240701__20250630__us-gaap--TypeOfArrangementAxis__custom--NathanielszEmploymentAgreementMember_zJWDJuWFk5i5" title="Percentage of bonus of annual base salary"&gt;200&lt;/span&gt;%, which bonus shall be determined by the Board and based upon the
performance of the Company. The Amended Agreement has a term of three (3) years from the 2022 Effective Date, with automatic one-year
renewal periods unless either party elects not to renew.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Amended
and Restated Employment Agreement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 14, 2019, the Company entered into an Amended and Restated Services Agreement (the &#x201c;Services Agreement&#x201d;) with Dr. Kenyon,
the Company&#x2019;s former Chief Scientific Officer and director, for a term of &lt;span id="xdx_907_ecustom--AgreementTerm_dc_c20190514__20190514__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrKenyonMember_zrGkJj59YxYh" title="Agreement term"&gt;three years&lt;/span&gt;, subject to automatic one-year renewals,
at an annual salary of $&lt;span id="xdx_90F_eus-gaap--SalariesAndWages_uAUD_c20190514__20190514__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrKenyonMember_z26wg41173Oh" title="Annual salary"&gt;54,000&lt;/span&gt; AUD ($&lt;span id="xdx_90A_eus-gaap--SalariesAndWages_c20190514__20190514__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrKenyonMember_zTUpfByXGlm2" title="Annual salary"&gt;41,580&lt;/span&gt; USD). In connection with the execution of the Services Agreement, Dr. Kenyon was designated
as an executive officer of the Company and assumed a more active executive role with the Company. Pursuant to the Services Agreement,
Dr. Kenyon was granted options to purchase a de minimis share of common stock (the &#x201c;Kenyon Options&#x201d;), a de minimis restricted
stock units of the Company (the &#x201c;Initial Kenyon RSUs&#x201d;), and an additional de minimis restricted stock units of the Company
(the &#x201c;Additional Kenyon RSUs&#x201d;). Such options and restricted stock units were granted pursuant to the 2019 Plan. The Kenyon
Options have a term of &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20190514__20190514__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrKenyonMember_zkmTJT4mHaNg" title="Option term"&gt;10&lt;/span&gt; years from the date of grant. The Kenyon Options and Additional Kenyon RSU&#x2019;s are subject to vesting periods
pursuant to the Services Agreement. There are de minimis vested options and restricted stock units that are considered issuable as of
June 30, 2026 and 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPANC
BIOPHARMA, INC. AND SUBSIDIARY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Starting
October 1, 2025, the Company agreed to pay Dr. Kenyon an annual director&#x2019;s fee of $&lt;span id="xdx_90C_eus-gaap--AdministrativeFeePayable_iI_uAUD_c20251001__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrKenyonMember_z3kaQQW9ctae" title="Director's fee"&gt;45,000&lt;/span&gt; USD. Effective February 20, 2026, Dr.
Kenyon retired and stepped down from the board of directors of the Company. Dr. Kenyon will remain a medical advisor to the Company.
That same day, the board filled the vacancy left by Dr. Kenyon and appointed Dr. Ralf Brant to serve on the board.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2026 and June 30, 2026, total accrued salaries of $&lt;span id="xdx_90E_eus-gaap--AccruedSalariesCurrent_iI_uAUD_c20260930_zjbDgh2I7Jsh" title="Accrued salaries"&gt;&lt;span id="xdx_909_eus-gaap--AccruedSalariesCurrent_iI_uAUD_c20260630_zNeegXWFUJSg" title="Accrued salaries"&gt;202,000&lt;/span&gt;&lt;/span&gt; AUD ($&lt;span id="xdx_90F_eus-gaap--AccruedSalariesCurrent_iI_c20260930_z1JtPHZljAP9" title="Accrued salaries"&gt;&lt;span id="xdx_904_eus-gaap--AccruedSalariesCurrent_iI_c20260630_zw8B6eU9RIZd" title="Accrued salaries"&gt;139,622&lt;/span&gt;&lt;/span&gt; USD) for both periods, were included in accrued
expenses in the accompanying condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Consulting
and Professional Fees Paid To Related parties&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended September 30, 2026 and 2025, the Company paid accounting fees amounting to $&lt;span id="xdx_903_eus-gaap--ProfessionalFees_uUSD_c20260701__20260930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrJosephHimyMember_zUJytd1HXJgg" title="Consulting fees"&gt;150&lt;/span&gt;USD and $&lt;span id="xdx_907_eus-gaap--ProfessionalFees_uUSD_c20250701__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrJosephHimyMember_zc0ywKc8iEX7" title="Consulting fees"&gt;3,700&lt;/span&gt;USD, respectively,
to an affiliated company whose managing director is one of the Company&#x2019;s directors, Mr. Joseph Himy, who was appointed in August
2025. The Company&#x2019;s Chief Financial Officer, Ms. Jeannine Zimmerman, also currently works in the same affiliated company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended September 30, 2026, the Company paid development consulting fees amounting to $&lt;span id="xdx_902_eus-gaap--PaymentsForFees_uAUD_c20260701__20260930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrRalfBrantMember_zP3tqjN9I7a2" title="Consulting fees paid"&gt;17,248&lt;/span&gt; AUD ($&lt;span id="xdx_90F_eus-gaap--PaymentsForFees_uUSD_c20260701__20260930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrRalfBrantMember_zUR7DKFrpxi1" title="Consulting fees paid"&gt;12,182&lt;/span&gt; USD) to an
affiliated company owned by one of the Company&#x2019;s directors, Dr. Brant, who was appointed in February 2026. Additionally, as of
September 30, 2026 and June 30, 2026, the Company recorded accounts payable of $&lt;span id="xdx_900_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_uAUD_c20260930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrRalfBrantMember_zV9KUG8AO192" title="Accounts payable"&gt;15,631&lt;/span&gt; AUD ($&lt;span id="xdx_90D_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_uUSD_c20260930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrRalfBrantMember_zzFkAcutbaH5" title="Accounts payable"&gt;10,862&lt;/span&gt; USD) and $&lt;span id="xdx_908_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_uAUD_c20260630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrRalfBrantMember_zq8su3XdmW84" title="Accounts payable"&gt;13,310&lt;/span&gt; AUD ($&lt;span id="xdx_906_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20260630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrRalfBrantMember_z3LEhKxhmR0h" title="Accounts payable"&gt;9,200&lt;/span&gt; USD)
due to Dr. Brant, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended September 30, 2026, the Company paid accounting fees amounting to $&lt;span id="xdx_90F_eus-gaap--ProfessionalFees_uAUD_c20260701__20260930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrCarloCampicianoMember_zyFJvEBQ4cP4" title="Consulting fees"&gt;3,250&lt;/span&gt; AUD ($&lt;span id="xdx_901_eus-gaap--ProfessionalFees_uUSD_c20260701__20260930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrCarloCampicianoMember_zB3Mhy3P6Gb7" title="Accounting fees paid"&gt;2,295&lt;/span&gt; USD) to an affiliated company
owned by one of the Company&#x2019;s directors, Mr. Carlo Campiciano, who was appointed in July 2026. Additionally, as of September 30,
2026, the Company recorded accounts payable of $&lt;span id="xdx_900_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_uAUD_c20260930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrCarloCampicianoMember_zYIQ63KdKMvi" title="Accounts payable"&gt;18,325&lt;/span&gt; AUD ($&lt;span id="xdx_900_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_uUSD_c20260930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrCarloCampicianoMember_zgGWTMf6LpIe" title="Accounts payable"&gt;10,862&lt;/span&gt; USD) due to Mr. Campiciano.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Employee
Benefit Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2026 and June 30, 2026, total employee benefit liability of $&lt;span id="xdx_909_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_c20260930_zQtW3PPiuKK1" title="Employee related liabilities current"&gt;770,910&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_c20260630_z8hFly0ztFGh" title="Employee benefit liability"&gt;754,038&lt;/span&gt;, respectively, consist of unpaid or
unused annual leave and long service leave by Mr. Nathanielsz and Sylvia Nathanielsz, as reflected in the accompanying condensed consolidated
balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Intercompany
Loans&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
intercompany loans were made by the parent to the Company&#x2019;s subsidiary, Propanc PTY LTD, none of which has been repaid as of September
30, 2026. Effective fiscal year 2021, the parent company determined that intercompany loans will not be repaid in the foreseeable future
and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment
on the condensed consolidated balance sheet as accumulated other comprehensive income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="AsOf2016-05-05_custom_NorthHorizonPtyLtdMember"
      id="Fact001578">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <PPCB:LeasesRentExpenseMinimumRentals
      contextRef="From2016-05-052016-05-05_custom_NorthHorizonPtyLtdMember"
      decimals="0"
      id="Fact001580"
      unitRef="AUD">39600</PPCB:LeasesRentExpenseMinimumRentals>
    <PPCB:LeasesRentExpenseMinimumRentals
      contextRef="From2016-05-052016-05-05_custom_NorthHorizonPtyLtdMember"
      decimals="0"
      id="Fact001582"
      unitRef="USD">28325</PPCB:LeasesRentExpenseMinimumRentals>
    <PPCB:GoodsAndServiceTax
      contextRef="From2016-05-052016-05-05_custom_NorthHorizonPtyLtdMember"
      decimals="0"
      id="Fact001584"
      unitRef="AUD">3600</PPCB:GoodsAndServiceTax>
    <PPCB:GoodsAndServiceTax
      contextRef="From2016-05-052016-05-05_custom_NorthHorizonPtyLtdMember"
      decimals="0"
      id="Fact001586"
      unitRef="USD">2575</PPCB:GoodsAndServiceTax>
    <PPCB:LeasesFutureMinimumPaymentsDue
      contextRef="AsOf2016-05-05_custom_NorthHorizonPtyLtdMember_custom_NathanielszMember"
      decimals="0"
      id="Fact001588"
      unitRef="AUD">198000</PPCB:LeasesFutureMinimumPaymentsDue>
    <PPCB:LeasesFutureMinimumPaymentsDue
      contextRef="AsOf2016-05-05_custom_NorthHorizonPtyLtdMember_custom_NathanielszMember"
      decimals="0"
      id="Fact001590"
      unitRef="USD">141629</PPCB:LeasesFutureMinimumPaymentsDue>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2016-05-052016-05-05" id="Fact001591">Such lease expired in May 2021 and was renewed for another
one-year term from May 2021 to May 2022.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="AsOf2022-05-04_custom_NewThreeYearOperatingLeaseAgreementMember"
      id="Fact001593">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:PaymentsForRent
      contextRef="From2022-05-042022-05-04_custom_ThreeYearOperatingLeaseAgreementMember_custom_NorthHorizonPtyLtdMember"
      decimals="0"
      id="Fact001595"
      unitRef="AUD">3000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2022-05-042022-05-04_custom_ThreeYearOperatingLeaseAgreementMember_custom_NorthHorizonPtyLtdMember"
      decimals="0"
      id="Fact001597"
      unitRef="USD">2176</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2025-05-042025-05-04_custom_OneYearOperatingLeaseAgreementMember_custom_NorthHorizonPtyLtdMember"
      decimals="0"
      id="Fact001599"
      unitRef="AUD">3300</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2025-05-042025-05-04_custom_OneYearOperatingLeaseAgreementMember_custom_NorthHorizonPtyLtdMember"
      decimals="0"
      id="Fact001601"
      unitRef="USD">2127</us-gaap:PaymentsForRent>
    <PPCB:RentPayable
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001603"
      unitRef="AUD">119159</PPCB:RentPayable>
    <PPCB:RentPayable
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001605"
      unitRef="USD">82804</PPCB:RentPayable>
    <PPCB:RentPayable
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001607"
      unitRef="AUD">119159</PPCB:RentPayable>
    <PPCB:RentPayable
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001609"
      unitRef="USD">82363</PPCB:RentPayable>
    <us-gaap:PaymentsForRent
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact001611"
      unitRef="USD">9523</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact001613"
      unitRef="USD">14789</us-gaap:PaymentsForRent>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2026-09-032026-09-03_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001615"
      unitRef="USD">96652</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestPaid
      contextRef="From2026-09-032026-09-03_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001617"
      unitRef="USD">26991</us-gaap:InterestPaid>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001619"
      unitRef="USD">364801</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2026-06-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001621"
      unitRef="USD">460809</us-gaap:LoansPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001623"
      unitRef="USD">118927</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2026-06-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001625"
      unitRef="USD">128318</us-gaap:InterestPayableCurrent>
    <us-gaap:RelatedPartyTransactionDate
      contextRef="From2015-02-252015-02-25_custom_NathanielszEmploymentAgreementMember"
      id="Fact001627">2019-02-25</us-gaap:RelatedPartyTransactionDate>
    <PPCB:BaseSalaryPerMonth
      contextRef="From2015-02-252015-02-25_custom_NathanielszEmploymentAgreementMember"
      decimals="0"
      id="Fact001629"
      unitRef="AUD">25000</PPCB:BaseSalaryPerMonth>
    <us-gaap:SalariesAndWages
      contextRef="From2015-02-252015-02-25_custom_NathanielszEmploymentAgreementMember"
      decimals="0"
      id="Fact001631"
      unitRef="AUD">300000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2015-02-252015-02-25_custom_NathanielszEmploymentAgreementMember"
      decimals="0"
      id="Fact001633"
      unitRef="USD">205680</us-gaap:SalariesAndWages>
    <PPCB:PercentageOfPensionOfMonthlySalary
      contextRef="From2015-02-252015-02-25_custom_NathanielszEmploymentAgreementMember"
      decimals="INF"
      id="Fact001635"
      unitRef="Pure">0.095</PPCB:PercentageOfPensionOfMonthlySalary>
    <PPCB:PercentageOfBonusOfAnnualBaseSalary
      contextRef="From2015-02-252015-02-25_custom_NathanielszEmploymentAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001637"
      unitRef="Pure">2</PPCB:PercentageOfBonusOfAnnualBaseSalary>
    <us-gaap:SalariesAndWages
      contextRef="From2018-03-162018-03-16_custom_NathanielszEmploymentAgreementMember_srt_MinimumMember"
      decimals="0"
      id="Fact001639"
      unitRef="AUD">300000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2018-03-162018-03-16_custom_NathanielszEmploymentAgreementMember_srt_MinimumMember"
      decimals="0"
      id="Fact001641"
      unitRef="USD">205680</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2018-03-162018-03-16_custom_NathanielszEmploymentAgreementMember_srt_MaximumMember"
      decimals="0"
      id="Fact001643"
      unitRef="AUD">400000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2018-03-162018-03-16_custom_NathanielszEmploymentAgreementMember_srt_MaximumMember"
      decimals="0"
      id="Fact001645"
      unitRef="USD">274240</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2022-08-012022-08-01_custom_NathanielszEmploymentAgreementMember_srt_MinimumMember"
      decimals="0"
      id="Fact001647"
      unitRef="AUD">400000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2022-08-012022-08-01_custom_NathanielszEmploymentAgreementMember_srt_MinimumMember"
      decimals="0"
      id="Fact001649"
      unitRef="USD">309313</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2022-08-012022-08-01_custom_NathanielszEmploymentAgreementMember_srt_MaximumMember"
      decimals="0"
      id="Fact001651"
      unitRef="AUD">600000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2022-08-012022-08-01_custom_NathanielszEmploymentAgreementMember_srt_MaximumMember"
      decimals="0"
      id="Fact001653"
      unitRef="USD">414900</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2025-10-172025-10-17_custom_MrsNathanielszMember_srt_MinimumMember"
      decimals="0"
      id="Fact001655"
      unitRef="AUD">120000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2025-10-172025-10-17_custom_MrsNathanielszMember_srt_MinimumMember"
      decimals="0"
      id="Fact001657"
      unitRef="USD">80904</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2025-10-172025-10-17_custom_MrsNathanielszMember_srt_MaximumMember"
      decimals="0"
      id="Fact001659"
      unitRef="AUD">150000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2025-10-172025-10-17_custom_MrsNathanielszMember_srt_MaximumMember"
      decimals="0"
      id="Fact001661"
      unitRef="USD">103680</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2021-08-122021-08-12_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001663"
      unitRef="USD">177840</us-gaap:OfficersCompensation>
    <PPCB:PaymentsForBonus
      contextRef="From2020-07-012021-06-30_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001665"
      unitRef="AUD">221890</PPCB:PaymentsForBonus>
    <PPCB:PaymentsForBonus
      contextRef="From2020-07-012021-06-30_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001667"
      unitRef="USD">166418</PPCB:PaymentsForBonus>
    <PPCB:BonusPayable
      contextRef="AsOf2021-06-30_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001669"
      unitRef="AUD">422610</PPCB:BonusPayable>
    <PPCB:BonusPayable
      contextRef="AsOf2021-06-30_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001671"
      unitRef="USD">316957</PPCB:BonusPayable>
    <us-gaap:OfficersCompensation
      contextRef="From2021-08-122021-08-12_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001673"
      unitRef="USD">177840</us-gaap:OfficersCompensation>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-08-122021-08-12_custom_MrNathanielszMember"
      decimals="INF"
      id="Fact001675"
      unitRef="Shares">4</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:OfficersCompensation
      contextRef="From2022-08-012022-08-01_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001677"
      unitRef="AUD">140000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-08-012022-08-01_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001679"
      unitRef="USD">96810</us-gaap:OfficersCompensation>
    <PPCB:PaymentsForBonus
      contextRef="From2023-07-012024-06-30_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001681"
      unitRef="AUD">25000</PPCB:PaymentsForBonus>
    <PPCB:PaymentsForBonus
      contextRef="From2023-07-012024-06-30_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001683"
      unitRef="USD">16070</PPCB:PaymentsForBonus>
    <us-gaap:OfficersCompensation
      contextRef="From2024-01-012024-01-31_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001685"
      unitRef="AUD">150000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2024-01-012024-01-31_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001687"
      unitRef="USD">102195</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2025-06-012025-06-30_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001689"
      unitRef="AUD">198000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2025-06-012025-06-30_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001691"
      unitRef="USD">130106</us-gaap:OfficersCompensation>
    <PPCB:BonusPayable
      contextRef="AsOf2025-06-30_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001693"
      unitRef="AUD">415540</PPCB:BonusPayable>
    <PPCB:BonusPayable
      contextRef="AsOf2025-09-30_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001695"
      unitRef="USD">273051</PPCB:BonusPayable>
    <PPCB:PaymentsForBonus
      contextRef="From2025-07-012026-06-30_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001697"
      unitRef="AUD">172939</PPCB:PaymentsForBonus>
    <PPCB:PaymentsForBonus
      contextRef="From2025-07-012026-06-30_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001699"
      unitRef="USD">115247</PPCB:PaymentsForBonus>
    <us-gaap:OfficersCompensation
      contextRef="From2025-07-012026-06-30_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001701"
      unitRef="AUD">330000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2025-07-012026-06-30_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001703"
      unitRef="USD">228096</us-gaap:OfficersCompensation>
    <PPCB:BonusPayable
      contextRef="AsOf2026-06-30_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001705"
      unitRef="AUD">572664</PPCB:BonusPayable>
    <PPCB:BonusPayable
      contextRef="AsOf2026-06-30_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001707"
      unitRef="USD">395825</PPCB:BonusPayable>
    <PPCB:PaymentsForBonus
      contextRef="From2026-07-012026-09-30_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001709"
      unitRef="AUD">112664</PPCB:PaymentsForBonus>
    <PPCB:PaymentsForBonus
      contextRef="From2026-07-012026-09-30_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001711"
      unitRef="USD">79574</PPCB:PaymentsForBonus>
    <PPCB:BonusPayable
      contextRef="AsOf2026-09-30_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001713"
      unitRef="AUD">460000</PPCB:BonusPayable>
    <PPCB:BonusPayable
      contextRef="AsOf2026-09-30_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001715"
      unitRef="USD">319251</PPCB:BonusPayable>
    <PPCB:AgreementTerm
      contextRef="From2019-05-142019-05-14_custom_ServicesAgreementMember_custom_DrKenyonMember"
      id="Fact001717">P3Y</PPCB:AgreementTerm>
    <us-gaap:SalariesAndWages
      contextRef="From2019-05-142019-05-14_custom_EmploymentAgreementMember_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001719"
      unitRef="AUD">400000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2019-05-142019-05-14_custom_EmploymentAgreementMember_custom_MrNathanielszMember"
      decimals="0"
      id="Fact001721"
      unitRef="USD">309313</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2022-10-262022-10-26_custom_NathanielszEmploymentAgreementMember"
      decimals="0"
      id="Fact001723"
      unitRef="AUD">600000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2022-10-262022-10-26_custom_NathanielszEmploymentAgreementMember"
      decimals="0"
      id="Fact001725"
      unitRef="USD">414900</us-gaap:SalariesAndWages>
    <PPCB:PercentageOfBonusOfAnnualBaseSalary
      contextRef="From2024-07-012025-06-30_custom_NathanielszEmploymentAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001727"
      unitRef="Pure">1</PPCB:PercentageOfBonusOfAnnualBaseSalary>
    <PPCB:PercentageOfBonusOfAnnualBaseSalary
      contextRef="From2024-07-012025-06-30_custom_NathanielszEmploymentAgreementMember"
      decimals="INF"
      id="Fact001729"
      unitRef="Pure">2</PPCB:PercentageOfBonusOfAnnualBaseSalary>
    <PPCB:AgreementTerm
      contextRef="From2019-05-142019-05-14_custom_ServicesAgreementMember_custom_DrKenyonMember"
      id="Fact001731">P3Y</PPCB:AgreementTerm>
    <us-gaap:SalariesAndWages
      contextRef="From2019-05-142019-05-14_custom_ServicesAgreementMember_custom_DrKenyonMember"
      decimals="0"
      id="Fact001733"
      unitRef="AUD">54000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2019-05-142019-05-14_custom_ServicesAgreementMember_custom_DrKenyonMember"
      decimals="0"
      id="Fact001735"
      unitRef="USD">41580</us-gaap:SalariesAndWages>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2019-05-142019-05-14_custom_ServicesAgreementMember_custom_DrKenyonMember"
      id="Fact001737">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:AdministrativeFeePayable
      contextRef="AsOf2025-10-01_custom_ServicesAgreementMember_custom_DrKenyonMember"
      decimals="0"
      id="Fact001739"
      unitRef="AUD">45000</us-gaap:AdministrativeFeePayable>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001741"
      unitRef="AUD">202000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001743"
      unitRef="AUD">202000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001745"
      unitRef="USD">139622</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001747"
      unitRef="USD">139622</us-gaap:AccruedSalariesCurrent>
    <us-gaap:ProfessionalFees
      contextRef="From2026-07-012026-09-30_srt_DirectorMember_custom_MrJosephHimyMember"
      decimals="0"
      id="Fact001749"
      unitRef="USD">150</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2025-07-012025-09-30_srt_DirectorMember_custom_MrJosephHimyMember"
      decimals="0"
      id="Fact001751"
      unitRef="USD">3700</us-gaap:ProfessionalFees>
    <us-gaap:PaymentsForFees
      contextRef="From2026-07-012026-09-30_srt_DirectorMember_custom_DrRalfBrantMember"
      decimals="0"
      id="Fact001753"
      unitRef="AUD">17248</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="From2026-07-012026-09-30_srt_DirectorMember_custom_DrRalfBrantMember"
      decimals="0"
      id="Fact001755"
      unitRef="USD">12182</us-gaap:PaymentsForFees>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2026-09-30_srt_DirectorMember_custom_DrRalfBrantMember"
      decimals="0"
      id="Fact001757"
      unitRef="AUD">15631</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2026-09-30_srt_DirectorMember_custom_DrRalfBrantMember"
      decimals="0"
      id="Fact001759"
      unitRef="USD">10862</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2026-06-30_srt_DirectorMember_custom_DrRalfBrantMember"
      decimals="0"
      id="Fact001761"
      unitRef="AUD">13310</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2026-06-30_srt_DirectorMember_custom_DrRalfBrantMember"
      decimals="0"
      id="Fact001763"
      unitRef="USD">9200</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:ProfessionalFees
      contextRef="From2026-07-012026-09-30_srt_DirectorMember_custom_MrCarloCampicianoMember"
      decimals="0"
      id="Fact001765"
      unitRef="AUD">3250</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2026-07-012026-09-30_srt_DirectorMember_custom_MrCarloCampicianoMember"
      decimals="0"
      id="Fact001767"
      unitRef="USD">2295</us-gaap:ProfessionalFees>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2026-09-30_srt_DirectorMember_custom_MrCarloCampicianoMember"
      decimals="0"
      id="Fact001769"
      unitRef="AUD">18325</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2026-09-30_srt_DirectorMember_custom_MrCarloCampicianoMember"
      decimals="0"
      id="Fact001771"
      unitRef="USD">10862</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001773"
      unitRef="USD">770910</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2026-06-30"
      decimals="0"
      id="Fact001775"
      unitRef="USD">754038</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact001777">&lt;p id="xdx_806_eus-gaap--ConcentrationRiskDisclosureTextBlock_zs7KIoSjNGI5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8 &#x2013; &lt;span id="xdx_820_zJWSrfEyErVe"&gt;CONCENTRATIONS AND RISKS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains its cash in banks and financial institutions in Australia. Bank deposits in Australian banks are uninsured. The Company
has not experienced any losses in such accounts through September 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company did not receive any funding from any debt lender and relied on funding from one equity investor and received net proceeds of
$&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20260701__20260930_zpKnUFF8lbg2" title="Proceeds from equity investor"&gt;2,000,000&lt;/span&gt; during the three months ended September 30, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company primarily relied on funding from one convertible and two non-convertible debt lenders and received net proceeds after deductions
of $&lt;span id="xdx_909_eus-gaap--ProceedsFromRepaymentsOfDebt_c20250701__20250930_zTOvxmDrhbw1" title="Proceeds from convertible debt"&gt;19,850&lt;/span&gt; for original issue discounts and debt issue costs during the three months ended September 30, 2025 from each of the three
lenders of $&lt;span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderOneMember_zz3ZLQsNuxl" title="Proceeds from convertible promissory notes"&gt;100,000&lt;/span&gt;, $&lt;span id="xdx_906_eus-gaap--ProceedsFromConvertibleDebt_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderTwoMember_z2b8sZv6EbLb" title="Proceeds from convertible promissory notes"&gt;75,000&lt;/span&gt;, and $&lt;span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_c20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderThreeMember_zpe38ldv9Ey8" title="Proceeds from convertible promissory notes"&gt;78,249&lt;/span&gt;, respectively which represents approximately &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ConvertibleDebtBenchmarkMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--LenderConcentrationRiskMember__srt--MajorCustomersAxis__custom--LenderOneMember_zVoMqbKzyNH4" title="Concentration risk percentage"&gt;39&lt;/span&gt;%, &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ConvertibleDebtBenchmarkMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--LenderConcentrationRiskMember__srt--MajorCustomersAxis__custom--LenderTwoMember_zMwg7I6AHi7h" title="Concentration risk percentage"&gt;30&lt;/span&gt;% and &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ConvertibleDebtBenchmarkMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--LenderConcentrationRiskMember__srt--MajorCustomersAxis__custom--LenderThreeMember_zGUTTXaSjVje" title="Concentration risk percentage"&gt;31&lt;/span&gt;%, respectively of total proceeds
received by the Company during the three months ended September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Receivable
Concentration&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2026 and June 30, 2026, the Company&#x2019;s receivables were &lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260701__20260930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CreditConcentrationRiskMember__srt--MajorCustomersAxis__custom--ReceivableMember_zjWhBPBLgnKj" title="Concentration risk percentage"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CreditConcentrationRiskMember__srt--MajorCustomersAxis__custom--ReceivableMember_zMqtkjZxnLcl" title="Concentration risk percentage"&gt;100&lt;/span&gt;&lt;/span&gt;% related to reimbursements on GST taxes paid.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Patent
and Patent Concentration&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has filed multiple patent applications relating to its lead product, PRP. The Company&#x2019;s lead patent application has been
granted and remains in force in the United States, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal,
Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Japan, Indonesia, Israel, New Zealand, Singapore,
Malaysia, South Africa, Republic of Korea, India and Brazil. In Canada and Mexico, the patent applications have been accepted as of fiscal
year 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2016 and early 2017, the Company filed other patent applications. Three applications were filed under the Patent Cooperation Treaty (the
&#x201c;PCT&#x201d;). The PCT assists applicants in seeking patent protection by filing one international patent application under the
PCT, applicants can simultaneously seek protection for an invention in over 150 countries. Once filed, the application is placed under
the control of the national or regional patent offices, as applicable, in what is called the national phase. One of the PCT applications
filed in November 2016, entered national phase in July 2018 and another PCT application entered national phase in August 2018. A third
PCT application entered the national phase in October 2018.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPANC
BIOPHARMA, INC. AND SUBSIDIARY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 85 granted,
allowed, or accepted patents and 5 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes
against solid tumors, covering the lead product candidate PRP.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Further
patent applications are expected to be filed to capture and protect additional patentable subject matter based on the Company&#x2019;s
field of technology relating to pharmaceutical compositions of proenzymes for treating cancer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Foreign
Operations&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2026 and June 30, 2026, the Company&#x2019;s operations are based in Camberwell, Australia; however, the majority of
research and development is being conducted in the European Union.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 22, 2016, the Company formed a wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales, for the purpose
of submitting an orphan drug application with the European Medicines Agency as a small and medium-sized enterprise. As of September 30,
2026, there has been no activity within this entity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2026-07-01to2026-09-30"
      decimals="0"
      id="Fact001779"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromRepaymentsOfDebt
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact001781"
      unitRef="USD">19850</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2025-07-012025-09-30_custom_LenderOneMember"
      decimals="0"
      id="Fact001783"
      unitRef="USD">100000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2025-07-012025-09-30_custom_LenderTwoMember"
      decimals="0"
      id="Fact001785"
      unitRef="USD">75000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2025-07-012025-09-30_custom_LenderThreeMember"
      decimals="0"
      id="Fact001787"
      unitRef="USD">78249</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012025-09-30_custom_ConvertibleDebtBenchmarkMember_us-gaap_LenderConcentrationRiskMember_custom_LenderOneMember"
      decimals="INF"
      id="Fact001789"
      unitRef="Pure">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012025-09-30_custom_ConvertibleDebtBenchmarkMember_us-gaap_LenderConcentrationRiskMember_custom_LenderTwoMember"
      decimals="INF"
      id="Fact001791"
      unitRef="Pure">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012025-09-30_custom_ConvertibleDebtBenchmarkMember_us-gaap_LenderConcentrationRiskMember_custom_LenderThreeMember"
      decimals="INF"
      id="Fact001793"
      unitRef="Pure">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-07-012026-09-30_us-gaap_AccountsReceivableMember_us-gaap_CreditConcentrationRiskMember_custom_ReceivableMember"
      decimals="INF"
      id="Fact001795"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012026-06-30_us-gaap_AccountsReceivableMember_us-gaap_CreditConcentrationRiskMember_custom_ReceivableMember"
      decimals="INF"
      id="Fact001797"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2026-07-01to2026-09-30" id="Fact001799">&lt;p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_zo9qfTOoSUC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 &#x2013; &lt;span id="xdx_824_zRgLwEiyXtsb"&gt;SUBSEQUENT EVENTS&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Shares
issued for exercise of Series C Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2026, the Company received aggregate gross proceeds of $&lt;span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_c20261001__20261031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zme1im5DrjMa" title="Proceeds from exercise of warrants"&gt;500,000&lt;/span&gt; from the exercise of approximately &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20261031__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBDQml0UcILa" title="Warrants exercised"&gt;50&lt;/span&gt; Series C Warrants with
an exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20261031__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zO4oPkrkz0j7" title="Warrant exercise price per share"&gt;10,000&lt;/span&gt; per share and issued &lt;span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pid_c20261031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfQXy3DIkFc4" title="Number of shares issued"&gt;50&lt;/span&gt; shares of Series C preferred stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Shares
issued for common stock issuable&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2026, the Company issued an aggregate of &lt;span id="xdx_907_eus-gaap--SharesIssued_iI_pid_c20261031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJRtPjIb9M9j" title="Shares issued for common stock issuable"&gt;64,972&lt;/span&gt; shares of common stock for common stock issuable as of September 30, 2026.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2026-10-012026-10-31_us-gaap_SubsequentEventMember_custom_SeriesCWarrantsMember"
      decimals="0"
      id="Fact001801"
      unitRef="USD">500000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2026-10-31_custom_SeriesCWarrantsMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001803"
      unitRef="Shares">50</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-10-31_custom_SeriesCWarrantsMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001805"
      unitRef="USDPShares">10000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-10-31_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001807"
      unitRef="Shares">50</us-gaap:PreferredStockSharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-10-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001809"
      unitRef="Shares">64972</us-gaap:SharesIssued>
</xbrl>
